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Abstract
Notch receptors (1 to 4) are highly conserved cell surface molecules that bind two
different families of ligands, Delta (1, 3 and 4) and Serrate (1 and 2, Jagged in
vertebrates). Notch signalling plays a fundamental role in cell fate decisions during
embryogenesis in both invertebrates and vertebrates, the best-characterised example
of this is neurogenesis in Drosophila. This process involves the specification of
neural versus epidermal precursors. In addition, other molecules have also been
implicated in this decision making process, and are termed neural inducers (noggin,
chordin, follistatin) and inhibitors (activin A, BMP-4, which are both transforming
growth factor-(3 (TGF-(3)-like molecules).
More recently, Notch signalling has been involved in lymphoid lineage
commitment and thymocyte differentiation. In addition, work from our group has
shown that antigen presented by murine dendritic cells over-expressing Jagged-1,
can induce a population of antigen-specific regulatory T cells, which can transfer
tolerance to naive mice. These findings demonstrate the role Notch signalling in
conjunction with T cell receptor (TCR) ligation, may play in the differentiation of
CD4+ T cells into regulatory T cells.
Furthermore, activin A and BMP-4, which like the Notch pathway are highly
conserved and also involved in developmental processes, are TGF-(3-like molecules
which may share functional properties with the immune-regulatory cytokine, TGF-
(3-
The aim of this study was to investigate further the potential role of components of
the Notch pathway and TGF-(3 superfamily members in CD4+ T cell responses in
vitro and in vivo.
The first question addressed if these developmentally related molecules were
expressed in lymphoid organs and cells of adult mice. I used reverse transcriptase
polymerase chain reaction (RT-PCR) to demonstrate that these molecules are
expressed in adult lymphoid compartments, and real-time PCR revealed that
activating CD4+ T cells and B cells in vitro differentially regulated genes of the
Notch signalling pathway and of the TGF-[3 superfamily.
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Second I investigated if components of the Notch signalling pathway were
modulated in murine splenic CD4+ T cells in response to peptide delivered
intranasally under conditions that induce tolerance or priming. Furthermore, I
phenotyped by antibody staining the CD4+ T cells in an attempt to characterise
regulatory T cells generated during tolerance induction.
Finally, I carried out in vitro experiments to investigate the functional effects of the
TGF-(3-like molecules, activin A and BMP-4, on murine splenic CD4+ T cells and






The mucosa of the respiratory, gastrointestinal and the urogenital tracts, as well as the
eye conjunctiva, the inner ear and the ducts of all exocrine glands, are lined with
epithelial cells that provide a physiochemical barrier to limit contact between
environmental antigens and the immune system. In addition, they are protected by
innate immune mechanisms and specialised adaptive immunity, that protects the
mucosal surface against potential insults from the environment. In a healthy adult, this
local immune system contributes almost 80% of all immunocytes. These cells have
accumulated in or are in transit between various mucosal tissues and glands and
together they form the mucosa-associated lymphoid tissue (MALT), the largest
mammalian lymphoid organ (1). The mucosal immune system can discriminate
between pathogenic microorganisms and innocuous matter such as dietary antigens,
inhaled particles or commensal microorganisms, by promoting specific immunological
unresponsiveness (tolerance). This form of tolerance is generally referred to as
mucosal tolerance, and is an active process mediated by more than one mechanism
including active suppression, clonal deletion, immune deviation, anergy and
imunological ignorance (2, 3). Whether antigen induces tolerance or productive
immunity is determined by a number of factors, including antigen dose, the nature of
the antigen, the genetic background and immunological status of the host, and mucosal
adjuvants.
Oral tolerance which is one form of mucosal tolerance can be achieved through the
ingestion of soluble antigen. It takes place in the gut and is associated with a decrease
in cell-mediated responses such as delayed-type hypersensitivity (DTH) reactions in
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vivo and lymphocyte proliferation in vitro, and in humoral responses such as IgE and
IgG production (2). The phenomenon of oral tolerance was first described by Well in
1911 (4), who found that anaphylactic reactions to ovalbumin (OVA) in guinea pigs
could be inhibited by prior oral administration of OVA. This process was active and
antigen specific, as repeated systemic immunisations failed to induce an OVA
responsive state. An important feature of oral tolerance is bystander suppression.
This involves the generation of regulatory T cells after feeding antigen, which are
capable of dampening T cell responses to a different antigen provided both are present
in the same anatomical microenvironment. This was first described in vivo by Miller et
al (5) in the Lewis rat model of experimental allergic encephalomyelitis (EAE),
induced by immunisation with myelin basic protein (MBP). They observed that in
OVA-fed animals given aqueous OVA in the foodpad following immunisation in the
footpad with MBP/complete Freund's adjuvant, EAE was suppressed. Suppression
was mediated by OVA-specific regulatory T cells that migrated to the draining lymph
node and secreted TGF-J3 on encountering OVA, thus inhibiting the generation of the
MBP-specific immune responses in the lymph node. Other mechanisms have been
attributed to oral tolerance including anergy and clonal deletion, however, description
of these is beyond the scope of this study.
As well as through ingestion, mucosal tolerance can be induced via the respiratory
tract through intranasal administration of antigen. This will be discussed in detail as it
forms the basis of the in vivo work reported in this thesis.
1.1. Respiratory Tolerance
The respiratory tract is continually exposed to a wide variety of antigens. There are a
number of innate mechanisms to limit contact between inhaled environmental
allergens and the immune system. These include the nasal filter, tight gap junctions
preventing diffusion of antigens across the epithelium, bronchial cilia, the muco¬
ciliary transport system and specific secretory antibodies and phagocytic cells
contained in the fluid layer overlying the epithelium. Moreover, the bronchial-
associated lymphoid tissue (BALT) is a well-developed mucosal surface in the
respiratory tract. Pulmonary alveolar macrophages in the lower respiratory tract have
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been shown to be efficient inhibitors of T cell activation both in vivo and in vitro (6)
and lack co-stimulatory molecules CD80 and CD86 (7). In addition, pulmonary
alveolar macrophages can prevent the maturation of dendritic cells which are the most
potent antigen presenting cells (APCs) of the immune system, and this would have the
effect of reducing T cell priming to inhaled antigen. In most instances, inhaled
antigens provided they are not pathogen-derived, induce immunological tolerance.
Tolerance induction to inhaled antigens via the nasal route was first reported in 1981
by Holt and co-workers (8). They found that brief exposure of mice to low-level
nebulised OVA induced allergen-specific IgE responses, which spontaneously stopped
after 3-4 weeks. When these mice were challenged parentally with OVA up to 6
months after the final exposure, IgE response was still suppressed along with IgGl
reactivity (Th2 cytokine-induced isotype, responsible for the allergic reaction). This
was accompanied by a compensatory rise in IgG2a (Thl cytokine-induced isotype,
responsible for protection), and represents an example of immune deviation.
Furthermore, this form of tolerance was an active process involving regulatory T cells
(9, 10). Therefore, respiratory tolerance to non pathogen-derived antigens has been
described in the context of immune deviation (from an allergic Th2 to a protective
Thl response), and in the context of regulatory T cells and the latter will be described
below in more detail.
1.1.1. Establishment of Respiratory Tolerance by Regulatory CD4+ T Cells
Much work in our group has been carried out on the role of CD4+ T cells in response
to protein antigens derived from the house dust mite (HDM), Dermatophagoides
pteronyssinus, (Der p) a common source of aeroallergen in the environment. Hoyne
et al (11) showed that in H-2b mice, intranasal (i.n.) administration of the major T
cell epitope of the Der p type 1 allergen (Der p 1), residues 111-139, followed by a
rechallenge with the intact protein antigen, significantly down regulated T cell
responses in vitro, when they were re-stimulated with the intact antigen, the major T
cell epitope, or other minor epitopes. Therefore, treatment with a single
immunogenic peptide could abrogate T cell responses to all the epitopes on the
antigen. This phenomenon is known as linked suppression, and is only observed if
18
tolerant animals are rechallenged with the whole protein. This mechanism is similar
to bystander suppression observed in oral tolerance in that both involve the
generation of regulatory T cells. However, bystander suppression can rely on two
different antigens, the one that generates the regulatory T cell population to suppress
disease induced by the second antigen.
It was also reported that high-dose intranasal delivery of HDM peptide (epitope 111-
139) elicited a strong but transient activation of CD4+ T cells. This was followed by
the down-regulation at day 14 of IL-2 and IFN-y secretion, and the inability to
provide B cell help for antibody production (a state of T cell unresponsiveness) in
vitro (12). They proposed that following antigenic challenge and activation, CD4+ T
cells differentiated into a regulatory population capable of dampening other CD4+ T
cell responses specific for the same antigen. Furthermore, these regulatory T cells
appeared to be maintained in the peripheral circulation for long periods, even 6
months after the original peptide treatment (13). From the work described in these
studies, the following regulatory mechanism for tolerance induction is proposed
(Figure 1).
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A. Initial exposure to peptide
B. Re-challenge with whole protein
TGF-0/ IL-10
Notch signalling
Figure 1. Proposed model for the generation of regulatory T cells after tolerance induction.
Initial immunisation with a single immunodominant epitope generates a population of regulatory
CD4+ T cells (Tr cells). These T cells arise from an initial naive population, which upon recognition of
the antigen (Ag) on the antigen presenting cell (APC) surface undergo clonal expansion and release
cytokines. However, they receive an additional signal(s) that diverts them from a T helper to a
regulatory T cell phenotype. This signal may result from a combination of factors including
physiochemical properties of antigen and dose, site of antigen delivery, mode of antigen presentation,
cytokine microenvironment (IL-10 and/or TGF-(3), APC-T cell interactions through co-stimulatory
molecules (B7-CTLA-4), and other cell-cell contact-mediated signals (MHC/Ag-TCR and/or Notch-
Jagged/Delta). The combination of all or some of these factors will bias the functional differentiation
of the CD4+ T cell into the regulatory pathway. Subsequent immunisation with the whole protein will
bring into close proximity the regulatory CD4+ T cells specific for the immunodominat epitope, as
well as naive CD4+ T cells specific for all other epitopes presented by the same or adjacent APCs. In
such an environment, the regulatory CD4+ T cells are activated, and exert their effects on other CD4+
T cells through the combined effect of inhibitory cytokines and cell-cell contact-mediated mechanisms
that bias the naive CD4+ T cells into the regulatory pathway.
The key feature of this model is that naive CD4+ T cells after antigen recognition are presented with
two choices. Thus, if the signal was stimulatory they would choose to differentiate into T helper cells,
and this would lead to productive immunity. However, in this model, T cells choose to differentiate
into the alternative cell fate, and become regulatory cells instead. The nature of the signal(s) that bias
T cells into a regulatory phenotype still needs to be defined.
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Cell fate choice is probably one of the most fundamental biological processes in
development that directs the process of organogenesis and tissue patterning. This
requires activation of tightly regulated spatial and temporal genetic pathways, which
determine the outcome of cells. One pathway that is key in specifying cells is the
Notch signalling pathway, which involves cell-mediated contact between a receptor
on one cell and its ligands on a neighbouring cell, and subsequent intracellular
signalling that affects transcription of target genes. This pathway is highly conserved
from invertebrates (Drosophila melanogaster) to humans.
The hypothesis described here implicates Notch signalling in the specification of
regulatory CD4+ T cells. The choice between productive immunity or tolerance is
prerequisite for immune homeostasis, therefore, it might involve a process that
evolutionary is very stable, and thus also highly conserved. Based on the model of
peripheral tolerance to HDM peptide given intranasally (11), I was prompted to
investigate if Notch signalling is involved in the generation of regulatory T cells.
Below is a more extensive account on regulatory CD4+ T cells and Notch signalling.
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2. Regulatory CD4+ T Cells
2.1. Induction of Regulatory CD4+ T Cells
The induction of experimental autoimmunity and allergy-associated responses can be
controlled in many cases by CD4+ regulatory T cells that are generated after oral or
intranasal exposure to specific antigen. Examples are found in experimental
autoimmune myesthenia gravis (14), autoimmune diabetes (15), collagen-induced
arthritis (16) or experimental autoimmune encephalomyelitis (17). In section 1.1.1 I
have also described the generation of regulatory CD4+T cells associated with
intranasal administration of the house dust mite allergen, Der p 1.
2.2. Constitutive Regulatory CD4+ T Cells
Increasing evidence suggests that a population of T cells called regulatory T cells (Tr
cells), may be acting to down-regulate other T cell responses, including those that are
directed against self, and help maintain peripheral tolerance. The earliest studies
defined a population of specialised regulatory or suppressor CD4+ T cells derived from
the thymus (18), that were able to prevent organ-specific autoimmunity induced in
mice that had been thymectomized on day 3 of life. The next major finding in support
of regulatory T cells involved their characterisation on the basis of expression of the
Lyt-1 (CD5) antigen (19). Lyt-llow cells when transferred to athymic nude (nu/nu)
mice resulted in autoimmunity in several organs. In contrast, transfer of the Lyt-1hlgh
population or co-transfer with the Lyt-1low population prevented the disease.
In the following account I give a description of some of the Tr cell populations that
have been described. The markers that have been used for their identification were
used in this thesis to characterise regulatory T cells in the spleen of unimmunised mice
and in a model of intranasal peptide tolerance.
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2.2.1. CD4+CD25+ Regulatory T Cells
Sakaguchi et al (20) further defined the regulatory T cell as a minor subset of CD4+
T cells (10%) expressing the IL-2 receptor a-chain (CD25) in the spleen of normal
mice. Studies using two different model systems have led to the suggestion that this
CD4+CD25+ population can prevent certain autoimmune diseases. The first model
involved mice that were thymectomized on day 3 of life and developed organ-
specific autoimmune disease involving one or more organs. The disease, however,
could be inhibited in the thymectomized animals receiving CD4+CD25+ T cells from
normal mice, when transferred on day 10 of life (20). In a second model, when
CD4+CD25" cells from normal BALB/c mice were injected into athymic recipients,
they all developed a high incidence of organ-specific autoimmune disease. This was
prevented by co-transfer of populations enriched in CD4+CD25+ T cells (21).
Thornton and Shevach (22) showed in vitro that CD4+CD25+ T cells from BALB/c
mice were unresponsive to stimulation with anti-CD3 antibody soluble or plate-
bound, anti-CD3 and anti-CD28 antibodies, high IL-2 concentration, and con A in
the presence of T cell-depleted spleen cells as a source of APCs. These cells could
suppress proliferation of CD4+CD25" cells cultured in vitro in the presence of APCs
and soluble anti-CD3 antibody (not plate-bound), and inhibited induction of IL-2
mRNA. Suppression was mediated by a cytokine-independent (neither IL-10 nor
TGF-(3), cell-cell contact-dependent mechanism.
2.2.2. CD4+CD45RBlow Regulatory T Cells
Powrie and Mason (23) also identified a sub-population of CD4+ T cells in the rat,
which displayed an immune regulatory function. These cells were characterised on
the basis of CD45RB expression. CD4+CD45RBhlgh T cells when transferred to
athymic rats led to severe wasting disease. However, no disease was observed when
unseparated cells or CD4+CD45RBlow T cells were transferred.
The same CD4+ sub-populations have also been found in the spleen of mice. The
CD45RB antigen is expressed at high levels in 60-70% of the CD4+ T cells, whilst
the remainder express intermediate or low levels (24). It is widely thought that naive
T cells are contained within the CD45RBhlgh whereas antigen-experienced T cells
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reside largely within the CD45RBlow population. Studies on the function of the
CD4+CD45RBhlgh and CD4+CD45RBlow subsets have shown that important
regulatory interactions occur between these subsets in vivo. Transfer of small
numbers of CD4+CD45RBh,gh T cells from normal BALB/c to C.B-17 severe
combined immunodeficient (SCID) mice led to a Thl cell-mediated wasting disease
and colitis in the recipients (25). In contrast, SCID mice restored with
CD4+CD45RBlow T cells alone did not develop disease, and this population when co-
transferred with CD4+CD45RBhlgh T cells, completely inhibited development of
colitis. These results indicated that in addition to containing antigen-primed cells
capable of mounting recall responses to antigen, the CD4+CD45RBlow T cell subset
also contained a population of regulatory T cells (Tr cells).
Takahashi et al (26) showed that purified BALB/c CD4+CD45RBlow populations
from the spleen and lymph nodes could be further sub-divided into CD25+ and
CD25" populations, consistent with Sakaguchi's original discovery (20). The
CD4+CD25+CD45RBlow T cells were unresponsive to anti-CD3 antibody or con A-
stimulation, and suppressed the CD4+CD25"CD45RBlow T cells in a dose-dependent
fashion when the two populations were mixed in various ratios. In contrast, the
CD4+CD25~CD45RBlow T cells were neither suppressive nor unresponsive,
indicating that this could be attributed to the CD25+ population.
This finding has also been demonstrated by Read et al in vivo (27). They showed that
co-transfer of splenic CD4+CD25+CD45RBlow and the CD45RBhlgh populations, even
at a ratio of 1:8, significantly inhibited colitis and wasting disease in SCID mice,
compared to mice restored with a mixture containing the CD25"CD45RBlow
population, which remained unprotected. To further investigate the regulation of
intestinal inflammation by the CD25+CD45RBlow T cells, they examined the
expression of the T cell co-stimulatory molecule, CTLA-4, as a potential candidate
that may be involved in the signalling pathway that leads to immune suppression by
Tr cells. CTLA-4 was expressed constitutively on CD4+CD25+CD45RBlow cells
(46.4%) and at lower levels on the CD25" subset (12.5%). Very low levels were
found on the CD45RBhigh (0.8%).
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If anti-CTLA-4 monoclonal antibody (mAb) was given to SCID mice which had the
CD25+CD45RBlow and the CD45RBhlgh, the mice did not recover from colitis,
suggesting that the CD25+ cells were dependent on CTLA-4.
In vitro, Takahashi et al (28) also demonstrated that anti-CTLA-4 mAb, especially in
the presence of anti-FcR mAb, or Fab-anti-CTLA-4 mAb, significantly neutralised
CD4+CD25+ T cell-mediated suppression of the activation and proliferation of
CD4+CD25" T cells. In addition, the Fab-anti-CTLA-4 mAb also neutralised the
CD4+CD25+ T cell-mediated control of antigen-specific activation and proliferation
of OVA-specific T cells from DO 11.10 transgenic mice.
2.2.3. CD4+CD38+ Regulatory T Cells
The CD38 antigen which is expressed in 23% of BALB/c splenic CD4+ T cells, has
also been found to sub-divide the CD45RB,0W into CD45RBlowCD38+ (40-50%) and
CD45RBl0WCD38" (15-20%) (29). Read et al found the CD4+CD38+ subset was
resistant to proliferation with soluble anti-CD3 antibody, as opposed to the CD38"
population. Furthermore, they tested the ability of the CD38+ and CD38" populations
to mount secondary responses to specific antigen. These CD4+ T cell subsets were
isolated from the spleens of Leishmania major-infected mice, and stimulated in vitro
with antigen. CD4+CD38+ T cells showed no detectable cytokine production
compared to CD4+CD38" which secreted IL-4, IL-10 and IL-3. Further still,
CD4+CD38+ T cells when transferred to L. major-infected SCID mice, were able to
produce a healing Thl response. They concluded that the CD38+ subset of CD4+ T
cells contained regulatory T cells, which could inhibit T cell activation in vitro.
At present there is a discrepancy between the suppressive activity of the
CD4+CD25+CD45RBlow cells seen in vivo which appear to be TGF-(3-dependent
(27), and the activity of the CD4+CD25+ cells (22) and CD4+CD45RBlowCD38+ (29)
seen in vitro which are TGF-(3-independent.
25
3. Notch Signalling
3.1. The Notch Signalling Pathway
Multicellular development arises from the combinatorial and sequential activity of
genetic pathways. One pathway that plays a central role in the specification of cell
fates through local cell interactions in a wide variety of tissues and organisms is the
Notch signalling pathway. The gene encoding the Notch receptor was discovered in
Drosophila melanogaster more than 80 years ago. This evolutionary conserved
pathway has also been identified in lower and higher vertebrates (30, 31), and related
proteins have been found in the nematode, Ceanorhabditis elegans (32) (Table I and
Figure 2).
Notch Receptors Notch Ligands Intracellular
effectors
Target Genes
Drosophila Notch Delta Serrate [Su(H)] [E(spl)]
Vertebrates
Human Notch 1-4 Delta-like 1, 3, 4 Jagged 1-2 CBF-1/RBP-Jk
Mouse Notch 1-4 Delta-like 1, 3, 4 Jagged 1-2 CBF-1/RBP-JK Hes 1,3,5
Rat: Notch 1-3 Delta-like 3 Jagged-1 Hes 1-3, 5
Zebrafish Notch 1-3, 5, 6 Delta A, B, D SerrateB
Xenopus Xotch X-Delta 1-2 XSu(H)l-2
C.elegans Glp-1 Apx-1 Lag-2 Lag-1
Lin-12







Figure 2. Conservation of the Notch Signalling pathway. Notch encodes for a 300-kD
transmembrane receptor. The extracellular domain consists of 36 epidermal growth factor (EGF)-like
repeats and three cysteine-rich Notch/Lin12 repeats (in blue). The intracellular domain is composed of 6
tandem ankyrin repeats (in red), a glutamine-rich domain (OPA, in orange) and a PEST sequence
(proline-glutamine-serine-threonine-rich region, in green). The extracellular domain of the Notch
receptor can bind to its two ligands; Delta and Serrate (or Jagged in vertebrates), which are membrane-
bound extracellular proteins. This interaction occurs between EGF repeats 11 and 12 on the Notch
receptor (in red) and a conserved cysteine-rich motif referred to as the Delta:Serrate:LAG-2 (DSL)
domain (in yellow), on the Notch ligands. Ligand binding activates the Notch receptor which is
proteolytically cleaved and translocates to the nucleus where it associates with the DNA-binding
molecule Suppressor of Hairless, Su(H) (CBFl/RJB-Jk in mammals: C promoter Binding
Factor/Recombination signal sequence Binding protein for Jk genes). Su(H) binds to regulatory
sequences of the Enhancer ofsplit, E(spl), genes (Hairy Enhancer ofSplit, HES, in mammals) which up
regulate expression of their encoded basic-Helix-Loop-Helix (bHLH) proteins. These, in turn, inhibit
expression of downstream target genes, like the Achaete-Scute complex {Mash-1 in mammals). Su(H)-
independent events have also been documented and these involve the action of a protein called Deltex.
Deltex is an evolutionary conserved cytoplasmic protein that binds to the ankyrin repeats of Notch and
does not appear to localise to the nucleus after Notch activation. Signals through the Notch/Deltex
pathway can result in repression of the bHLH protein E47 through a mechanism involving Ras and c-
Jun N-terminal kinase (JNK) (33).
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3.2. Types of Notch Signalling and Neural Specification
Cell fate determination requires signalling events that can take place either within
different cell types or within an equivalent group of cells. In both instances, studies in
Drosophila and C.elegans, have shown the involvement of the Notch signalling
pathway (34). One type of regulative signalling, termed inductive signalling operates
between non-equivalent cells. In this case intrinsic and extrinsic factors confer a bias
to one of two neighbours, which is then consolidated by Notch-Notch ligand
interactions. An example of the mechanism is the induction of the R4 cell by the R3
cell during Drosophila eye development (35). In the Drosophila imaginal eye disc a
gradient of an unknown signal exists between the adjacent R3 and R4 photoreceptor
precursor cells. This signal is capable of up regulating Delta expression on the R3 cell,
and in turn R3 signals to R4 via its Notch receptor, so that it acquires the R4 fate.
In the second type of signalling event, there is a group of initially equivalent cells, and
one cell from within the group of cells is singled to follow a different path of
differentiation to the remaining cells. As signals will be transmitted back and forth
between the two emerging cell types, this has been termed lateral specification or
lateral inhibition. The molecular details of lateral specification are still largely
undefined, however, it appears to require three regulatory steps (34). First, the
interacting cells express both ligand and receptor. Over time, fluctuations occur in the
expression of Notch receptor and ligand on the neighbouring cells, such that one cell
will express more ligand compared to the other cells that express more receptor. The
Notch ligand-expressing cell signals to the neighbouring cells, and these acquire
alternate cell fates. The segregation of neural and epidermal precursor cells in the
ventral ectoderm of the Drosophila embryo is considered a classic example of lateral
specification. During normal development of the fly central nervous system, an
ectodermal monolayer of equipotent cells gradually segregate into two distinct cell
populations, namely neuroblasts which give rise to neurons, and dermoblasts which
give rise to epidermal structures. A group of transcription factors that are encoded by
the Achaeta-Scute (AS) gene complex (Figure 2) have been implicated in this process
(36). All competent cells will be expressing Notch and Delta. A signal as yet
unidentified will lead to up regulation of the Notch ligand, Delta, in one such cell. This
cell is destined to become a neural precursor, and upon binding to Notch on a
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neighbouring cell, will send an inhibitory signal along the Notch pathway to the
receiving cell, that will lead to the suppression of the AS gene complex and therefore
of its neural potential. As a result this cell will consequently down regulate Delta
expression and adopt an epidermal fate. On the contrary, in the signalling cell the AS
genes will maintain Delta expression, and this cell will adopt a neuronal fate.
Therefore, Notch is the receptor for a signal that diverts cells from adopting a primary,
neuronal fate (the default pathway) and directs them toward a secondary, epidermal
fate.
Studies on the Xenopus homologues of Drosophila Delta suggest that the formation
of neural precursors in vertebrate embryos may also be negatively regulated by
lateral inhibition (37, 38).
In vertebrates, the process of generating a mature neuron can be divided into two
distinct phases which take place during embryonic development: the specification of
the neuroectoderm which takes place at the onset of gastrulation, and the specification
of neural precursors, which takes place during neurula stages and after. The first
process involves a series of molecules, which have been defined as neural inducers
that specify neural ectoderm, and their inhibitors that antagonise their actions. The
second process involves the Notch signalling pathway.
It is possible that a process involving Notch signalling may induce regulatory CD4+
T cells. Thus, when Notch is activated, CD4+ T cells are diverted from their primary
(default) effector T helper fate, to their alternate regulatory T cell fate. Furthermore, I
propose that the molecules that specify neuroectoderm (neural inducers and
inhibitors) may also influence the differentiation of T cells in the periphery. Before
describing the hypothesis on which this study is based, I will describe the process of
neuroectoderm specification in vertebrates and the molecules involved.
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4. Vertebrate Neural Inducers and Inhibitors
In all vertebrates, the development of the nervous system is directly linked to the
establishment of the dorso-ventral axis, which in amphibians is initially established by
a microtubule-directed rotation of the egg cortex. In Xenopus embryos about 9 hours
after fertilisation, gastrulation (or cell rearrangement) begins. Cells located at the top
of the embryo, or animal pole, are specified as ectoderm, and the cells at the bottom, or
vegetal pole, are specified as the endoderm. When the embryo contains 16 or 32 cells,
the specification of the third germ layer, the mesoderm, begins in the equatorial region,
or marginal zone. Because dorso-ventral polarity is established during the first cell
cycle, blastomeres of each germ layer at this stage also have a dorso-ventral identity,
though it is not irreversibly fixed.
The ectodermal cells will make a choice between two possible fates; neural on the
dorsal side of the embryo, and epidermal on the ventral side. Thus, the origin of the
nervous system can be traced to ectodermal cells located on the prospective dorsal side
of the embryo at gastrula stages (39).
Newly formed ectoderm thickens to form a flat neural plate, characterised by a central
groove (neural groove) and thickened lateral edges (neural folds). The neural folds
eventually fuse at the dorsal midline to form the neural tube, which will differentiate
into brain at its anterior end and spinal cord at its posterior end (40). Primary neurones
in lower vertebrates (Xenopus) arise from neuronal precursors in the posterior part of
the neural plate, and this is regulated through a process of lateral inhibition by Notch-
Delta signalling (37).
4.1. The Mechanism ofNeural Induction
The concept of neural induction was first proposed in 1924 by Spemann and Goldman
(41) in their studies of amphibian embryos. They identified a region in the dorsal side
of the embryo, the Spemann Organiser, consisting of mesoderm, which contained
factors that could divert cells in the ectoderm from an epidermal to a neural fate.
Structures functionally equivalent to the amphibian organiser have been identified in
other vertebrates, suggesting that the mechanism of neural induction is conserved.
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However, this experiment was difficult to reconcile with cell dissociation experiments
carried out in the late 1980's. Three groups (42, 43, 44) independently observed that
ectodermal cells subjected to prolonged dissociation culture during gastrula stages,
expressed neural markers or formed histologically recognisable neural tissue after
reaggregation. These results were a considerable surprise because in all cases, the
ectoderm had been isolated from contact with the organiser. It was proposed that
neural inhibitors within the ectoderm had been lost on dissociation, allowing the
ectoderm to acquire by default its neural fate.
The possibilities raised by the dissociation experiments were given new force by the
discovery that ectodermal explants were neuralised by expression of a dominant-
negative activin receptor (45, 46). Activin is a member of the transforming growth
factor (TGF-P) superfamily. When truncated type II activin receptor mRNA was
injected into embryos, the formation of mesoderm was blocked, demonstrating that
signalling through this receptor was required for mesoderm induction in vivo (45).
Furthermore, it was shown that upon injection of this receptor into ectodermal
explants, the ectoderm adopted a neural fate in the absence of neural inducing signals
from the mesoderm. Therefore, these studies proposed that neural fate represents the
default state of ectodermal cells, and that signalling within the ectoderm (for example
by activin and its receptors) inhibits neural specification. When this signalling is
interrupted by cell dissociation or by molecular antagonists, neural tissue forms. Since
these concepts were first proposed, a number of neural inducing factors and neural




Noggin was the first neural inducer identified (47). It can induce neural tissue directly
in ectodermal explants (animal caps) both as an injected RNA and as a soluble protein
(48). At gastrula stages noggin is expressed exclusively in the organiser region.
4.2.2. Follistatin
Follistatin is a direct inhibitor of activin (49), and ectopic expression of follistatin in
embryonic ectodermal explants can turn on neural markers in the absence of
mesoderm, suggesting that neural induction is direct. Follistatin is expressed in the
organiser region in Xenopus, where it can act to block activin signalling in the dorsal
ectoderm and permit neural tissue to form (50). As well as binding to activin,
follistatin has been found in a complex with bone morphogenetic protein 4 (BMP-4),
which is a neural inhibitor (51). Activin A and BMP-4 are both TGF-(3-like molecules,
and direct interaction of follistatin with these TGF-(3-like molecules prevents them
from reaching their receptors and initiating TGF-(3-like signalling.
4.2.3. Chordin
It is a secreted factor localised in the organiser of the early Xenopus gastrula. It was
later demonstrated that chordin is a vertebrate homologue of the Drosophila gene
product, short gastrulation (sog) (52), and that the two proteins can in fact substitute
for one another (53). Chordin has direct neural-inducing ability when provided as
RNA or protein (54, 55), and it has been suggested that the neuralising activity of
chordin is mediated through the inhibition of BMP-4 activity (54). This hypothesis
parallels the genetic evidence demonstrating that sog inhibits the activity of the TGF-(3
protein decapentaplegic (dpp) (56, 57), which is the Drosophila homologue of BMP-2





The role of BMP-4 has been assessed by adding the purified protein to dissociated
cultures of gastrula ectoderm. BMP-4 not only inhibits neuralisation but can also
induce an epidermal fate (58). Moreover, dominant-negative forms of BMP-4, which
cannot be cleaved to give mature protein, as well as dominant-negative BMP-4
receptors, induce the formation of neural tissue in Xenopus ectoderm (58). These
different studies suggested that cells of the gastrula animal cap are predisposed to form
neural tissue in the absence of additional signals, and that an epidermal fate arises as a
result of BMP signalling. This however, can be prevented by direct association of
noggin, chordin and follistatin with BMP-4 (59, 54, 51) so it can no longer access its
receptor.
4.3.2. Activin A
Activin A is a TGF-(3-like molecule, and activin A signalling by binding to its receptor
can inhibit the neural fate. However, unlike BMP-4, it cannot induce epidermis in the
presence of dissociated ectodermal cells. Rather, these cells are shifted to a
mesodermal fate.
The information presented above has attempted to describe the complex process of
neural specification that takes place in vertebrates. Neural induction within the
ectoderm is specified as early as gastrulation, by soluble neural inducers contained
within the Spemann Organiser, such as noggin, chordin or follistatin. These
molecules can bind to and antagonise the TGF-(3-like neural inhibitors BMP-4 and
activin A, preventing their access to specific receptors so they cannot initiate
signalling. Access of BMP-4 and activin A to their specific receptors prevents neural
induction in favour of epidermis and mesoderm, respectively. Additionally, the
functional similarities between the sog/dpp gene products in Drosophila and
chordin/BMP-4 in Xenopus, suggest that the mechanism that determines cell fate
during neural patterning is highly conserved.
The antagonism of TGF-(3 signalling appears to establish the domain in which neural
precursors can be further specified. This later specification is mediated by intercellular
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signalling between precursor cells involving the Notch signalling pathway.
Interestingly, a degree of overlap between the Notch signalling pathway and the
dpp/TGF-P signalling pathway has been found in different studies of Drosophila
development (60, 61, 62), which may also take place in vertebrate development,
although as yet there is no evidence for this.
Therefore, adding to the model of Notch signalling and regulatory CD4+ T cell
differentiation previously described, I propose that the BMP/activin signalling
pathway may also be involved in regulating the differentiation of CD4+ T cells in the
periphery, by co-operating with or acting independently of the Notch signalling
pathway.
From an immunological point of view it is of interest that activin A and BMP-4 are
both TGF-(3-like molecules, and TGF-p has been implicated in the regulation of
mucosal tolerance in vivo (17, 63, 64), and in regulatory T cell effector function (65).
Therefore, it is possible that activin A and/or BMP-4 might also contribute to tolerance
induction by affecting the same downstream target genes as TGF-P.
Therefore, the main aim of this thesis was to determine the role of Notch and TGF-P
signalling in the regulation of peripheral immune responses. The hypothesis was to
determine if signals from Notch and/or TGF-P-like molecules might influence,
together with other factors, the specification of CD4+ T cells. Activation of these
conserved signalling pathways may facilitate the cell fate decision making process
that directs CD4+ T cells to the helper (Th) or regulatory (Tr) pathway.
Before presenting the aims of this thesis I would like to review in more detail the
biology of activin A and BMP-4, as well as to present evidence supporting a role for
Notch signalling in the development and regulation of the immune system. The
information described below reveal that Notch and TGF-P signalling are involved in
similar biological processes.
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5. Notch Signalling in the Immune System
5.1. Notch Signalling and Hematopoiesis
Hematopoesis is a continuous developmental process, in which pluripotent stem cells
and their progeny make sequential cell fate decisions, producing mature blood cells
of the various lineages. Given the extensive evolutionary conservation of Notch
function and its role in cell fate determination, the Notch pathway has been
implicated in the regulation of hematopoiesis.
5.1.1. Myeloid Differentiation
The myeloid progenitor in the bone marrow is the precursor of granulocytes
(neutrophils, eosinophils, basophils and mast cells) and macrophages. The first
evidence for Notch function in myelopoiesis came from studies in 32D cells, a
progenitor cell line used as a model system for granulocytic differentiation (66). 32D
cells can be induced to differentiate in the presence of granulocyte- and granulocyte-
macrophage-colony stimulating factor (G-CSF and GM-CSF). Bigas et al (67)
observed that constitutively active Notch-1 could inhibit 32D differentiation in
response to G-CSF, whereas Notch-2 could inhibit 32D differentiation in response to
GM-CSF. This finding suggests a potential link between Notch and cytokine
signalling pathways in hematopoietic regulation.
More recently, however, two independent studies have reported that Notch signalling
promotes, rather than inhibits, myeloid differentiation. In the first study Tan-Pertel et
al (68) expressed constitutively active forms of the Notch-1 and Notch-2 proteins in
32D cells. During differentiation in the presence of G-CSF, 32D cells expressing
either receptor had significantly higher numbers of viable cells compared with
controls. They also displayed enhanced entry into granulopoeisis and exhibited
postmitotic terminal differentiation. Furthermore, elevated numbers of viable cells
were also observed in 32D cells over-expressing Hes-1, consistent with activation of
the CBF1 pathway.
In the second study, Schroeder and Just (69) also expressed the constitutively active
intracellular domain of Notch-1 in 32D cells. They found that Notch-1 promoted
granulocytic differentiation of these cells. Furthermore, they tested whether ligand
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binding to Notch would induce the same phenotype. For this, they used a fibroblast
cell line engineered to express the Notch ligand, Jagged-1. Co-culture of Notch-1-
expressing 32D cells with Jagged-1-expressing fibroblasts, resulted in an accelerated
onset of differentiation compared to Notch-1-expressing cells co-cultured with the
parental fibroblasts. They found that Notch signalling during granulocytic
differentiation in 32D cells occurred via CBF1 signalling as a transcriptionally active
form of CBF1 also increased granulocytic differentiation.
Human Notch-1 is expressed in bone marrow hematopoietic CD34+ precursors (70),
and Jagged-1 is expressed in human and murine stromal cell lines (71). This is
consistent with a model in which Notch and Jagged mediate an interaction between
hematopoietic cells and the bone marrow stroma, which could function in regulating
cell type differentiation during hematopoiesis. Therefore, Walker et al (71) studied
the role of Notch receptors and ligands in the lineage commitment and maturation of
human CD34+ cells. These cells were cultured in the presence or absence of
recombinant cytokines on feeder layers that either did or did not express the Notch
ligand, Jagged-1. They found that only in the absence of recombinant growth factors,
the Jagged-1/Notch-1 pathway acts to preserve cells in an immature state and to
prevent their proliferation. In the presence of colony-stimulating factor (CSF) which
enhances the viability of hematopoietic progenitors but on its own does not drive




The development of mature T cells from lymphoid progenitor cells involves a series
of cell fate choices in the bone marrow and thymus that direct cells along one of
several distinct developmental pathways (72). These include the choice of a common
lymphoid progenitor to commit to the T cell rather than the B cell lineage, the choice
of CD4 CD8" double negative (DN) thymocytes to commit to the a(3 or y5 lineage,
and the choice of CD4+CD8+ double positive (DP) thymocytes to commit to the
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Figure 3. Schematic diagram to illustrate the differentiation check points in T cell development.
Felli et al (73) reported that Notch-1 and 3 as well as Jagged-2 and the Notch
signalling downstream intracellular targets, Hes-1 and Hes-5, were present in both
lymphoid and stromal components of murine embryonic and adult thymus.
Recent experiments indicate that Notch signalling plays a critical role in the lineage
choice between B and T cell fates. Radke et al (74) showed that following inducible
deletion of Notch-1 using the cre/lox targeted recombination system in the bone
marrow and thymus, the majority of DN cells in the thymus contained markers of the
B cell lineage. They suggested that, in the absence of Notch-1 signalling, a common
lymphoid progenitor cell entering the thymus differentiates into the B cell lineage.
Conversely, retroviral transduction of constitutively active Notch-1 (NotchIC) in
bone marrow stem cells transferred to irradiated hosts, resulted in the development of
a thymus-independent population of cells in the bone marrow that expressed markers
37
of the T cell lineage (75). This suggested that Notch signalling blocked the
differentiation of lymphoid progenitor cells into the B cell lineage.
Interestingly, Notch signalling via Deltex results in the repression of E47 activity
(76), and this protein is necessary for B cell development (77, 78). E47 is one of the
four mammalian bHLH transcription factors (El2, E47, E2-2 and HEB), collectively
known as E proteins, which can bind to sites in DNA called E boxes. The E2A gene
encodes both proteins E47 and El2, and Pui et al found that constitutively activated
Notch-1 inhibited E2A-dependent transcription, which could explain why Notch
signalling blocks differentiation of lymphoid progenitors into the B cell lineage. This
has also been confirmed by Ordentlich et a\ (79) who showed that constitutive
Notch-1 and Notch-2 inhibited E47 activity in a murine fibroblast cell line, NIH 3T3.
In addition, Hes-1 also affects the expansion of early thymocyte precursors. Hes-T7"
mice (80) do not survive past birth, and most embryos completely lack a thymus or
have a significantly smaller one, but expression of TCRP and TCRyS is not detected
suggesting that mature T cells are virtually absent. Examination of chimeras in which
Hes-1" fetal liver was injected into irradiated RAG-2"" mice revealed that B cells
developed normally while T cells were arrested at the DN stage of development. This
provided evidence that Hes-1 transcription factor is required for thymocyte
expansion.
Notch signalling has also been implicated in later stages of thymocyte development
involving the differentiation of DN thymocytes into the a(3 or y8 lineage. Washburn
et al (81) used mice reconstituted with bone marrow stem cells derived from mice
containing two copies of a functional Notch-1 gene (Notch+/+) or just one (Notch +/~).
They found that the Notch+/" stem cells contributed less than the Notch+/+ stem cells
to the aP T cell lineage, but only when the Notch+/" and Notch+/+ cells developed
next to each other. They proposed that Notch signalling was favouring aP over y8 T
cell lineage commitment, by a process akin to lateral inhibition. Thus, cells
expressing less Notch adopted the primary y8 fate, whereas thymocytes expressing
more Notch adopted the alternate aP fate.
Other studies (82) have also revealed the importance of the Notch ligands in y5 T cell
lineage commitment. Jagged-2 mutant mice, with a deletion in the portion of Jagged-
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2 that interacts with Notch, died perinatally. Examination of El8 (18th day of
gestation) embryos, revealed impaired differentiation of the y8 T cell lineage.
At a later stage in thymocyte development, Notch signalling has been shown to bias
CD8+ SP thymocyte commitment over CD4+ (83). Robey et al showed that
transgenic mice with NotchIC under control of the proximal Ick promoter expressed
in DP thymocytes, had a 10-fold increase in the number of CD8+ SP thymocytes and
a slight decrease in the number of CD4+ SP thymocytes. Expression of the Notch-1
transgene in major histocompatibility complex class I (MHC class I)-deficient mice
permitted the development of CD8+ T cells in the absence of MHC class I molecules,
which are normally required for differentiation to this lineage. However, expression
of Notch-1 was not sufficient to promote the generation of CD8+ T cells in mice
lacking both MHC class I and II, suggesting that MHC ligation is required for the
developing thymocyte to commit to the CD8+ T cell fate, and is not just reliant upon
a Notch signal. They proposed that DP thymocytes that are selected on MHC class I
also receive a Notch-1 signal that directs them to the CD8+ lineage, whereas DP
thymocytes that interact with MHC class II do not receive a Notch-1 signal and
develop along the CD4+ lineage. In the presence of constitutive Notch-1 signalling,
DP thymocytes selected on MHC class II are diverted from the CD4+ to the CD8+
lineage. However, an intriguing finding was that these transgenic mice had normal
ratios of CD4:CD8 in peripheral lymphoid tissues, such as lymph nodes.
These results were consistent with the work of Kim et al (84) who examined the
effects of Hes-1 on CD4 expression. This is developmentally regulated, in part, by a
silencer element that prevents its expression in DN and CD8+ SP thymocytes. They
found that the CD4 silencer contained a Hes-1-binding site to which Hes-1 was
binding in vitro, and over-expression of Hes-1 inhibited endogenous CD4
expression.
The findings of Robey et al (83), however, have been challenged by Deftos et al
(85). They retrovirally transduced a DP thymoma cell line (AKR1010) with NotchlC.
Their data revealed that active Notch signalling in this cell line conferred phenotypic
changes associated with the transition from DP to both SP thymocytes, including
resistance to glucocorticoid-induced apoptosis, up-regulation of TCR and Bcl-2.
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Furthermore, they found that Deltex was expressed at higher levels in DN and both
CD4+ and CD8+ SP thymocytes, compared to DP thymocytes. In a more recent study
(86), they generated trangenic mice expressing NotchIC under the control of the Ick-
proximal promoter in thymocytes. They found that, contrary to Robey's et al data
(83), NotchIC promoted the differentiation of both CD4+ and CD8+ SP thymocytes,
and this happened even in the absence of MHC molecules, when bone marrow cells
from NotchIC were transferred to irradiated MHC-deficient hosts. Retroviral
transfection of a DP thymoma cell line (AKR1010) with NotchIC also promoted SP
thymocytes in the absence of MHC molecules. Despite the finding that ectopic Notch
signalling can overcome the normal requirement for TCR-MHC interactions for SP
thymocyte maturation, they did not exclude the necessity of TCR-dependent signals.
Rather, they favoured a model in which the strength of the initial TCR signal
influences CD4 versus CD8 cell fate choice (87, 88). Thus, thymocytes that receive a
weak TCR signal are induced by Notch to mature into the CD8+ SP lineage, and
those that receive a strong TCR signal are induced by Notch to the CD4+ SP lineage.
Therefore, the majority of unselected DP thymocytes expressing TCRs with a low
affinity for MHC molecules, which would normally die by neglect are rescued by
Notch to the CD8+ lineage. This would explain the earlier findings of Robey et al.
They also proposed that DP thymocytes from NotchIC mice that had not seen MHC
may have received a Notch signal in the absence of a TCR signal, and the CD4
versus CD8 cell fate choice may have been made stochastically.
In a very recent study Wilson et al (89) analysed the role Notch-1 plays in the
development of extrathymic T cells that are present in the epithelium of the intestinal
mucosa. These cells differ phenotypically from conventional mature T cells, and in
their TCR-associated signalling components which also affects their requirements for
positive and negative selection. The gut epithelium itselfmight provide the inductive
microenvironment necessary for their development (90, 91). Wilson et al used a
competitive mixed bone marrow (BM) chimera, where BM from Notch-1-deleted
mice was mixed with wild type BM and injected into irradiated hosts. They found
that these mice had virtually no thymus-dependent or independent intraepithelium
lymphocytes, and proposed that Notch-1 receptor mediated an essential inductive
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signal for T cell development in both the thymus and the gut. Importantly, though,
the T cell progenitors in the gut did not differentiate as B cells, unlike those in the
thymus, suggesting that the intestinal epithelium cannot support the differentiation of
B cell progenitors.
5.2. Notch Signalling and Apoptosis
Two groups have independently reported that Notch-1 has anti-apoptotic properties
in T cells. The observations reported suggest that Notch-1 may regulate 'death by
neglect' and/or negative selection.
As described previously, Deftos et al (85) reported that retrovirally transduced
NotchIC inhibited glucocorticoid-induced cell cycle arrest and apoptosis in a thymic
lymphoma line (AKR1010) and a T-cell hybridoma (2B4.11). They found that this
was CBFl-dependent and Deltex expression was up regulated suggesting both
pathways might be activated in this event. Furthermore, the anti-apoptotic protein
Bcl-2 was up regulated in AKR1010 cells but not in 2B4.11 cells. In addition, they
found that thymocytes from transgenic mice expressing NotchIC showed some
resistance to dexamethasone-induced apoptosis.
Jehn et al (92) showed that in a T cell hybridoma (DOl 1.10), NotchIC inhibited Nur-
77-dependent apoptosis, which is required for TCR-mediated apoptosis during
negative selection. This occurred through a direct interaction between Nur-77 and the
intracellular portion of Notch-1.
Taken together, data from Deftos et al and Jehn et al suggest that Notch signalling
may regulate apoptosis during thymocyte maturation by preventing death by neglect
and/or negative selection in cells destined to die.
Very different, however, is the effect Notch-1 has been reported to have on the
viability of B cells and monocytes. Morimura et al (93) found that Notch-1 is
expressed in the follicles of the bursa of Fabricius, which is the central organ for
chicken B cell development. To examine the function of Notch-1 in B cells, a
constitutively active form of chicken Notch-1 was expressed in a chicken cell line,
DT40, by a Cre/loxP mediated inducible expression system. The active Notch-1
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caused growth suppression of the cells, accompanied by a cell-cycle inhibition at the
G1 phase and apoptosis. The expression of Hes-1 also induced apoptosis, although
no cell-cycle inhibition. They suggested that Notch-1 signalling induced apoptosis of
the B cells through Hes-1, and the G1 cell-cycle arrest through other pathways.
Ohishi et al (94) investigated the effects of Notch signalling in monocyte survival.
They observed that expression levels of Notch-1 and Notch-2 were increased as bone
marrow-derived CD34+ cells matured into monocytes, but decreased as they
differentiated into granulocytes. They tested the role of the Notch ligand, Delta-1, in
monocyte survival. An immobilised, truncated form of Delta-1 was incubated with
monocytes, in the presence of the monocyte survival/differentiation factor, M-CSF,
and this lead to a significant increase in monocyte apoptosis.
The interpretation of selected experiments described in this section on Notch should
be viewed with some caution. For example, in studies showing the anti-apoptotic
effects of Notch or its role in thymocyte differentiation, constitutively active forms of
Notch were used. These constructs encode Notch-1 forms that lack all or most of the
extracellular portion of the receptor, and they have biological properties, such as
transforming activity (95), that have not been observed with intact Notch-1 receptor.
Additionally, these truncated forms of Notch proteins localise to the nucleus in
readily detectable amounts (95). This is different to what has been observed with
intact Notch receptors, where extensive immunocytochemical analyses have
consistently failed to detect Notch in the nucleus, and evidence for its nuclear
translocations comes indirectly from its effects on gene transcription (33).
5.3. Notch Signalling and Oncogenesis
Notch-1 was first identified in vertebrates as a gene involved in chromosomal
translocations with the TCRfi gene in a subset of cases of human T cell acute
lymphoblastic leukemia (96). These translocations result in the expression of
truncated Notch-1 polypeptides that lack most of the extracellular domain and
constitutively activate the Notch signalling pathway (97).
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More recently, Bellavia et al (98) investigated the capacity of Notch-3 to regulate
thymocyte development, by generating transgenic mice in which expression of the
constitutively active Notch-3 intracellular domain (Notch3IC) was driven by the
proximal Ick promoter. These mice had dysregulated thymocyte development, and
after 6-8 weeks developed T cell lymphomas in the spleen and lymph nodes,
implicating Notch-3 in T-cell tumorigenesis.
5.4. Notch Signalling and Peripheral Tolerance
The role of Notch signalling in cell fate decisions and the increasing evidence in
support of its contribution to thymocyte differentiation prompted us to investigate its
potential role in cell fate decisions during an immune response. The role of Notch
signalling in the differentiation of CD4+ T cells into regulatory T cells was initially
reported by Hoyne and colleagues (99). Murine dendritic cells (DCs) in which human
Jagged-1 was over-expressed, were pulsed with the immunodominant peptide of house
dust mite, pi 110-131, and then transferred to naive recipients which were
subsequently challenged to induce productive immunity. When the T cells from these
mice were cultured in vitro with the whole protein, the major epitope pll0-131 or a
minor T cell epitope, the cells were hyporesponsive. Furthermore, the transfer of CD4+
T cells from mice injected with the pulsed DCs into recipient mice, induced tolerance
in the latter when they were re-challenged with the intact house dust mite protein, Der
p 1. These studies suggest that Notch signalling at the time of antigen priming may





TGF-P superfamily members are multifunctional cell-cell signalling proteins that play
pivotal roles in tissue development and homeostasis in multicellular animals.
They mediate their pleitropic effects from membrane to nucleus through distinct
combinations of type I and type II serine/threonine kinase receptors and their
downstream effectors, known as Smad proteins (Table II). These signal transducers are
highly conserved, and the first protein was identified in Drosophila and termed
Mothers against dpp (Mad) (100). Subsequently, three Mad homologues called Sma-2,
Sma-3 and Sma-4 were found in C.elegans (101). At present, eight different Sma- and
Mad-related proteins have been identified in mammals and are termed Smads. In
vertebrates, they can be subdivided into three distinct subclasses: receptor-activated
(R-Smads, Smad 1, 2, 3, 5 and 8), common-partner Smads (Co-Smads, Smad 4) and
inhibitory Smads (I-Smads, Smad 6 and 7). TGF-P 1 and activins initially bind to their
corresponding type II receptors with high affinity, after which the type I receptors are
recruited into the signalling complex, and phosphorylated by the type II receptor
kinase (102). BMPs, however, have low affinity for type II or type I receptors
individually, and high-affinity binding requires formation of a heteromeric type 11
typell receptor complex (103, 104). Specificity of signal propagation to Smad







Figure 4. TGF-P signalling pathway. The type I receptors for TGF-|3 and activin A (in red) recognise
and phosphorylate the R-Smads 2 and 3, whereas the BMP type I receptors (in blue) recognise and
phosphorylate the R-Smads 1, 5 and 8. Phosphorylation of the R-Smads triggers their dimerization with
Co-Smad 4 or other R-Smads, and this complex translocates to the nucleus, where it is involved in
transcriptional regulation of target genes. The principal Smads in the TGF-p/Activin pathway lead to
target genes different from those controlled by the Smads in the BMP pathway. In addition, inhibitory
Smads (Smad 6 and 7 in mammals, Dad in Drosophila) can suppress TGF-P signal transduction by
associating with type I receptors and interfering with receptor binding and activation of R-Smads. The
expression of the inhibitory Smads is quickly induced upon stimulation by TGF-p superfamily
members, providing an autoinhibitory mechanism in TGF-P signalling. Whereas Smad 7 inhibits both
TGF-P and BMP-mediated signalling, Smad 6 appears to play a more pronounced role in inhibition of
BMP signalling.
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Analysis of Smad genes by targeted mutagenesis is beginning to provide insight into
Smad function during vertebrate development and tumorigenesis. For example, Smad
4 null mice die around embryonic day 6.5 (107) and Smad 2 null mice show defects in
axis formation and mesoderm induction (108). More recently, Yang et al (109)
disrupted exon 8 of the Smad 3 gene in mice. In contrast to the early effects of Smad 2
deletion, Smad 3 disruption generated viable mutant mice that had extensive
inflammation at mucosal surfaces. T cell receptor-induced activation of thymocytes
and T cells in these mutant mice was completely resistant to inhibition by TGFp.
Ligand Type I Receptor Type II Receptor R-Smad Co-Smad I-Smad













Table II. Summary of the different type I / type II receptors and Smad molecules that
TGF-P, activin A and BMP-4 interact with for signal propagation.
6.2. TGF-P
The prototype of this family, transforming growth factor 1 (TGF-P 1) was isolated and
characterised from the supernatants of transformed fibroblasts, and it was described as
a growth-stimulating polypeptide. The further nomenclature 'transforming growth
factor' was adopted because of its ability to confer on untransformed indicator
fibroblasts functional properties associated with neoplastic transformation (110). At
present, the generic term TGF-P refers to the three isoforms TGF-pi, 2, and 3, which
have been identified in mammalian species. Two other isoforms TGF-P4 and TGF-P5
have been cloned in the chicken (111) and Xenopus (112), respectively. TGF-P 1 is a
predominant TGF-P isoform in lymphoid organs and is the major TGF-P species
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constitutively present in serum. Conversely, TGF-(32 and 3 are predominantly
expressed in mesenchymal tissues and bones. Differential tissue distribution of the
TGF-(3 isoforms and their differential affinity for the TGF-(3 receptors may account for
the wide range of physiological activities of the TGF-J3 isoforms in vivo.
Numerous studies have revealed the significance of TGF-(3l in immune regulation.
Thus, TGF-(3l-deficient mice die about 2 weeks after birth from a wasting syndrome
associated with a multifocal infiltration of lymphocytes and macrophages into targeted
organs, especially the heart, lungs and salivary glands (113). More recently, Gorelik
and Flavell (114) have generated transgenic mice expressing a dominant-negative form
of the TGF-(3 receptor type II in CD4+and CD8+ T cells. These mice had impaired
TGF-P signalling exclusively in T cells and developed autoimmune disease
characterised by inflammatory infiltration in several organs, and the presence of
circulating autoimmune autoantibodies.
TGF-Pl is produced by every leukocyte lineage, including lymphocytes, macrophages
and dendritic cells. Its expression serves in both autocrine and paracrine modes to
exert a positive or negative effect on the differentiation, proliferation and state of
activation of these immune cells, depending on their developmental stage, the in vivo
environment or the medium used for in vitro studies.
TGF-Pl has an inhibitory effect on B-cell maturation and differentiation, and can
inhibit B cell proliferation and induce apoptosis (115). It also enhances the maturation
of DCs (116) and induces CD8 expression in the triple negative, TCR CD4 CD8",
thymocytes during T cell development.
Many lines of evidence have implicated TGF-(3 in the pathogenesis of autoimmune
diseases. Studies of experimental allergic encephalomyelitis (EAE) and collagen-
induced arthritis (CIA) in mice and rats demonstrated that systemic administration of
TGF-(3 suppressed the symptoms of the disease, whereas antibodies to TGF-(3
enhanced the disease process, demonstrating that endogenous TGF-(3 has an effect on
disease progression (117, 118).
Furthermore, TGF-(3 plays a critical role in oral tolerance. In the EAE model, oral
tolerisation with myelin basic protein induces peripheral tolerance by generating both
a population of CD8+ T cells that secrete active TGF-J3 and a regulatory population of
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CD4+ Th2-like cells producing IL-4, IL-10, and secreting TGF-(3 in an antigen-specific
manner (17, 63, 64). As well, secretion of TGF-(3 after oral administration of a MBP
peptide that does not induce EAE, can suppress EAE induced in rats after feeding
them with a encephalitogenic peptide. This phenomenon is known as bystander
supression (5) (described in section 1) and in this EAE model, it may be mediated by
TGF-p-producing CD4+ T cells or Th3 cells, as they have been referred to. TGF-P is
also a critical effector molecule of CD4+CD45RBlow regulatory T cells, which can
suppress colitis in SCID mice (65). Paradoxically, TGF-P 1 is also the most abundant
isoform at sites of inflammation/injury, and is the major isoform secreted by
circulating monocytes and tissue macrophages (119, 120). Other biological processes
in which TGF-P has been implicated are listed in Table III.
6.3. Activin A
The activins are a family of proteins that consist of disulphide-linked homodimers and
heterodimers of the (3 subunits of inhibin termed PA and PB. These three proteins are
known as activin AB (PA-PB), activin A (PA-PA) and activin B (pB-BP) (121). More
recently, three additional members of this family have been identified, called PC, PD
and PE, but as yet their actions remain to be defined (122, 123, 124).
Activin A was originally purified from ovarian follicular fluid, which stimulates the
synthesis and release of pituitary follicle-stimulating hormone (FSH) (125). Molecular
analysis has revealed that the structure of activin A is the same as that of erythroid
differentiation factor (126). Since its original discovery, activin A has been implicated
in a wide spectrum of biological activities. The gonads, liver and kidney are also able
to synthesise activin A (127), as are bone marrow stromal cells (128) and monocytes
(129). Expression of activin A has also been detected in a number of breast cancer cell
lines and prostate carcinoma (Table III). Furthermore, activin A has been implicated
in inflammatory processes, and is present at sites of tissue inflammation, fracture
repair and wound healing (Table III).
Activin A can induce differentiation of a number of cell types including
hematopoietic cells, osteoblasts (130), endocrine cells (131) and lung fibroblasts
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(132). As well, it can inhibit proliferation of gonadal cell lines (133), hepatocytes
(134) and endothelial cells (135). Furthermore, it modulates proliferation in
fibroblasts (136) and vascular smooth muscle (137), and induces apoptosis of B cell
hybridoma cell lines (Table III).
In addition, activin A constitutes an inhibitor of neuronal cell differentiation and plays
a role in mesoderm induction during amphibian development (section 4.3.2.), and in
mammalian organogenesis. Activin (3A-deficient mice die within 24 hours of birth,
and morphological and histological analysis reveals that activin A is required for the
normal development of whiskers and teeth (138).
Activins can be functionally regulated by follistatin (section 4.2.2.), which is a
monomeric glycoprotein structurally unrelated to activins (139). It binds to activin A
and B with high affinity, neutralising their biological activities (140). It is not known
whether follistatin binds the other activin members. mRNA transcripts for activin (3A
and PB subunits and for follistatin were shown to be co-expressed in mid-gestational
human fetal tissues (141), and mice lacking the activin (3A chain (138) or follistatin
(142) both showed similar patterns of disturbed whisker development, suggesting the
activin/follistatin system is involved in this biological process. As well, this system
has been implicated in fracture healing (143) and inflammation (144).
6.4. BMP-4
Bone morphogenetic proteins (BMPs) were first described as constituents of bone
extracts that induce ectopic bone formation when injected into animals (145). They
comprise an ever-growing number of homologues, representing almost one third of the
TGF-P superfamily, with more than 30 members already described (146). BMPs are
synthesised as large precursor proteins. Upon dimerisation, they are proteolytically
cleaved to yield carboxy-terminal mature dimers, which once secreted fulfil their
signalling function by binding to their specific type I/II receptors (147).
It is now clear that the name BMP is misleading because there is strong genetic and
experimental evidence indicating that these molecules regulate biological processes as
diverse as cell proliferation, apoptosis, differentiation, cell-fate determination and
49
morphogenesis (Table III). Moreover, the vertebrate BMPs are involved in the
development of nearly all organs and tissues (147). Studies in Xenopus embryos have
revealed that BMP-4 is crucial for specifying ventral mesoderm during gastrulation,
and in inhibiting neural induction in favour of epidermal specification in the ectoderm
(section 4.3.1.), and in contributing to erythropoiesis (148). In mammals, studies in
BMP-4 homozygous null mice have revealed that the majority die at or around the
time of gastrulation without making embryonic mesoderm (149). Studies of BMP-4
expression in embryonic mice have revealed its involvement in limb patterning,
kidney, tooth, lung and gut development (147). In chick embryos it has been reported
that BMP-4 is involved in dorsal-ventral patterning of the neural tube (150), in
regional neural development by inducing apoptosis (151) and in somite patterning that
specifies muscles in the limbs and body wall (152). In addition BMP-4 is expressed at
sites of fracture repair (153) and in vitro studies using rat osteoblasts have revealed its
importance in bone formation (154). More recently, BMP-4 has been shown to be
involved in human hematopoietic stem cell development (155). All these roles have
been demonstrated by examining BMP-4 expression patterns in vivo and by direct
functional tests, including treating embryonic cells and tissue with BMP-4 in vitro,
over-expressing BMP-4 in vivo, and inhibiting BMP signalling in vivo using dominant
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7. Aims
The Notch and the TGF-(3 superfamily signalling pathways, which exhibit a high
degree of conservation across species, are involved in numerous developmental
processes, being neurogenesis the one I have described in this account. The
experimental findings summarised in Table III indicate that both pathways are also
implicated in a number of similar biological processes including those associated
with functions of the immune system. Furthermore, there is a degree of overlap
between the two pathways, as studies in Drosophila development have demonstrated
(61, 62, 63).
Both pathways are involved in directing cell fate decisions, and both operate by an
inhibitory mode of action. Thus, activation of Notch signalling inhibits cells from
their neural potential, and activation of the activin or BMP signalling pathway
inhibits tissue from its neural potential. Thus, they ensure that one phenotype is
adopted at the expense of another. From an immunological point of view Notch
signalling has been implicated in lymphoid and myeloid differentiation, and activin
A and BMP-4 have both been found to affect erythropoiesis. Furthermore, Activin A
shares a lot of the immune regulatory features of TGF-(3. Both have been found at
sites of tissue inflammation and wound repair. As well, both can induce apoptosis in
B cells and inhibit T cell proliferation.
In the murine model of mucosal tolerance described previously, I propose that Notch
and/or activin/BMP signalling may influence cell fate decisions of CD4+ T cells, by
promoting their differentiation into a regulatory phenotype. Evidence for the
involvement of Notch signalling is based on our studies in which we demonstrate
that Jagged-1 retrovirally-transfected DCs are capable of inducing regulatory T cells
that can transfer tolerance in an antigen-dependent manner to other T cells.
The purpose of the work presented in this thesis was to gain further insight into the
involvement of the Notch and TGF-(3 signalling pathways during CD4+ T cell
responses in vivo and in vitro.
The initial aim was to determine if components of the Notch and TGF-(3 pathways
were expressed in lymphoid organs and cells of unimmunised mice, and if these
genes were modulated upon lymphocyte activation in vitro.
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Next, I wanted to investigate the regulation of Notch signalling genes during
peripheral immune responses in vivo. To do this, I measured the expression of gene
transcripts from components of the Notch pathway in CD4+ T cells from mice that
had been tolerised or primed to intranasal administration of peptide. In addition, I
characterised by flow cytometry the splenic CD4+ T cells from these mice, in an
attempt to describe the regulatory T cells generated following intranasal-induced
peptide tolerance.
Finally, I wanted to investigate in vitro the effects of the TGF-(3 superfamily
members, activin A and BMP-4, on CD4+ T cell responses, in an attempt to describe
similar effects to those attributed to the immune-regulatory cytokine, TGF-(3.
Furthermore, I wished to investigate if the effects of TGF-P, activin A and/or BMP-4
on CD4+ T cells could be attributed to modulation of genes of the Notch signalling






6-8 week old C57BL/6 mice were slightly anaesthetised with halothane. The priming
protocol consisted in administering mice intranasally with 25pl of 0.03pg of E.coli
heat labile enterotoxin (LT) alone as the control group, or in the presence of lOOpg
of HDM pi 10-130, as the experimental group. The mice were sacrificed at days 2, 4
or 7 after treatment and the spleens were removed.
For the tolerance protocol, the mice were administered on three consecutive days
with 25pl of phosphate buffered saline without CaCU and MgCl2 (PBS) (SIGMA,
UK) alone for the control group, or in the presence of lOOpg of pi 10-130. The mice
were sacrificed at days 2, 4 or 7 after the last peptide treatment and the spleens were
removed. For all the experiments two mice were set up per group.
2. Cell Biology Techniques
2.1. Organ Preparations
Spleen, lymph nodes and thymus were removed from C57BL/6 (H-2b) or BALB/c
(H-2d) female mice, aged 6-8 weeks. Lymph nodes (LNs) and thymus were removed
for total RNA extraction. The organs were placed in a 70pm cell-strainer (Becton
Dickinson, USA) sitting on a 6cm petri-dish containing 5ml of PBS (SIGMA, UK).
The tissues were ground using the end of a 1ml syringe plunger. Cell suspensions
were passed through 30pm pre-separation filters (Miltenyi Biotech, Germany) and
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washed by centrifuging at 1200 revolutions per minute (rpm) for 7 minutes (mins) at
room temperature (RT). The supernatant was discarded and the LN and thymus
pellets were resuspended in an appropriate volume of PBS for cell counting, using a
haemocytometer chamber with 0.4% trypan blue exclusion (SIGMA). The cells were
washed and used for total RNA extraction.
For spleen preparations, the supernatant was discarded and the pellet was
resuspended in 1ml of PBS and 4 ml of cold red blood cell (RBC) lysis buffer, and
left on ice for 5 minutes. Cell suspensions were then diluted down in cold PBS to
20ml and washed as before. The pellet was resuspended in 10ml of PBS, and the
spleen cells were counted. Typically 70-100xl06 cells were obtained per spleen.
For removal of dead cells, the spleen suspension were spun down, diluted in 1ml of
RT PBS and gently pipetted over 2ml of RT lympholyte-M (Cedarlane, UK) per
spleen, and centrifuged at 2200rpm, RT for 20 mins. The interface was carefully
removed and washed 2 times with RT PBS. The cells were counted and used for cell
isolation or RNA extraction.
2.2. Cell Isolations
Cell populations were isolated from the spleens of BALB/c or C57BL/6 mice using
a magnetic cell sorting method (MACS) (Miltenyi Biotech). This technique relies
on antibodies conjugated to magnetic microbeads that recognise cell-specific
surface markers, which will bind to a magnetic column when placed in a magnetic
field. Therefore, the cells that are recognised by the antibodies will bind to the
column and will be eluted out as a highly pure population, and all other cell types
are collected in the negative fraction.
The following antibodies were used:
• CD 19 microbeads-antibody for separation of B cells.
• CD1 lc microbeads-antibody for separation of DCs.
• CD4 (LT34) microbeads-antibody for separation of CD4+ T cells.
• CD8 (Ly-2) microbeads-antibody for the separation of CD8+ T cells.
For the separation of DCs, the spleens were removed from C57BL/6 or BALB/c
mice placed in a 6cm petri-dish and covered with 5ml of lmg/ml collagenase D
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(Boehringer Mannheim, Germany). Each spleen was injected with 500pl of
collagenase D, cut into smaller pieces and incubated at 37°C for 1 hour.
Afterwards, spleens were prepared as described in section 2.1.
For separation of CD4+, CD8+ and B cells, spleens were processed as described in
section 2.1. After cell counting, the spleen suspension was washed and the pellet
was resuspended in 400|ul/108 total cells of cold MACS buffer for DCs, or 900p,
1/108 total cells for all other cell types. 100jil/108 cells of specific microbeads-
antibody were added, and the cell suspension was mixed and incubated for 15 mins
at 4°C. The cells were washed and the pellet resuspended in 500pl of cold MACS
buffer before loading into an LS (for CD4+ and B cell isolation) or MS (for CD8+
and DC isolation) MACS column sitting on a VarioMACS or MidiMACS
separator, respectively. The column was washed with cold MACS buffer (3x3ml
for LS columns and 3x500pl for MS column) and the positive fraction eluted out
using the supplied plunger in 5ml (for LS columns) or 1ml (for MS columns) of
cold MACS buffer. The cells were counted. A fraction was kept for flow cytometry,
and the rest were kept for use in proliferation assays or RNA extraction.
CD4+ T cells from mice that had been primed or tolerised using the house dust mite
peptide pi 10-130, were isolated by negative selection using the MACS CD4+ T cell
isolation kit. This relies on a cocktail of magnetically labelled antibodies specific
for all cell types other than CD4+ T cells. Briefly, the spleens were red blood cell
lysed and passed over lympholyte as described in section 2.1. The cells were
incubated in 400pil/108 total cells of MACS buffer and lOOptl of the supplied
biotinylated antibody cocktail for 10 mins at 4°C. Following on, another 300pil/10s
cells of MACS buffer were added together with 200pl of anti-biotin microbeads.
The cells were incubated for 15 mins at 4°C, after which they were washed with
15ml of MACS buffer, and resuspended in 500pl/108 cells of MACS buffer, before
loading into an LS column as described previously. The negative fraction was
eluted out in 9 ml of MACS buffer and the CD4+ T cells were counted. A fraction
was kept for flow cytometry, and the rest were kept for RNA extraction.
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2.3. Flow Cytometry (Flourescence Associated Cell Sorting-FACS)
Fluorescence analysis of cells for cell surface expression of proteins was carried out
in a FACScan flow cytometer (Becton Dickinson, USA). All the antibodies used
were purchased from Pharmingen/BD (USA) or e-Bioscience (UK). Phycoerythrin
(PE)-conjugated antibodies were used for single staining. Fluorescein
isothiocyanate (FITC)- and PE-conjugated antibodies for double staining and Cy-
Chrome-(CyC), FITC- and PE-conjugated antibodies for triple staining. The
appropriate isotype controls were included for each antibody. 2.5xl05 cells were
used per FACS sample. For surface antibody labelling, 2xl05 splenocytes or
MACS-separated cells were added to flexible 96 round-bottom well plates (BD,
USA), and washed for 3 mins at 1200rpm, 4°C. The cells were pre-incubated in
PBS + 0.5% BSA + 10% mouse serum for 15 mins at 4°C, to decrease non-specific
binding of the antibodies. The cells were washed and resuspended in 50 jllI of FACS
buffer containing 0.5pg of FITC-labelled and/or 0.2pg of PE- and/or CyC-labelled
antibody. The cells were incubated in the dark at 4°C for 15 mins, and washed 2
times in cold FACS buffer. Cells were resuspended in 300pl of cold FACS buffer
and were ready for FACS analysis. Cells that were not analysed immediately after
were fixed with 300pl of PBS and 2% paraformaldehyde final concentration, and
stored at 4°C for a maximum of 2 days.
Cell sorting by flow cytometry was performed for MACS-separated splenic CD4+ T
cells, from 8 wild-type C57BL/6 mice. The cells were double stained with 15pg/108
cells of PE-CD4 and FITC-CD25 antibodies in 4ml/108 cells of PBS + 0.5% BSA +
10% mouse serum, and incubated for 30 mins at 4°C in the dark. The cells were
washed 2 times in FACS wash, and resuspended in PBS + 0.5% BSA at 5xl06
cells/ml ready for FACS sorting.
For intracellular labelling, the cells were first surface stained as previously
described. They were then fixed in lOOpl of 4% paraformaldehyde and washed.
They were pre-incubated for 5 mins at RT with permeabilisation solution + 10%
mouse serum to reduce non-specific binding of the antibody. The appropriate PE-
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labelled antibody was added at 0.2pg to the sample and incubated in the dark for
20mins at RT. The cells were washed in permeablisation buffer, and resuspended in
300|il of PBS + 0.5% BSA before proceeding to FACS analysis.
2.4. Apoptosis Assay (AnnexinV-FITC staining)
Annexin-V conjugated to FITC was used to detect early apoptotic cells. Propidium
iodide (PI), on its own or together with Annexin-V, was used to detect late apoptotic
cells or necrotic cells.
AnnexinV-FITC staining of cells was performed using an apoptosis detection kit
following the manufacturer's instructions (Pharmingen, BD, USA). Briefly, freshly
isolated cells or cells that had been in culture were washed twice in cold PBS
(1200rpm, 7mins, 4°C), resuspended at 105 cells/lOOp.1 of the supplied lx binding
buffer, and added to flexible 96 round-bottom well plates (BD). 5pl of AnnexinV-
FITC were added per 105 cells and incubated at RT in the dark. Cells were washed
once in 200pl of cold PBS and resuspended in 400pl lx Binding Buffer. Immediately
before flow cytometry, lpl of PI was added per sample. Cells were analysed with a
FACScan flow cytometer (BD).
2.5. Enzyme Linked ImmunoSorbant Assay (ELISA)
Cytokine secretion was analysed by detecting soluble protein in supernatants
collected from cultures at 48 hours. Similar methods were used for murine and
human cytokine detection. The capture and detection antibodies as well as the
standards were purchased from Pharmingen/BD.
Briefly, anti-cytokine capture antibodies were diluted to 2pg/ml (human cytokines)
or lpg/ml (murine cytokines) in ELISA binding buffer. 50pl/well of diluted capture
antibody were added to 96 flat-bottomed well plates, with enhanced protein binding
capacity (Corning, USA). The plates were sealed and incubated overnight at 4°C.
Next day, the plates were washed 4 times with RT ELISA wash buffer and blotted
dry in tissue. 200|ilAvell of blocking buffer were added and left at RT for 30 mins,
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and the plates were washed as before. 50pl/well of the standards (8 double dilutions
in blocking buffer) and of the supernatants were added, and the plates were incubated
overnight at 4°C. The standards were, recombinant human IL-4 and IL-5 at 4ng/ml,
IL-10 at 2ng/ml and IFN-y at 66ng/ml, or recombinant mouse IL-4 at 20ng/ml, IL-10
at 30ng/ml and IFN-y at 40ng/ml.
Next day, the plates were washed 6 times, and 50pl/well of the biotinylated detection
antibody was added at lpg/ml (diluted in blocking buffer) for 2 hours at RT. The
plates were washed 8 times before the addition of 50pl/well of Streptavidin-alkaline
phosphate conjugate (Amersham Life Sciences, UK) diluted 1:2000 in blocking
buffer. The plates were left at RT for 30 mins and washed 8 times. Finally,
100pl/well of substrate solution were added and the plates left to develop for 20-60
minutes in the dark, at RT. The plates were read in a Microplate Reader 450 (BioRad
Laboratories, U.K).
2.6. Human PBMC Isolation
Human peripheral blood mononuclear cells (PBMCs) were isolated by centrifugal
separation over Histopaque 1077. Briefly, blood was obtained from adult volunteers
by intravenous puncture into heparinised syringes (5000 units Heparin sodium
salt/ml of blood). The blood was diluted in a 1:1 ratio with RT PBS and carefully
layered onto RT Histopaque 1077, and centrifuged at 2200rpm, 20 mins, RT. The
mononuclear cell layer was gently aspirated and washed 3 times with 3 volumes of
PBS, and centrifuged at 1200rpm, 7 mins, RT. Cells were resuspended in complete
RPMI-1640 medium and counted using a haemocytometer chamber with 0.4%
trypan blue exclusion. PBMC numbers typically recovered using this method ranged
from l-2.5xl06 cells/ml of blood.
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2.7. Maintenance of Human CD4+ T Cell Clone
The HA1.7 CD4+ human T cell clone is specific for the haemagglutinin peptide, HA
306-318, and restricted by HLA-DRB1*0101. PBMCs were isolated from
histocompatible HLA-DRB1*0101 donors and y-irradiated with 2000 rad. Irradiated
PBMCs were washed, and added to 24-well plates (Costar, USA) in complete RPMI
medium at 106/ml/well. HA1.7 CD4+T cells were added at 106/ml/well, and HA
peptide 306-318 at lp,g/ml. The cultures were supplemented with 10% final
concentration of recombinant IL-2 (BIOGEN, Switzerland). 1ml of medium was
replaced with 1ml of fresh medium containing 10% IL-2, every 3 days. When the
cells were confluent, they were split 1 in 2. Every week the cells were pooled,
washed in complete RPMI medium, counted and re-stimulated with fresh PBMCs
and peptide.
2.8. Human CD4+ T Cell Clone Proliferation Assay
Irradiated PBMCs were washed and added to 96 round-bottom well plates at 2.5x104
cells/well in complete RPMI medium. HA peptide 306-318 was added to appropriate
wells at lpg/ml. Confluent HA1.7 CD4+ T cells were washed once in RT PBS, and
added to feeder cells at 2xl04 cells/well in complete RPMI medium. Alternatively,
HA1.7 T cells were grown in 10% IL-2 (Lymphocult) or with lp,g/ml HA peptide
final concentration, in the absence of feeder cells. Recombinant proteins were added
to the appropriate wells at the following concentrations: Activin A was added at 1, 10
and/or lOOng/ml, BMP-4 at 1, 10 and/or lOOng/ml and TGF-(3 at 0.1, 1 and/or
lOng/ml. Cells were incubated at 37°C in a humidified incubator 5% CO2 for 3 days.
50p.l aliquots of supernatants were removed after 48 hours of culture to measure
cytokine production. Proliferation was assessed by incorporation of 2.5|iCi/well of
tritiated thymidine, 3[H]-TdR (Amersham Life Sciences, UK), 16 hours before
harvesting. All samples were tested in triplicate.
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2.9. Polyclonal Stimulation of Lymphocytes
Stimulation of human HA 1.7 T cells or MACS-purified murine CD4+ T cells was
performed using immobilised monoclonal antibodies against CD3e and soluble
monoclonal antibodies directed against CD28 (Pharmingen, USA). Briefly, anti-
CD3e antibody was immobilised onto 96 flat-bottom well plates (for proliferation
assays) or 24 flat-bottomed well plates (For RNA extraction or FACS analysis), by
adding at lpg/ml/well (murine cells) or 5pg/ml/well (human cells) in RT PBS. The
plates were incubated for 2 hours at 37°C. Wells were washed 3 times with RT PBS
to remove excess unbound antibody. Murine CD4+ T cells were added in complete
DMEM medium at 2.5xl05/well (96-well plates) or 2xl06/well (24-well plates), and
human HA1.7 T cells at 2xl04/well (96-well plates) in complete RPMI medium.
Soluble anti-CD28 antibody was added at 5pg/ml/well. 96-well plates were
incubated at 37°C in a humidified incubator with 5% CO2 for 72 hours and
proliferation was measured by incorporation of [H]-TdR, 16 hours before
harvesting. Each sample was tested in triplicate.
24-well plates were incubated over different time points and the cells were used for
RNA extraction or FACS analysis.
Stimulation of MACS-purified C57BL/6 splenic B cells was performed by culturing
2xl06 cells/well in 24-well plates in complete DMEM medium, and adding lOOpg
final concentration of E. coli lipopolysaccharide (LPS) (serotype 055:B5, SIGMA).
The cells were incubated at 37°C in a humidified incubator with 5% CO2 over
different time points, and used for RNA extraction.
2.10. Murine CD4+ T Cell Proliferation Assay
CD4+ T cells were isolated by MACS from the spleens of wild type C57BL/6 or
BALB/c mice and they were plated at 2.5xl05/well to 96 flat-bottomed well plates,
that had been pre-coated with lpg/ml of anti-CD3e antibody. Soluble anti-CD28
antibody was added at 5pg/ml. Recombinant activin A and BMP-4 were added at 1,
10 and/or lOOng/ml to the appropriate wells, and TGF-[3 was added at 0.1, 1 and/or
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lOng/ml. The cells were incubated in a humidified incubator with 5% CO2 for 72
hours. 50)0.1 aliquots of supernatants were removed after 48 hours of culture to
measure cytokine production. Proliferation was assessed by incorporation of
2.5p,Ci/well of [H]-TdR, 16 hours before harvesting. All samples were tested in
triplicate.
Statistics
Statistics were performed using GraphPad InStat.
The Bonferroni Multiple Comparison Test was used to compare the significance of
the data obtained from the test samples against the data of the control.
When p<0.05 it was represented as * and regarded as significant.
When p<0.01 it was represented as ** and regarded as highly significant.
When pcO.OOl it was represented as *** and regarded as very significant.
3. Molecular Biology Techniques
3.1. Extraction of Total RNA
Extraction of total RNA from cells was done using QIAGEN's RNeasy Mini Kit,
according to the manufacturer's instructions. Briefly, cells were resuspended in an
appropriate volume of the supplied LRT lysis buffer, and the samples homogenised
using QIAGEN's QIAshredder spin columns. The homogenised lysate was mixed
with one volume of 70% ethanol, which provides the appropriate binding conditions,
and applied to an RNeasy spin column. This was centrifuged for 15 sees, 10000 rpm
at RT, as the total RNA would bind to the column. The spin column was washed
briefly in the supplied RW1 buffer, and any contaminating DNA was digested and
washed out using QIAGEN's RNAse-Free DNase according to the manufacturer's
instructions. The spin column was washed again twice in the supplied RPE buffer.
Finally, the RNA was eluted out in 20-30pl of RNAse/DNAse-free water, and
quantified.
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3.2. Quantification of Nucleic Acids
To determine the concentration of nucleic acids in solution, absorbance (A) at 260
and 280 nanometers (nm) was measured in a spectrophotometer (Ultrospec 200,
Pharmacia Biotech).
The readings were converted to concentrations using the following formulae
(175).
1 A260 unit of double-stranded deoxy ribonucleic acid (dsDNA) = 50|ag/ml
1 A260 unit of oligonucleotide = 20pg/ml
1 A26o unit of RNA = 40|ag/ml
To determine the purity of solutions of DNA and RNA, the ratio of absorbance at
260nm and 280nm (OD26o/28o) was taken. This value should ideally be about 1.8 for
DNA and 2.0 for RNA.
3.3. Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
3.3.1. Designing Gene-Specific Primers
DNA sequences of interest were obtained from PubMed's DNA nucleotide
sequence program (Internet Navigator), and primers were designed using
Holyrood's gcg Prime program, or MacVector program. They were tested for
binding specificity using DNA Strider program.
All PCR primer pairs met the following criteria:
• They were not GC rich (as this creates high annealing temperatures).
• They did not form primer-dimers (primer pairs could not have more than 3
consecutive bases complementing each other).
• The primer pairs had similar annealing temperatures.
• They were at least 16 bases long, optimum 20-24.
• They did not form hairpin-loop folding with energy less than 1.0, and had a
free 3' tail.
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3.3.2. Murine Gene-Specific Primers for PCR
GENE













Notch-4 5' - TTCTACTGCGAGTGTCTCCC -3'
5'- ACAAGCTGTCACCTCCTCACTAC -3'
183 58
Jagged-1 5'- CAAAAATCAGGACACACAAC -3'
5'- CAGCCAACCACAGAAACTAC -3'
289 58
Jagged-2 5' - CCGTGCCTTAATGCTTTTTC -3'
5' - CAGTTCTTGCCACCAAAGTC -3'
282 58




























3.3.3. Setting up an RT-PCR
The reverse transcription of total RNA into first strand DNA, and the synthesis of
second strand complementary DNA (cDNA) and its amplification, was performed
using Promega's Access RT-PCR kit (USA), which allows the two reactions to take
place in a single tube. The reaction was set up according to the manufacturer's
instructions.
Prior to study expression of specific genes, different RNAs were adjusted to equal
levels, by performing an RT-PCR on the house keeping gene, (3-actin.




5x Reaction Buffer 5.0 lx
25mM Magnesium Sulphate (MgS04) 1.0 1 mM
dNTP mix 0.5 200 /rM of each dNTP
Primer mix 1.0 25 pmol of each
primer
Avian Myeloblastosis Virus (AMV) RT
(5 units/^tl)
0.5 0.1 U/jLtl
Thermus flavus (Tfl) DNA polymerase
(5u//xl)
0.5 0.1 U/yrtl
RNA 50 ng 16.5
To test for DNA contamination in the RNA samples, the reaction was set up with
all the reagents except AMV reverse transcriptase.
RNAse/DNAse-free water was included as a negative control for each gene tested,
to ensure there was no DNA contamination in the reagents.
The thermocycler was programmed as follows:
• First strand synthesis:
1 cycle 48°C, 45 mins (RT)
1 cycle 94°C, 2 mins (RT inactivation and RNA/cDNA/primer denaturation).
• Second strand cDNA synthesis and PCR amplification:
35 cycles 94°C, 30 seconds (denaturation)
primer-specific Trn, 1 min.
68°C, 2 mins (amplification).
1 cycle 68°C, 7 mins.
65
3.4. Preparation of Agarose Gels
2% agarose gels (SeaKem LE agarose, FMC) were prepared in lxTAE buffer
(GibcoBRL UK), containing 10jig/|il of ethidium bromide (SIGMA) per ml of
agarose. The gel was transferred to a gel tank containing lxTAE buffer. 10/xl of the
PCR reaction were mixed with 2/rl 6x PCR loading buffer and loaded into each
well. A 50ml gel was run at 80 volts for 1 hour. The UVGrab program connected to
a white/ultraviolet transilluminator (UVP) was used to detect the expression of PCR
products. SIGMA's PCR marker or Gibco's lkb DNA ladder were used as
molecular weight markers.
Alternatively, to visualise the quality of RNA, 1 Oju.1 of lp,g RNA were mixed with
one volume of RNA loading buffer (SIGMA), and the mixture was heated at 65°C
for 10 mins and cooled on ice for 3 mins, before loading into the agarose gel.
SIGMA's RNA marker was used to visualise the 28S and 18S rRNA bands.
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3.5. Real-Time PCR
Higuchi R et al (176) pioneered the analysis of PCR kinetics by constructing a
system that detects PCR products as they accumulate in 'real time'. Two chemistries
are available to detect PCR product accumulation. One is the use of a DNA-binding
dye, which has the disadvantage of binding to all double-stranded DNA, including
non-specific reaction products.
The other relies on the 5'nuclease activity of DNA polymerase (177), which
cleaves a probe that binds specifically to its target DNA sequence. Only when the
PCR product is amplified is the probe cleaved, therefore the signal emitted by the
probe corresponds to the amount ofproduct amplified in real-time (Figure 1).
Figure 1. Fluorogenie 5' Nuclease Chemistry. PE Biosystems make use of fluorogenic
probes, that incorporate a reporter fluorescent dye (FAM or VIC) at the 5' end (R), and a
quencher dye (TAMRA) at the 3' end (Q). 1. The probe anneals downstream from one of
the primer sites on the target sequence. During PCR amplification, as the primer is
extended by Taq DNA polymerase, the probe is cleaved at its 5' end and removed from
the target sequence allowing primer extension to proceed. 2. Cleavage of the probe
separates the reporter dye from the quencher dye, and the reporter emits its characteristic
fluorescence. Flourescence intensity increases proportional to the amount of PCR product
amplified.
Diagram adapted from PE Biosystems.
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3.5.1. Real-Time PCR Amplification
Reactions are characterised by the point in time during cycling when amplification of
a PCR product is first detected. Figure 2 shows a representative amplification plot.
CT
Figure 2. Model of a single amplification plot. An amplification plot is the plot of fluorescence
signal versus cycle number. In the initial cycles of PCR there is little change in fluorescence
signal. This defines the baseline for the amplification plot. An increase in fluorescence above the
baseline indicates the detection of accumulated product. A fixed fluorescence threshold can be set
above the baseline.
• CT (threshold cycle) is defined as the cycle number at which the fluorescence passes the fixed
threshold.
• Rn is the value obtained by dividing the emission intensity of each reporter dye signal with
that of an internal reference dye (ROX), which normalises for non-PCR related fluorescence
fluctuations occurring well-to-well or over time.
• Rn+ is the Rn value of a reaction containing all components including the template.
• Rn is the Rn value obtained from either the early cycles of a real-time run (prior to detectable
increase in fluorescence) or from a reaction not containing template.
• ARn is the difference between the Rn+ and the Rn" value. It reliably indicates the magnitude of
the signal generated by the given set of conditions.
Diagram adapted from PE Biosystems.
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3.5.2. Real-Time PCR Optimisation
The following parameters need to be optimised for efficient real-time amplification
of target cDNA:
A) Primer and Probe Design and Optimisation
Ideally, the primers should be designed to span at least an intron to distinguish
between mRNA and genomic sequences, and ensure only the cDNA is amplified.
However, all the sequences obtained from PubMed's nucleotide sequence program
corresponded to mRNA sequences, and therefore this distinction was not possible.
For this reason I treated all the RNA samples with DNAse (section 3.1) to remove
any genomic DNA contaminants, and I always ran a PCR on the RNA samples using
(3-actin to test for contamination.
(R)
Primers and probes are designed using Primer Express software, supplied by PE
Biosystems. The primers are optimised by independently varying forward and
reverse primer concentrations (50, 300, 900 nM). Optimal performance is achieved
by the primer concentration that provides the lowest Ct and the highest ARn.
The probe can also be optimised by varying the concentration 50-250 nM. Optimal
performance is obtained at the concentration that provides the lowest Ct and the
highest ARn. However, a probe limiting concentration should be avoided when
wishing to detect low copy numbers of a target sequence.
In real-time PCR assays examined here, primer concentrations of 300 nM for both
the forward and reverse primer, and probe concentrations of 200 nM per reaction,
were used.
B) Choosing a Method of Quantitation
Relative quantitation of gene expression can be performed using the standard curve
method or the comparative (AACt) method. Either method needs:
• A standard, which is the sample to be tested.
• A reference. This can be an endogenous control with its own set of primers and
probe. It is used to standardise all the cDNA samples used in a reaction, and as a
control of the PCR reaction itself.
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• A calibrator, is the positive control used in the reaction, which all the standards
are made relative to. Thus, the calibrator becomes the lx sample, and all other
quantities are expressed as an n-fold difference relative to the calibrator.
The standard curve method relies on a known stock of RNA or DNA which is
diluted down to get the standard curve. Standard curves for the gene of interest and
for an endogenous control can be obtained, by running the stock sample in separate
reactions. The equation on the standard curves is then used to find the amount of
gene of interest and endogenous control in the target sample tested. Dividing these
two values allows quantitation normalised to the endogenous reference. This value
can then be further divided by the value of the normalised calibrator (xl) to generate
relative expression levels.
The comparative method is similar to the standard curve method, except it uses
arithmetic formulas to achieve the same result.
The amount of target, normalised to an endogenous reference and relative to a
calibrator, is given by 2"aact, where
• ACt is the Ct of the gene of interest - Ct of the endogenous control (normalises
the amount of target to the endogenous control).
• AA CT is the ACt - Ct of the calibrator (makes the amount of target relative to the
calibrator).
For the AA CT to be valid, the efficiency of the target amplification and of the
reference amplification must be approximately equal. This can be assessed by
running dilutions of a stock cDNA and plotting the standard curves for the gene of




Multiplex PCR is the use of more than one primer pair in the same tube. This method
can be used in relative quantitation where one primer pair amplifies the target and
another primer pair amplifies the endogenous reference in the same tube.
For accurate quantitation it is important that the two reactions do not compete. This
can be avoided by limiting the concentration of primers of the most abundant
species. The desired concentration is that which shows a reduction in ARn but little
effect on Cx-
It can be performed for both the standard curve method and the comparative method.
For the real-time PCR studies I used the comparative method of quantitation in
multiplex PCR reactions.
The following components were used throughout these studies:
• Endogenous control: PE Biosystems 18srRNA. This is already primer limited to
avoid competition for the amplification of the target sample. It contains specific
primers and a probe that is labelled with a fluorogenic dye called VIC.
• Calibrator: this depends on the type of experiment that is set up. In this study I
used the following calibrators:
• Wild type spleen, if the test samples where lymphocytes or dendritic cells (DCs).
• Wild type CD4+ T cells, if the test samples were CD4+ T cells that had been
treated in vitro or isolated from mice that had been treated in vivo.
• Wild type DCs, as above.
• Wild type B cells, as above.
• No template control for each specific gene tested, to ensure that there was no
genomic DNA contaminating the samples.
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3.5.4. Reverse Transcription of Total RNA
RNA samples for real-time PCR were reverse transcribed into cDNA using
TaqMan MultiScribe Reverse Transcriptase kit (PE Biosystems, UK). A 20pl
reaction was set up as follows:
Reagent Volume/Tube (pi) Final Concentration




dNTP mix 4 500 pM of each dNTP
Random hexamer 1 2.5 pM
RNase inhibitor 0.4 0.4 U/pl
MultiScribe RT (50 U/pl) 0.5 1.25 U/pl
RNA 400ng 7.7
The thermocycler (Perkin Elmer) was programmed as follows:
1 cycle 25°C, 10 mins. (incubation)
1 cycle 48°C, 30 mins. (reverse transcription)
1 cycle 95°C, 5 mins. (RT inactivation)
3.5.5. Preparing the Plates for Real-Time PCR
cDNA synthesised by reverse transcription was used for real-time PCR. The method
uses a fluorogenic probe that specifically anneals the template between the PCR
primers. The use of a sequence detector (ABI Prism 7700, PE Biosystems, USA)
measures amplification of the product, in direct proportion to the increase in
fluorescence emitted by the probe. Each sample was run in duplicates in 96-well
optical reaction plates (PE Biosystems). 25jul of the PCR reaction were added per
well.
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A 25)0.1 PCR reaction consisted of the following reagents:
Reagent Volume/Well (pi) Final Concentration
lOx Universal Master Mix 2.5 lx
20x Pre-Developed 18S ribosomal
RNA (rRNA)
1.25 lx
Primer/Probe Mix 7 300nM for both primers
200nM for probe
Water 1.75
The thermal cycler conditions were standard for all the genes tested. These were




The comparative method of quantitation was used for data analysis. All the values
obtained were normalised to 18S rRNA, which was included in the PCR reaction as
an internal endogenous control. Furthermore, each sample was made relative to a
relevant positive control, which always had a value of 1. The data was plotted
relative to the positive control in a column-graph format (Microsoft Excel).
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All chemicals were purchased from SIGMA (Dorset, U.K.) unless otherwise stated.
• Red Blood Cell Lysis Buffer
ImM ammonium hydrogen carbonate (NH4HCO3) (BDH, UK) and 114mM
ammonium chloride (NH4C1) (A-0171) in distilled water. Kept at 4°C.
• MACS Buffer
0.5% BSA (A-9418) in PBS (D-5652). Kept at 4°C.
• Collagenase D
At lmg/ml in lOmM Hepes-NaOH pH 7.4, 150mM NaCl, 5mM KC1, ImM MgCB,
1.8mM CaCB. Freshly prepared.
• FACS Buffer
10% normal mouse serum (Scottish Antibody Production Unit-SAPU, Scotland,
U.K.-NMS) and 0.5% BSA (A-9418) in PBS (D-5652). Kept at 4°C.
• FACS Fixing Buffer
4% paraformaldehyde (P-6148) in PBS (D-5652). Kept at 4°C.
• Permeabilisation Buffer
0.1% sodium azide (S-2002), 0.2% BSA (A-9418) and 0.1% saponin (S7900) in PBS
(D-5652). Kept at 4°C.
• ELISA Binding Buffer
Carbonate-Bicarbonate buffer (C-3041). 1 capsule dissolved in 100ml of distilled
water yields a 50mM Carbonate-Bicarbonate buffer, pH 9.6. Kept at 4°C.
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• ELISA Wash Buffer
PBS tablets diluted in water (1 tablet/lOOml distilled water) containing 0.05%
Tween-20 (P-7949). Kept at room temperature.
• ELISA Blocking Buffer
ELISA washing buffer containing 1% BSA (A-9418). Freshly prepared.
• ELISA Substrate Solution
ELISA ethanolamine buffer (Don Whitley Scientific, Shipton, U.K. E-016)
containing lmg/ml pNPP (N-2770). Made fresh.
• Complete Human RPMI Culture Media
500mls RPMI 1640 (R-0883) with 5% human AB serum [heat inactivated] (H-1513),
lOOIU/ml penicillin/streptomycin (Gibco, Paisley, U.K. 15070-071), 2mM L-
Glutamine (Gibco, Paisley, U.K., 25033-010). Kept at 4°C.
• Complete Murine DMEM Culture Media
500mls DMEM (D-5921) with 10% foetal calf serum (FCS) (F-9665), 5x10 5M
mercaptoethanol (M-7522), lOOIU/ml penicillin/streptomycin (Gibco, Paisley, U.K.
15070-071), 2mM L-Glutamine (Gibco, Paisley, U.K., 25033-010). Kept at 4°C.
• Preparation of LPS
E. coli LPS (serotype 055:B5) powder was reconstituted to lmg/ml in complete
DMEM medium. Aliquots were prepared and stored at -20°C.
• Recombinant Proteins
Recombinant human activin A (R&D Systems, UK) and recombinant human BMP-4
(mature protein identical to mouse) were reconstituted in filter-sterilised PBS (D-
5652) containing 0.1% BSA (A-2153), to a final concentration of 10pg/ml. Aliquots
were prepared and stored at -20°C for up to 3 months.
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Recombinant human TGF-(3 (mature protein identical to mouse) was reconstituted in
filter-sterilised 4mM HC1 containing 0.1% BSA, to a final concentration of lpg/ml.
Aliquots were prepared and stored at -20°C for up to 3 months.
• Synthetic Peptides and Mucosal Adjuvant
The Der p 1 peptide pi 10-130 and the HA1.7 T cell-specific peptide 306-318 are
synthesised as lyophilised pellets by the Advanced Biotechnology Centre (Imperial
College School of Medicine, Charing Cross Hospital, London). Der p 1 pi 10-130
was reconstituted in PBS to the desired concentration for use in immunisations. HA
p306-318 was reconstituted to lmg/ml in complete RPMI medium and aliquots
stored at -20°C. The mucosal adjuvant, Escherichia coli (E.coli) heat labile
enterotoxin was a gift from Dr. G. Douce (University of Glasgow). It originated from
the periplasm of recombinant E. coli strains (179). It was made up to the appropriate
concentration in PBS.
• PCR Loading Buffer
0.25% weight/volume of bromophenol blue (BDH, UK) and 40% weight/volume of
sucrose in distilled water. Stored at 4°C.
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CHAPTER III
Expression of Developmental Genes in
Lymphoid Organs and Cells
1. Background
The Notch signalling pathway plays a central role in the specification of cell fates
through local cell interactions in a wide variety of tissues. Notch is a transmembrane
receptor that can bind to its ligands Delta and Jagged. This evolutionary conserved
pathway was originally identified in Drosophila and it has also been identified in
lower and higher vertebrates, and related proteins have been found in the nematode,
Caenorhabditis elegans. Activation of the pathway leads to cleavage of the
intracellular portion of Notch, which is translocated to the nucleus and associates
with DNA binding proteins to initiate transcription of target genes (33).
Studies over the last 5 years suggest that components of the pathway are expressed
differentially in the different thymic compartments (73), and Notch signalling plays a
critical role at multiple steps during T cell development. Notch-1 signalling is
required to commit precursor cells to the T cell rather than B cell lineage (74, 75) and
for a(3 but not y5 T cell specification (81).
The ability of Notch signalling to direct cell growth and differentiation during
embryonic development prompted to investigate its involvement in the regulation of
peripheral immunity. Overexpression of the Notch ligand, Jagged-1, in murine DCs
pulsed with the immunodominant epitope of house dust mite, could induce long-
lived antigen specific tolerance (99). These studies revealed that the recognition of
antigen by CD4+ T cells in the presence of a Notch ligand, could direct T cells to
differentiate as Tr cells.
Additionally, I was also interested in another group of developmental-related proteins,
which are known as the neural inducers and inhibitors, because of their capacity to
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induce neural tissue or inhibit it. These molecules have been described in Drosophila
as well as lower and higher vertebrates (39). In this study I have concentrated on the
neural inducer, noggin, and the neural inhibitors and TGF-(3 superfamily members,
activin A and BMP-4. These molecules, like components of the Notch pathway, are
highly conserved and are involved in neurogenesis. As well, activin A and BMP-4 are
both TGF-(3-like molecules, and TGF-(3-is a well known immune-regulatory cytokine
which has been implicated in regulatory T cell function and oral tolerance induction
(17, 63, 64, 65). Therefore, I propose that signals derived from the Notch and the TGF-
(3 signalling pathways (TGF-(3, activn A and /or BMP-4) may co-operate to bias the
differentiation of nai've CD4+ T cells into regulatory T cells in a situation that favours
tolerance induction such as intranasal peptide treatment.
At the time of starting this work for my PhD there was little information regarding
the expression pattern of components of the Notch pathway, as well as the neural
inducers and inhibitors in cells of the immune system. This information is necessary
if we are to understand their potential relevance in the adult immune system. It is
worth mentioning that expression could only be studied at the gene level, because at
the time this work was initiated there were no antibodies available for many of the
molecules here involved.
Therefore, in this study I investigated the expression of genes associated with the
Notch signalling pathway (Notch-1, -2 and -4, Jagged-1 and -2, Delta-1 and the
downstream target gene, Hes-1). I also examined the expression of neural
inducers/inhibitors (noggin, activin A and BMP-4) in lymphoid tissues and cells of
adult mice by reverse-transcription polymerase chain reaction (RT-PCR).
Furthermore, to gain some insight into the potential relevance of these genes in
immune responses, 1 investigated by real-time PCR their differential regulation in
CD4+ T cells and B cells that had been activated in vitro.
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2. Results
2.1. Gene Expression in Lymphoid Organs
The spleen, LNs and thymus of adult (6-8 weeks-old) unimmunised, wild type
C57BL/6 (C57) and BALB/c mice were removed and processed for total RNA
extraction. The integrity of the RNA was confirmed using agarose gel
electrophoresis and all the samples were normalised to the house-keeping gene, |f-
actin, by reverse-transcriptase polymerase chain reaction (RT-PCR). In addition,
each sample was checked for genomic DNA contamination using PCR (Figure 1).
C57BL6 BALB/c
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Figure 1. RNA control tests. The spleen (S), lymph nodes (LNs) and
thymus (T) of C57 and BALB/c mice were processed for total RNA
extraction, lpg of each sample was run on a 2% agarose gel (A). The 5.3
kilobase (Kb) band is the 28S rRNA and the 2Kb band is the 18S rRNA. An
RT-PCR (B) using 50ng of total RNA was done with (3-actin primers, to
normalise all RNA samples to equal amounts. The 151 base pair (bp) band
corresponds to the amplified PCR product run on a 2% agarose gel. Water
(H20) was included as a control for genomic DNA contamination. In
parallel, a PCR (C) was performed on the RNA samples as a control for
genomic DNA contamination. M is the RNA (A) or DNA (B, C) marker.
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Tissue RNA from spleen, thymus and LNs of C57 and BALB/c mice were examined
for expression of component genes of the Notch signalling pathway, including
Notch-1, 2 and 4, the Notch ligands, Jagged-1, 2 and Delta-1 and the donwstream
signalling target, Hes-1, by RT-PCR. (Figure 2). They were also checked for
























Figure 2. Notch and its related genes are expressed in murine spleen,
LNs and thymus. The spleen, LNs and thymus of C57 or BALB/c mice
were removed and prepared for RNA extraction. An RT-PCR using 50ng
of total RNA was done for Notch-], 2 and 4, Jagged-1 and 2, Delta-1
and Hes-1, and the PCR-amplified products were run in a 2% agarose
gel. ft-actin was used as a house-keeping gene to normalise all the RNA
samples to the same amount of starting template, and as a control of the
PCR reaction itself. Water (H20) was used as a negative control, to
ensure the reactions were not contaminated with genomic DNA. The
figure also shows the expected length of each PCR-amplified product in
base pairs (bp), and the annealing temperature (Tm) of each primer.
Figure 2 shows that all the genes tested were expressed at varying levels in the
spleen, LNs and thymus of both C57 and BALB/c mice. The Notch receptors tested,
1, 2 and 4, were expressed in all the organs, although Notch-2 was the most abundant
in both mouse strains. The Notch ligands, Jagged-1, 2 and Delta-1 were also
expressed in these organs. Jagged-2 was more abundant in the thymus. Finally, Hes-
1 was also expressed in all the tissues tested. I cannot however, exclude the role
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Deltex might be playing in signalling (Introduction, section 3.1), as this gene was not
included in this analysis.
Figure 3 reveals that the TGF-|3-like molecule, activin A, was expressed in all three
lymphoid tissues in both mouse strains. In C57s it was strongly expressed in the
spleen. The activin receptor type II B (ActRIIB), to which activin A binds, was
expressed weakly in lymphoid tissues. However, it should be noted that the type II
receptor tested here is not the only receptor involved in activin signalling. There are
two type II receptors (ActRJI and the closely related ActRIIB) that bind activin with
high affinity, after which the newly formed complex interacts with the type I activin
receptor, ActRIB (178). Activins have also been shown to interact with ActRI,
although this receptor appears to play a minor role in activin signalling.
Follistatin was not found in any of the organs tested (not shown), but this could
relate more to inefficient primers than to levels of expression, as no message was
ever found in any sample tested. Finally, Noggin and BMP-4 were only weakly














Figure 3. Neural inducers and inhibitors are expressed in murine
spleen, LNs and thymus. The spleen, LNs and thymus of C57 or BALB/c
mice were removed and prepared for RNA extraction. An RT-PCR using
50ng of total RNA was done for Activin A, activin type It B receptor
(ActARIl), Noggin and BMP-4, and the PCR-amplified products were run
in a 2% agarose gel. /3-actin was used as a house-keeping gene to
normalise all the RNA samples to the same amount of starting template,
and as a control of the PCR reaction itself. Water (H?0) was used as a
negative control, to ensure the reactions were not contaminated with
genomic DNA. The figure also shows the expected length of each PCR-
amplified product in base pairs (bp), and the annealing temperature (Tm) of
each primer.
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2.2. Gene Expression in Lymphoid Cells
Having confirmed the expression of genes associated with Notch and TGF-(3-like
signalling in various lymphoid organs, I next focused on the expression of these
genes within purified cell populations isolated from the spleen.
2.2.1. Cell Separation
Cell isolation was performed using the MACS technique (described in Chapter II,
section 2.2). This relies on magnetically labelled antibodies specific for each cell
type. Mouse anti-CD4 and anti-CD8 antibodies were used for CD4 and CD8
isolation, respectively. Anti-CD19 and anti-CDllc antibodies were used for the
isolation of B cells and DCs, respectively. High purities were expected after cell
separation with the anti-CD4, anti-CD8 and anti-CD 19 antibodies, as they are
specific for their cell type. CD1 lc was the only antibody available for DC separation,
and this is not DC-exclusive (it is weakly expressed on NK cells, B cells and T cell
subsets), therefore, purities in the range of 50-70% were expected after isolation.
On average, a normal C57 or BALB/c spleen contained about 60-75 million cells
after lysing the red blood cells, of which about 15-20% were CD4+ T cells, 7-10%
CD8+ T cells, 25-30% B cells and 2-5% CDllc+ cells. After isolation, some of the
cells were kept for antibody staining and flow cytometry. The remaining cells were
lysed in RNA lysis buffer, and the cells stored at -70°C until the RNA was required
for extraction.
2.2.2. Phenotyping Lymphoid Cells
Flow cytometry was used to determine the purity of the cells isolated by MACS and
the cell viability (Figure 4). Typically, CD4+ T cells and B cells were >95% pure.
CD8+ T about 90% pure and the CDllc positives ranged from 50-70% pure.
Propidium iodide (PI) staining (Figure 4) showed that the isolation procedure was
not disruptive to cells as the percentage of total live cells after MACS was still high
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Figure 4. Purity and viability of MACS-separated murine lymphoid cells. Splenic CD4+ T
cells, CD8+ T cells, B cells and enriched DCs were isolated from C57BL/6 female mice by
MACS, and the purity assessed by antibody staining with PE-CD4, CD8, CD19 and CDllc,
respectively (red lines). Each marker was accompanied by its corresponding isotype control
(shaded grey) (A). The percentage values correspond to the purity of each cell preparation gated
on the live population (B). Cell viability was tested after each cell separation by addition of PI
(C). The values indicate the percentage of dead cells in the total, ungated population.
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2.2.3. RT-PCR on Lymphoid Cell Populations
The isolated splenic lymphoid populations were processed for RNA, checked for
genomic DNA contamination and prepared for RT-PCR (Figure 5). The Notch-1
receptor was expressed in all the lymphoid populations tested, and more so Notch-2,
whereas Notch-4 was weakly expressed. The Notch ligands Jagged-1 and 2 were
barely detected, except for Jagged-1 in DCs, but this could have been a problem with
the primers as the agarose gel revealed that they were annealing non-specifically to
other products. Delta-1 was expressed in all the cell types although more strongly in
the APC populations. TGF-/3 and Activin A were strongly expressed in all the cells.
Transcripts for Noggin were found in all the cells but at low levels and no BMP-4
was detected in any of the samples tested (not shown), confirming the finding that
BMP-4 was not present in the spleen either (Figure 2).
C57BL/6
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Notch-4 183 58 TGF-P
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Figure 5. Expression of neurogenic genes in murine lymphoid cells. Splenic CD41 T cells, CD8+ T
cells, B cells and DCs from C57 mice were isolated by MACS and prepared for RNA extraction. An
RT-PCR using 50ng of total RNA was done for all the genes listed above, and the PCR-amplified
products were run in a 2% agarose gel. /3-actin was used as a house-keeping gene to normalise all the
RNA samples to the same amount of starting template, and as a control of the PCR reaction itself. The
figure also shows the expected length of each PCR-amplified product in base pairs, and the annealing
temperature (Tm) of each primer.
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2.2.4. Real-Time PCR of in vitro-activated Lymphocyte Populations
A limitation to RT-PCR analysis of gene expression is that it is difficult to make
quantitative comparisons of genes between different samples. Therefore, to
overcome this I used real-time PCR technology. This was pioneered by Higuchi et al
(176), and involves a system that detects PCR products as they accumulate in 'real¬
time' making quantitation possible. For a more detailed account of real-time PCR
technology see Chapter II, section 3.5.
The use of technologies that measure gene expression raises a point of concern, as an
increase in the expression of a specific gene does not always equate to an increase in
the amount of protein that is being synthesised, and questions its functional
relevance. However, at the time of conducting these experiments there were no
antibodies available to facilitate the study of protein expression in either lymphoid
tissues or cells of components of the Notch pathway.
Indeed most of the work that has been done involving the differential expression of
Notch receptors or ligands or intracellular mediators in the pathway, has relied on
gene expression at the RNA level. Felli et al (73) investigated the expression of
Notch-1, -2 and -3, Jagged-1 and -2, and Hes-1 and -5 in lymphoid and stromal
components of murine thymus, by Northern blot analysis. Similarly, Kaneta et al
(180) investigated by RT-PCR the expression of Notch receptors, ligands and Hes
molecules in individual thymocyte populations (double negative, double positive and
single positive) and thymic stroma. As well, Deftos et al (85) used Northern blot
analysis to demonstrate that constitutive intracellular Notch in a double positive
thymoma cell line provided a continuos source of Notch activity, that led to an up
regulation of the intracellular Notch mediator Deltex. They also analysed by RT-PCR
expression levels of Deltex (85) and Hes-1 (86) in double positive, double negative
and single positive thymocytes.
Therefore, having confirmed by RT-PCR that lymphoid tissues and organs express
genes associated with the Notch pathway and TGF-(3-related genes, I wanted to
characterise by real-time PCR if these genes were modulated during the activation of
CD4+ T cells or APC populations in vitro.
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I choose to look at CD4+ T cells based on our previous findings that DCs over-
expressing Jagged-1 could induce a population of antigen-specific regulatory CD4+ T
cells (99), therefore, I was interested in investigating if Notch signalling was active
in other type of CD4+ T cell responses. B cells were chosen as the source of APCs,
for practical reasons. They are very abundant in the spleen, their isolation by
magnetic beads (unlike dendritic cells) yields a very pure population, and they can be
easily activated in vitro. C57BL/6 CD4+ T cells were activated using anti-CD3 and
anti-CD28 antibodies for 24 and 48 hours, and C57/BL6 B cells were stimulated with
LPS for 24, 48 and 72 hours. The RNA was extracted from these cell populations,
checked for genomic DNA contamination and reverse transcribed into
complementary DNA (cDNA). Real-time PCR using fluorogenic probes was used to
measure expression levels of Notch-1 and 2, Jagged-1 and 2, Delta-1 and 3, Hes-1,
Deltex, Activin A, and TGF-/3. Noggin and BMP-4 were also included, however, only
the data for Noggin in B cells is shown, as no message was detected in any of the
other samples tested.
18S rRNA was used as the endogenous control to which all the samples were
normalised. Wild type (wt) untreated CD4+ T cells or B cells from the spleens of 6-8
weeks old C57BL/6 mice were used as the positive control (calibrator), against
which the data from the activated CD4+ T cell or B cell samples were made relative
to. Therefore, the calibrator was assigned a value of 1. The values obtained after real¬
time PCR analysis for each gene were plotted as individual graphs (Figures 6 and 7).
An important point to address is what fold-increase in the level of expression of a
specific gene relative to the calibrator is regarded as significant. The work of
Chtanova et al (181) described the differential expression of genes in Thl and Th2 as
well as CD8+ T cells (Tel) and Tc2, by using microarray analysis. They found the
same patterns of gene expression when they compared their results to real-time PCR,
and established that genes were differentially expressed if a change of at least two¬
fold or greater was observed. Similarly, Granucci et al (182) used microarray
analysis to investigate differential effects of TNF-a versus LPS on DC priming.
Again, they only considered differential regulation of gene expression where at least
87
a two-fold change in the level of mRNA expression was observed compared to the
control.
There, is however, no specific consensus as to what is considered a significant fold
increase. Other groups include statistical analysis (error bars) where the samples
have been run in triplicates (183, 184), or where the values represent the means of
more than three independent experiments (185), to address significant changes in
gene expression. Further still, other groups do not comment on what they consider
significant or not (186, 187).
In view of the lack of consensus, I relied on the work of Chtanova et al (181) and
Granucci et al (182) to consider a fold-increase in gene expression of 2.5 or greater
above the calibrator as significant.
It is important to mention that the data displayed for Hes-1 prior to the review of this
thesis showed that Hes-1 was up regulated in CD4+ T cells by more than 200-fold
after 48 hours of activation. However, this data was included by mistake in Figure 6
and corresponded to Hes-1 primers that were found to anneal to genomic sequences.
This data has been replaced in Figure 6 by the data obtained from a different set of
Hes-1 primers that was tested in all the samples analysed for the work presented in
this thesis.
Figure 6 reveals that upon TCR-mediated CD4+ T cell activation, levels of
expression for the Notch receptors -1 and -2 are similar to the untreated, wild type
(wt) CD4+ population. However, a very different pattern emerges for the Notch
ligands. Jagged 1 and Jagged 2 are significantly up regulated (20-fold and 7-fold,
respectively) 24 hours after activation, although by 48 hours the levels drop. More
so, Delta-1 is up regulated by about 50-fold relative to wt CD4+ T cells, as well 24
hours after TCR-mediated activation.
Interestingly, the increased expression of the Notch ligands correlates with a
significant up regulation at the same time point of Hes-1 (7-fold), suggesting Notch
signalling may have occurred in the activated population by 24 hours. Furthermore,
the observation that Deltex levels go down upon activation suggests that CD4+ T
cells may not be using Deltex as a downstream target of Notch signalling. The TGF-
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p-like molecule activin A is significantly up regulated by 24 hours following
activation (50-fold), whereas transcripts for TGF-fi do not change.















Delta-1 Hes-1 Deltex Activin A TGF-fi
naive 24hrs 48hrs naive 24hrs 48hrs naive 24hrs 48hrs naive 24hrs 48hrs naive 24hrs 48hrs
Activation with anti-CD3/anti-CD28 antibodies
Figure 6. Activating CD4+ T cells in vitro leads to differential regulation of Notch signalling and
TGF-/3 superfamily genes. Splenic CD4+ T cells were MACS purified from C57BL/6 mice and
activated with lpg/ml of anti-CD3 and 5pg/ml of anti-CD28 antibodies. The cells were collected after
24 or 48 hours, and the RNA was extracted, and reverse transcribed for cDNA synthesis. The samples
were tested for gene expression (Notch-J and 2, Jagged-1 and 2, Delta-1, Hes-1, Deltex, Activin A and
TGF-fi) by real-time PCR analysis. For each gene, there was a positive control, which was the wt
(naive) CD4+ T cell population to which all the values are made relative, and a negative control (no
cDNA) to ensure there was no genomic DNA contamination. Furthermore, an internal control, 18s
rRNA, was included per sample as a monitor of the PCR reaction and of the amount of cDNA used. A
2.5-fold increase above the positive control is regarded as significant (in orange).
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naive 24hrs 48hrs 72hr naive 24 hrs 48 hrs 72 hrs
TGF-ft
naive 24 hrs 48 hrs 72 hrs naive 24 hrs 48 hrs 72 hrs
Figure 7. Activating B cells in vitro leads to differential regulation of Notch signalling and
TGF-/3 superfamily genes. Splenic B cells were MACS purified from C57BL/6 mice and
activated with lOOpg/ml of LPS. The cells were collected after 24, 48 or 72 hours, and the
RNA was extracted, and reverse transcribed for cDNA synthesis. The samples were tested for
gene expression (Notch-1 and 2, Jagged-1 and 2, Delta-1 and 3, Hes-1, Deltex, Activin A,
Noggin and TGF-/5) by real-time PCR analysis. For each gene, there was a positive control,
which was the wt (naive) B cell population to which all the values are made relative, and a
negative control (no cDNA) to ensure there was no genomic DNA contamination.
Furthermore, an internal control, 18s rRNA, was included per sample as a monitor of the PCR
reaction and of the amount of cDNA used. A 2.5-fold increase above the positive control is
regarded as significant (in orange).
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Interestingly, Figure 7 reveals a very different pattern of gene expression. Activated
B cells significantly up regulate Notch 1, which by 24 hours has more than a 15-fold
increase in expression relative to the control. In addition, levels of Notch-1 are
maintained even 72 hours after activation. Similar to CD4+ T cells, the Notch ligands
Jagged-2 and Delta-1, and in addition Delta-3, are also significantly up regulated by
24 hours following activation (6-fold, 7-fold and 4.5-fold, respectively), but by 48
hours levels drop to and below the calibrator. Activin A shows a similar patterns of
gene up-regulation to the Notch ligands, a significant (4.5-fold) induction by 24
hours that drops sharply by 48 hours, whereas TGF-/3 message steadily increases,
peaking at 72 hours (more than 5-fold). Interestingly, Hes-1 expression in B cells
drops at 48 hours, whereas Deltex expression increases steadily, and peaks at 72
hours (8-fold), suggesting that Deltex may be the downstream transducer of Notch
signalling in B cells.
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3. Discussion
At the time of starting this work for my PhD, little information was available
regarding the expression of Notch signalling genes as well as the neural inducers and
TGF-(3-like inhibitors, in peripheral lymphoid organs and cells. I was prompted to
study their expression in the spleen, thymus and lymph nodes of adult wild type mice
(C57BL/6 and BALB/c), as well as in splenic lymphocytes and DCs. This would
provide us with a better understanding of their potential role in peripheral immunity.
By RT-PCR I studied the expression of Notch-1 -2 and -4 receptors, the Notch
ligands, Jagged-1, -2 and Delta-1, and the downstream target gene, Hes-1 (Figure 2).
Notch 2 was strongly expressed in all the organs tested of both mouse strains,
consistent with the finding that Notch-2 is highly expressed in the spleen (188).
Notch-4 was weakly expressed and Notch-1 was also found in all the tissues,
including the thymus, confirming the findings of previous reports (73). The ligand
Delta-1 and the downstream intracellular effector, Hes-1, were expressed in all the
organs of both mouse strains, and Jagged-1 and Jagged-2 showed differential
expression in the various organs, but were both present in the thymus consistent with
the work of other groups (73, 189, 190). As well, the findings of Jagged-1 expression
in spleen and lymph nodes agreed with the work of Bash et al (191).
Isolation of the different splenic lymphoid populations, namely CD4+, CD8+, B and
DCs, gave further insight into the differential regulation of the Notch signalling
genes in cells of the immune system (Figure 5). Consistent with the previous data,
Notch-2 was strongly expressed in all cell types, whereas Notch-4 and Jagged-2 were
weakly expressed. Jagged-1 was preferentially expressed in DCs, and Delta-1 and
Hes-1 in B cells and DCs.
By RT-PCR I also examined the expression of the neural inducer, noggin, and the
TGF-(3-like neural inhibitors activin A and BMP-4 in lymphoid organs (spleen,
thymus and lymph nodes) and lymphoid cells (Figure 3). I found that noggin and
BMP-4 were only weakly expressed in lymphoid tissues, whereas activin A was
highly expressed. A similar pattern of expression of these genes was observed within
individual splenic CD4+, CD8+, B cells and enriched DC populations (Figure 5). This
study reports for the first time the expression of Notch signalling genes and neural
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inducers/inhibitors in lymphoid tissues and cells of adult mice, and provides valuable
information as to their possible involvement in the immune system.
CD4+ T cells and B cells were also activated in vitro to study the changes in gene
expression of the Notch signalling and TGF-(3-like signalling genes.
The cells were isolated by positive selection using antibody-labelled magnetic
microbeads specific for each cell type. These remain attach to the cells throughout
the isolation procedure and therefore, I cannot exclude the possibility that binding of
the antibody may trigger signalling pathways that interfere with the expression of
components of the Notch pathway. Nevertheless, it has to be considered that all the
cells were isolated by the same procedure. Therefore, as far as real-time PCR gene
analysis is concerned, any effects triggered by the MACS antibodies contribute
equally to all the samples. In effect, as untreated cells become the calibrator, any
changes within this population constitute baseline levels, and therefore, the changes
observed for all the other samples relative to the calibrator represent real differences
in gene expression.
CD4+ T cells were activated via their T cell receptor, TCR, with anti-CD3 antibody
and the co-stimulatory molecule, CD28, and B cells were activated via their Toll-like
receptor, TLR-4, using LPS (192). The expression of genes was monitored by real¬
time PCR. I observed (Figure 6 and 7) that the expression of the Notch ligand genes,
Jagged-2 and Delta-1 were both significantly up-regulated in the lymphocyte
populations following activation. From this observation I could make the assumption
that activation of lymphocytes affects a common downstream signalling pathway that
results in transcriptional activation of the Notch ligand genes. Indeed, one possible
candidate is nuclear factor kB (NF-kB), which is found in all cell types and is
activated in response to a variety of extracellular stimuli, including LPS, microbial
and viral pathogens, cytokines and growth factors (193, 194). Mammalian cells
contain five NF-kB subunits; RelA (p65), c-Rel, RelB, p50 and p52, which form
various hetero-and homo-dimers. Activation of NF-kB in the cytoplasm involves
liberation of the dimers from a family of inhibitory proteins (IkBs), and their
translocation to the nucleus where they activate transcription of target genes,
93
including cytokines, chemokines, immunoreceptors, growth factors, acute phase
proteins and adhesion molecules (195).
NF-kB is activated in B cells after mitogenic stimulation (196), and in T cells after
anti-CD3/anti-CD28 antibody-mediated activation (197, 198), suggesting that NF-kB
might be the common transcription factor that affects Notch ligand gene expression
after lymphocyte activation. Evidence for this was provided by the studies of Bash et
al (191) who used the CCR43 cell line, which conditionally expresses c-Rel under
the control of a tetracyclin-regulated transactivator. c-Rel expression in these cells
led to induction of Jagged-1 transcripts. Similarly, they used phorbol 12-myristate
13-acetate (PMA) plus ionomycin to activate endogenous NF-kB factors in human
Jurkat T cells. They found that under these conditions, there was a 4-fold increase in
Jagged-1 mRNA levels compared to unstimulated cells. Furthermore, when they co-
cultured the c-Rel expressing CCR43 cell line with Jurkat T cells, there was a 2- to 3-
fold increase in Hes-1 levels in the Jurkat T cells. This would suggest that NF-kB up-
regulates Jagged-1 expression in the CCR43 cells, which in turn activates Notch
signalling in the neighbouring Jurkat T cells. Furthermore, other groups have also
shown an association between Notch signalling and the NF-kB pathway (98, 199,
200).
Therefore, the in vitro real-time data support a model whereby activation of
lymphocytes may lead to activation of NF-kB, which in turn induces transcription of
the Notch ligands, Jagged-2 and/or Delta-1.
This investigation can be carried out by performing electrophoretic mobility shift
assays (EMSAs). This technique can identify the DNA binding activity of
transcription factors in the nuclear extracts of cells, as they anneal to radioactively
labelled oligonucleotides containing their specific DNA binding sites. In addition,
the DNA binding capacity of individual components within the transcription factors
can be tested by the use of specific antibodies. The assumption that NFkB activation
leads to Jagged-2 and/or Delta-1 transcription, could be investigated in two different
ways. One way could involve the over-expression of IkB, which upon cellular
activation would inhibit NFkB translocating to the nucleus and binding to its specific
consensus sequence on the DNA. Therefore, it would prevent the transcription of
target genes, such as Jagged-2 and/or Delta-1. EMSA would detect the inhibition of
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NF-kB from binding to its probe. An alternative approach would be the use of
dominant negative mutants of NF-kB, which retain their DNA binding capacity but
contain a mutation in the p65 subunit which blocks transcription. In this way NFkB
binding would still be visualised by EMSA, but its function as a transcriptional
activator would be inhibited, thus affecting expression of target genes.
Expression of Hes-1 and Deltex were also assessed in this study. Both are
intracellular mediators of the Notch pathway. Interestingly, both were up regulated in
CD4+T cells and B cells, respectively, suggesting that Notch signalling was active in
these cells.
Hes-1 up-regulation results from the binding of the Notch receptor to its ligand,
Jagged or Delta. After ligand binding, translocation to the nucleus of the intracellular
portion of Notch promotes Hes-1 transcription. In developmental studies, Hes-1 has
been defined as a transcriptional repressor of Mash-1 activity (32). The mechanism
of repression of Hes-1 involves three proteins, the bHLH and Orange domains which
repress specific transcriptional activators, and the WRPW domain which binds to
corepressors that inhibit other activators (84). In development it has been defined as
a negative regulator of neurogenesis. Ishibashi et al (201) found that in the
developing brains of Hes-F/_ embryos expression of the neural differentiation factor
Mash-1 was up-regulated and post-mitotic neurons appeared prematurely. Therefore,
they concluded that by limiting the expression of Mash-1, Hes-1 was participating in
mechanisms that control the timing of neurogenesis. In other studies they have
demonstrated that over-expression of Hes-1 in precursor cells represses Mash-1
activity and leads to a block in neuronal differentiation in the brain and retina (202).
Hes-1 has also been implicated as a transcriptional repressor during thymocyte
development (84). Kim et al determined by EMSA that Hes-1 was binding a
functional site in the CD4 silencer, which repressed the CD4 promoter, and led to a
down regulation of endogenous CD4 expression in CD4+ Th cells.
In similar experiments I could use EMSAs to confirm the up-regulation of Hes-1 in
activated T cells, as they reveal or not its DNA binding activity.
Another gene, Deltex, is also involved in regulating Notch signalling, through a Hes-
1-independent way (79, 203). Deltex encodes a protein that physically interacts with
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the Notch ankyrin repeats in the intracellular portion (203, 204). Matsuno et al (204)
defined Deltex as a positive regulator of the Notch pathway. Additionally Deftos et
al (85) have proposed that Deltex is a target of Notch signalling in T cell
development. They found that over expression of NotchIC in a double positive
thymoma cell line, led to an up regulation of Deltex.
Although Hes-1 was up regulated in CD4+ T cells and Deltex in B cells, it is
unknown how their effects on transcription of other target genes would participate in
the events that follow activation of these cells, such as differentiation, cytokine
secretion or cell survival.
In this study I have shown that genes of the Notch and TGF-(3 superfamily signalling
pathways are differentially expressed in lymphoid tissues and cells. Furthermore, the
finding that activation of lymphocytes up regulates Notch ligand expression suggests
that a common downstream effector molecule such as NF-kB may affect




Expression of Notch Signalling Genes in CD4+ T
Cells during Priming or Tolerance Induction
1.1 Background
Notch is a highly conserved transmembrane protein that can bind to two separate
families of ligands, Delta and Jagged (32). Activation of the Notch receptor after
ligand binding leads to a series of intracellular events that affect transcription of
certain target genes, involved in the specification of cell and tissue fates during
development (33). The signalling pathway is evolutionarily highly conserved and has
been described in Drosophila and vertebrates, including man (31). Its involvement in
the immune system is known from studies that have associated Notch signalling with
different stages of thymocyte and myeloid differentiation (69, 73, 74). We have also
demonstrated that the Notch signalling pathway may be important in regulating
peripheral immune responses, as over-expression of the Notch ligand, Jagged-1, in
DCs, induced a population of antigen-specific regulatory T cells that was capable of
transferring tolerance to recipient mice (99).
Additionally, in Chapter III I have provided evidence to show that the Notch ligands
(Figure 6) are differentially regulated when CD4+ T cells are activated in vitro with
anti-CD3 and anti-CD28 antibodies. Although the mechanism of Notch ligand up
regulation after CD4+ T cell activation is still unknown, I was prompted to
investigate whether the same effect would be seen in vivo, and more importantly if
two different modes of CD4+ T cell activation would result in differential regulation
of the Notch pathway genes. One mode results in the differentiation of effector CD4+
T cells and the other in the differentiation of regulatory CD4+ T cells. For this
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purpose I used a murine model of CD4+ T cell recognition of the immunodominant
peptide (pi 10-130) derived from the group 1 allergen of house dust mite (HDM).
Initially, the experimental set up for these in vivo studies entailed intranasal
administration of pi 10-130 on three consecutive days which induces tolerance, or
when injected intraperitoneally in the presence of incomplete Freund's adjuvant,
primes mice for a Thl response. However, results from these experimental protocols
are compromised by the fact that the route of antigen administration is different, and
therefore, I cannot control for the differences in antigen delivery to the spleen, which
was the chosen organ of study. Thus the two modes cannot be compared directly
which restricts the analysis of gene expression of components of the Notch pathway.
In order to control for this limitation, further experiments were performed in which
pi 10-130 was administered via the intranasal route to induce either tolerance or
productive immunity. The latter can be achieved with the use of mucosal adjuvants.
In this study I have used Eschericchia coli heat labile enterotoxin (LT), which when
administered via the respiratory mucosa acts as a powerful adjuvant in combination
with soluble antigen.
This section is divided into two parts. In the first part I report on the experimental
conditions that had to be optimised for the priming protocol using LT, as this
information was not available at the time of carrying out this investigation. In the
second part I report on the patterns of gene expression of components of the Notch
signalling pathway, in splenic CD4+ T cells from mice that had been tolerised or
primed to house dust mite pi 10-130 via the respiratory mucosa.
1.2. The immunisation protocols
Mucosal surfaces provide a physical barrier between the external environment and
the body, and substances that come into contact with the respiratory mucosa usually
do not interact with them. However, those that do will encounter the nasal associated
lymphoid tissue (NALT) and the bronchial associated lymphoid tissue (BALT). Both
structures are important for the induction of either immunity or tolerance. Encounter
of harmless environmentally derived antigens will lead to tolerance, whereas the
98
presence of pathogenic substances can trigger a powerful immune response.
Experimentally, tolerance can be induced when soluble antigen is administered
intranasally (11, 12, 13), whereas in combination with bacterial-derived toxins such
as cholera toxin or E. coli heat labile toxin (LT), a strong immune response is
elicited.
LT is a powerful mucosal immunogen when administered at a high dose on its own,
and in combination with antigen at lower doses acts as a mucosal adjuvant (205). LT
belongs to a family of AB5 bacterial toxins consisting of a pentameric B oligomer
that binds the receptor(s) on the surface of eukaryotic cells, and an enzymatically
active A subunit that is responsible for the toxicity. The B subunit can act as a
mucosal adjuvant following intranasal delivery. This has been shown in studies
looking at responses to a range of antigens including herpes simplex virus,
glycoproteins, influenza virus haemagglutinin, Streptococcus pneumoniae
pneumolysin and diptheria toxoid (206).
LT is a weak toxin for mice, but highly toxic for humans, therefore, in attempts to
use LT as a vaccine or an immunomodulator in the treatment of diseases, mutants of
the protein have been developed that retain adjuvant effect but lose toxicity.
Takahashi et al (207) assessed LT both as an immunogen and as an adjuvant for
tetanus toxoid (TT). They showed that oral administration of 25gig of LT alone to
BALB/c mice could induce high levels of IgA in faecal extracts and IgGl, IgG2a and
IgG2b in serum. Additionally, cells from Peyer's patches and spleen, re-stimulated in
vitro with LT produced both Thl and Th2 cytokines. Additionally, LT had adjuvant
properties when administered orally at lower doses (lOjig) in the presence of tetanus
toxoid. The antibody isotype response and the expression of cytokine mRNA was
identical to that seen when mice were orally immunised with LT alone, but not when
TT was given alone.
The first, and to date only study to report on the effects of a HDM peptide given
intranasally on the response to subsequent respiratory immunisation has come from
Jarnicki et al (208). Conventionally, intranasal exposure of mice to house dust mite
peptides can induce tolerance which is not reversed by injection of the whole protein
in complete Lreund's adjuvant (11). Jarnicki et al investigated the effects of
99
respiratory, rather than parenteral sensitisation following intranasal peptide exposure.
For this they used a mutated subunit of E.coli LT which has little toxicity and
enhanced adjuvant activity. The adjuvant in the presence of Der p 1 protein induced a
rise in IgE titers as well as Th2-associated cytokines. However, prior exposure to
intranasal pi 14-128 or Der p 1 protein did not alter IgE titers but led to a reduction in
the levels of the Th-2-associated cytokines IL-4 and IL-13 (but not IL-2,1L-5,1L-10
or IFN-y).
The basis of this study was to determine the concentration of LT required as a
mucosal adjuvant in the presence of one of the major CD4+ T cell epitopes of house
dust mite, peptide 110-130. Different groups have used different amounts of LT as
adjuvants for their experiments. Bowman and Clements (209) used 10pg of tetanus
toxoid and 5qg of LT to immunise mice intranasally once per week for three weeks.
Alternatively, Jarnicki et al (208) treated mice intranasally with lOOpg of house dust
mite peptide 118-126 in combination with lOptg of a mutated form of LT. In contrast,
Millar et al (210) used LT at a range of concentrations (0.6, 6 and 30pg) in
combination with lpg of hen egg lysozyme to treat mice intranasally on two
occasions, seven days apart. Therefore, in the context of each experimental model, it
is very important to establish the right concentration at which LT on its own will not
induce an immune response, but in combination with antigen will act as an adjuvant.
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Figure 1 shows that 5pg of LT on its own given intranasally (which is within the
concentration range of what other groups have used as an adjuvant-references 208,
209, 210) was enough to prime mice to house dust mite. Jarnicki et al (208)
administered intranasally lOfig of a mutated form of LT with lOOpg of pi 14-128,
however, they did not report on the responses to HDM peptide after intranasal
admisnitration ofLT alone.
The splenic CD4+ T cells proliferated vigorously when stimulated in vitro with the
major CD4+ T cell epitope pi 10-130, at day 7 after the intranasal treatment (Figure
1). As the mice were housed in conventional cages, small amounts ofHDM antigens
would be expected to be present in their environment. Thus if given at too high a
dose, LT can induce a response to traces of foreign bystander antigen present
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Figure 1. 5pg of E.coli heat-labile toxin (LT) can prime
mice to environmental HDM antigen. Two C57BL/6 female
mice were set up per group. The mice were administered
intranasally once with 5pg of E.coli LT. At days 2, 4 and 7
after the immunisation the spleens were removed, and the
cells from each group pooled and cultured in round-bottomed
96-well plates at 4xl05 cells/well in the presence of varying
concentrations of pi 10-130 (0.1, 1 10 pg/ml). The cells were
cultured for 3 days, and pulsed with 2.5pCi 3[H]dT for the last
16 hours before harvesting.
a = p<0.001 for O.lpg/ml pi 10-130 at day 7 versus the
corresponding concentration at day 2. NA = not available.
The points without a label are not significant with respect to
day 2.
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Therefore, to determine the concentration of LT to use, where no response to
environmental antigen was detectable, mice were immunised intranasally with LT at
a range of concentrations (Figure 2). The spleens were removed at day 7 after
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Figure 2. High doses of E.coli heat-labile toxin (LT) alone can prime mice to environmental
HDM antigen. Two C57BL/6 female mice were set up per group. The mice were administered
intranasally once with varying concentrations of E.coli LT (0.01, 0.03, 0.1, 0.3, lpg) or with
saline (PBS) alone as a control group. At day 7 after LT administration the spleens were removed
and the cells from each group pooled, and cultured in round-bottomed 96-well plates at 4x105
cells/well in the presence of varying concentrations of pi 10-130 (0.1, 1 10 pg/ml). The cells were
cultured for 3 days, and pulsed with 2.5pCi J[H]dT for the last 16 hours before harvesting,
a = p<0.001 at lOpg/ml pi 10-130 for lpg LT versus its corresponding concentration in the PBS
group.
c = p<0.05 at 0.1, lpg/ml or lOpg/ml pi 10-130 for 0.3pg or lpg LT groups versus their
corresponding concentrations in the PBS group. The points without a label are not significant
with respect to the PBS group.
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Low doses of LT administered intranasally did not prime mice to pi 10-130, and the
proliferative responses of splenic CD4+ T cells in vitro were comparable to mice
given saline alone. However, a dose as low as 0.1 pg of LT already showed a subtle
difference with respect to the control group, and when the dose was increased to 0.3
or lpg of LT, the CD4+ T cells responded in a dose-dependent manner to pi 10-130.
This experiment demonstrates the powerful adjuvant effect of LT, and shows the
importance of titering the concentration of this molecule for the experimental context
in which it is being used.
At this point another experiment was necessary to determine whether a low dose of
LT was sufficient to use as a mucosal adjuvant in combination with pi 10-130. The
effect of 0.03pg of LT, which had no effect on HDM peptide CD4+ T cell responses
in vitro (Figure 2), was compared against higher doses (0.1 and 0.3pg) in the
presence of lOOpg ofpi 10-130 given intranasally (Figure 3).
[pi 10-130) pg/ml
Figure 3. Low doses of E.coli LT in the presence of HDM
pll0-130 can prime mice to the peptide. Two C57BL/6 female
mice were set up per group. The mice were immunised
intranasally once with 100pg of pi 10-130 alone or in the
presence of varying concentrations of E.coli LT (0.03, 0.1 and
0.3pg). Mice were administered saline (PBS) intranasally as a
control group. At day 7 after the immunisation the spleens were
removed and the cells from each group pooled, and cultured in
flat-bottomed 96-well plates at 4xl05 cells/well in the presence of
varying concentrations of pi 10-130 (0.1, 1 10 pg/ml). The cells
were cultured for 3 days, and pulsed with 2.5juiCi 3[H]dT for the
last 16 hours before harvesting.
a = p<0.001 for each LT group at 0.1, 1 or lOpg/ml of pi 10-130
versus the PBS group alone.
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Figure 3 shows that by day 7 after the immunisation, lOOfxg of peptide alone was not
enough to trigger a CD4+ T cell response to the peptide vitro, and the response
induced was the same as that observed in the control group of mice which received
saline alone. However, when the peptide was given in combination with as little as
0.03pg ofLT, the splenic CD4+ T cells displayed proliferation responses to pi 10-130
in a dose-dependent manner. These increased accordingly if the concentration of LT
was raised to 0.1 or 0.3 pg, however, these had proved to have weak adjuvant
activity when given alone (Figure 2). Therefore, from this experiment the optimal
concentration of LT to use as a mucosal adjuvant was established at 0.03 pg. It is
worth mentioning that LT was not used in these experiments to break tolerance, since
lOOpg of peptide given intranasally were insufficient to establish a tolerogenic
response (data not shown).
Mice were, therefore, primed with lOOpg of pi 10-130 and 0.03pg of LT and the
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Figure 4. Priming C57BL/6 mice to HDM pi 10-130 using E.coli LT as a mucosal adjuvant.
A. Two C57BL/6 female mice were set up per group. The mice were treated intranasally once with
0.03pg of E.coli LT alone or in the presence of lOOpg of pi 10-130. At days 2, 4 and 7 after the
immunisation the spleens were removed, and the cells from each group pooled and cultured in flat-
bottomed 96-well plates at 4xl05 cells/well in the presence of varying concentrations of pi 10-130 (0.1, 1
10 pg/ml). The cells were cultured for 3 days, and pulsed with 2.5pCi [H]dT for the last 16 hours before
harvesting. B The same experiment as (A) but represented is the proliferative response of CD4+ T cells
from the LT and LT+peptide-treated groups to pi 10-130 at lOpg/ml over the seven day period,
a = p<0.001 for day 7 LT+pep group at 1 or lOpg/ml of pi 10-130 versus the day 7 LT group alone. The
points without a label are not significant with respect to the LT groups.
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Mice primed intranasally with 0.03pg of LT alone did not respond to pi 10-130 when
splenic CD4+ T cells were re-stimulated in vitro with the peptide (Figure 4A).
However, when given intranasally in the presence of 100)ag of pi 10-130, CD4+ T
cells proliferated maximally in a dose-dependent manner by day seven after the
immunisation (Figure 4B).
Having optimised the conditions of priming, mice were challenged with peptide
alone for tolerance induction. The observation of Hoyne et al (11, 12) demonstrated
that mice given lOOpg of pi 11-139 in saline intranasally on three consecutive days
became unresponsive to immunogenic challenge with the whole Der p 1 protein in
complete Freund's adjuvant. The lymph node T cells from these mice were
unresponsive to whole Der p 1 protein and Der p 1 peptides in vitro (11).
Furthermore, the cervical lymph node and splenic T cells from tolerised mice
secreted high levels of IL-2, IL-3 and IFN-y at day 4 after intranasal challenge, but
levels dropped by day 8, suggesting that CD4+ T cells underwent transient activation
before the induction of tolerance (12). This same immunisation protocol was used for
the induction of tolerance using house dust mite peptide 110-130. Spleen T cells
were re-stimulated in vitro with the same peptide at days 2, 4 and 7 after the last
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Figure 5. Intranasal administration of HDM pi 10-130 induces tolerance. Two C57BL/6 female
mice were set up per group. The mice were treated intranasally on three consecutive days with lOOpg of
HDM pi 10-130 or saline alone. At days 2, 4 and 7 after the last immunisation the spleens were
removed, and the cells from each group pooled, and cultured in flat-bottomed 96-well plates at 4xl05
cells/well in the presence of varying concentrations of pi 10-130 (0.1, 1 10 pg/ml). The cells were
cultured for 3 days, and pulsed with 2.5pCi 3[H]dT for the last 16 hours before harvesting.
B. The same experiment as (A) but represented is the proliferative response of CD4+ T cells from the
PBS and PBS+peptide-treated groups to pi 10-130 at lOpg/ml over the seven day period,
a = p<0.001 for day 2 and 4 PBS+pep groups at 1 or lOpg/ml pi 10-130 versus day 2 and 4 PBS groups
alone, respectively. The points without a label are not significant with respect to the PBS groups.
Mice that received saline alone did not respond to pi 10-130 when splenic CD4+ T
cells were re-stimulated in vitro with the peptide (Figure 5A). However, splenic
CD4+ T cells from mice that received the peptide intranasally could already respond
by day 2 after the last antigenic challenge, and by day 4 there was maximal T cell
response (Figure 5B). By day 7 proliferation dropped to levels of the control group.
Therefore, these results are in agreement with those ofHoyne et al (12).
Since tolerance can be transferred by CD4+ T cells isolated from mice that have
received peptide intranasally, it seems that Tr cells may have been induced. The
inhibitory cytokine IL-10 is associated with their induction (211) and effector
function (212, 213) therefore, I was prompted to analyse by real-time PCR
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expression of IL-10 in CD4+ T cells during the induction of intranasal peptide
tolerance or priming. In the original experiments presented in this thesis, where mice
had been tolerised or primed by peptide given intranasally or intraperitoneally,
respectively, the real-time data had revealed an up regulation of IL-10 in the CD4+ T
cells of tolerised mice by day 2 after the last peptide treatment. However, this pattern
of gene regulation was not observed in the CD4+ T cells of primed mice. I concluded
that perhaps the up-regulation of IL-10 was associated with the differentiation of Tr
cells in this model of mucosal tolerance. However, it is possible that this difference
in gene expression may have resulted from variability in the kinetics of antigen
delivery to the spleen and activation of the CD4+ T cells, as the routes of antigen
administration differed for both experimental groups. In this set of experiments
expression of IL-10 was also assessed by real-time PCR to determine if the gene was
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Figure 6. IL-10 expression is not modulated during intranasal
tolerance or priming induction. Mice were tolerised or primed to
pi 10-130 as described in Figures 4 and 5. The spleens from each group
of mice were removed after the last intranasal treatment and CD4+ T
cells were isolated by negative selection. The RNA was extracted and
reversed transcribed for cDNA synthesis. The samples were tested for
gene expression (IL-10) by real-time PCR analysis. The gene was run
with a positive control, which was the untreated CD4+ T cell
population (N) to which all the samples are relative, and with a
negative control (no cDNA) to ensure there was no genomic DNA
contamination. Furthermore, an internal control, 18srRNA, was
included per sample as a monitor of the PCR reaction and of the
amount of cDNA used. A 2.5-fold increase above the positive control
is regarded as significant.
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The data presented in Figure 6 show that priming mice with LT and peptide did not
affect the expression of IL-10 compared to the control or untreated CD4+ T cells.
Additionally, treating the mice intranasally with saline or peptide in saline did not up
regulate expression of IL-10.
The data so far presented show the effects on systemic CD4+ T cell activation of two
different experimental protocols that rely on the CD4+ T cell epitope of house dust
mite peptide 110-130. Both use the same route of antigen delivery (nasal route) but
the outcome is very different. Giving E.coli LT once in combination with lOOpg of
pi 10-130 primes mice to this peptide by day 7. In contrast, when lOOpg of the
peptide are given in saline alone on three consecutive days the mice undergo an
initial phase of CD4+ T cell activation which peaks at day 4, before becoming
unresponsive by day 7.
1.3. Expression of Notch signalling in CD4+ T cells during
peripheral immune responses
The role of Notch in lymphocyte development has been studied over the last 5 years.
Gene expression studies have revealed expression of the four Notch receptors, as
well as the Notch ligands Jagged-2 and Delta-1 in double negative, double positive
and CD4/CD8 single positive thymocytes from adult mice (73, 180). Functional
studies to address the role of Notch signalling in lymphocyte development have
relied mainly on the use of two independent experimental systems. One involves
gain-of-function approaches, mainly over-expressing the intracellular portion of
Notch (NotchIC) with cell or tissue-specific promoters, or by retrovirally transducing
NotchIC into bone marrow precursors (to study B versus T lineage fate), thymocytes
or thymoma cell lines (to study CD4 versus CD8 and a(3 versus y5 commitment).
The other is a loss-of-function approach that relies on the Cre/loxP recombination
system in bone marrow precursors or thymocytes, where lox P sites are introduced to
delete a portion of the Notch-1 gene by the Cre-recombinase enzyme. Using these
experimental systems different groups have demonstrated that Notch signalling
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favours T cell over B cell specification (74, 75), a(3 over y5 lineage commitment (81,
82) and may play a role in CD4/CD8 T cell differentiation (83, 85, 86), although the
data for the latter is still very conflicting. A more detailed account of the role of
Notch in lymphopoiesis is given in the Introduction (section 5.1.2).
Very few studies have addressed the role of Notch signalling in the adult immune
system. The first report came from our group (99). Murine DCs were transfected
with Jagged-1 and pulsed with the house dust mite peptide 110-131 before injecting
into mice, which were primed with whole Der p 1 protein two weeks later. Lymph
node cells from these mice were unresponsive to re-stimulation in vitro with the
whole protein or HDM peptides. Additionally, when CD4+ T cells from mice that
had received the Jagged-1-infected DCs were transferred to recipient mice and the
latter primed with whole Der p 1, the mice showed reduced LN responses to the
protein in vitro. This study demonstrated the ability of Jagged-1 on DCs to induce a
population of regulatory T cells which could also transfer tolerance.
More recently Wan Fai Ng et al (187) have shown by real-time PCR analysis that
transcripts for Delta-1, Notch-4 and Hes-1 were up-regulated in human CD4+CD25+
T cells after activation with anti-CD3/anti-CD28 antibodies compared to CD4+CD25"
T cells, whereas levels of Deltex were down-regulated.
Having established the immunisation protocols to induce tolerance or productive
immunity via the nasal route with the major CD4+ T cell epitope of HDM, peptide
110-130, I addressed the question as to whether or not functionally different
outcomes of antigen recognition also affected expression of components of the Notch
signalling pathway. Mucosal tolerance induced by pi 10-130 delivered intranasally
induces a population of regulatory CD4+ T cells, (11, 12, 13) which remain
unresponsive to re-stimulation in vitro with whole Der p 1 protein or peptides,
whereas nasal priming results in the generation of effector Th2-like CD4+ T cells
(208). Therefore, I selected to analyse whether or not the functional difference in
CD4+ T cells in pi 10-130 primed and tolerised mice, correlated with a difference in
gene expression of components of the Notch pathway. The results of this study
would provide with further information on the involvement of the Notch pathway in
peripheral immune responses, and more specifically in the induction of tolerance
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and/or productive immunity. At the present time there is a lack of antibody reagents
that can be used to specifically identify expression of the various Notch receptors and
ligands. Therefore, to circumvent this problem I examined the expression of genes
associated with the Notch signalling pathway using real-time PCR. It is worth
mentioning that in this study I am not comparing the primed and tolerised groups
directly as the antigen dose and frequency varied for the two experimental groups.
Rather, both groups are compared back to untreated CD4+ T cells. Therefore,
untreated CD4+ T cells, which serve as the calibrator, always have a value of one and
the other samples are relative to that value.
Based on the experimental protocols described previously, mice were primed or
tolerised by the intranasal route with HDM pi 10-130, the CD4+ T cells were isolated
by negative selection and the purity determined (Figure 7). This method of isolation
ensures that the CD4+ T cells are unmanipulated, and therefore, prevents the risk of
activation by a positive selection method, which may modulate Notch signalling. The
purity of CD4+ T cell isolation was always in the region of 87-89% (Figure 7). The
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Figure 7. Purity of negatively selected CD4+ T cells.
Splenic CD4+ T cells (A) were isolated from untreated,
control or experimental C56BL/6 mice by negative
selection. The cells were stained with Cy-Chrome-CD4
(B) to determine the purity of the isolation procedure (red
bar) or with the corresponding isotype control (grey
shaded bar). The purity (89%) is representative of all the
CD4+ T cell isolations carried out.
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Priming mice to pi 10-130 in the presence ofLT (Figure 8), did not result in changes
in gene expression of the Notch receptors {Notch-1 and 2) or ligands {Jagged-1, -2
and Delta-1) analysed at days 2 and 4 following antigen challenge. Additionally, at
day 7 when the peak of the CD4+ T cell response to pi 10-130 was detected (Figure
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Figure 8. The effect of priming mice to HDM pi 10-130 in gene expression ofNotch
receptors and ligands. Splenic CD4+ T cells were isolated by negative selection from
mice that had been immunised intranasally with 0.03pg of E.coli LT alone, or in the
presence of lOOpg ofpi 10-130 for 2, 4 or 7 days. The RNA was extracted and reversed
transcribed for cDNA synthesis. The samples were tested for gene expression {Notch-1
and Notch-2, Jagged-1 and Jagged-2, Delta-1) by real-time PCR analysis. Each gene
was run with a positive control, which was the untreated CD4+ T cell population (N) to
which all the samples are relative, and with a negative control (no cDNA) to ensure
there was no genomic DNA contamination. Furthermore, an internal control, 18srRNA,
was included per sample as a monitor of the PCR reaction and of the amount of cDNA
used. A 2.5-fold increase above the positive control is regarded as significant.
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A number of events follow binding of the Notch receptor to its ligands, Delta or
Jagged. One of the consequences results in translocation of the intracellular portion
of Notch (NotchIC) to the nucleus where it interacts with the DNA-binding protein
Su(H)/CBF-l which promote transcription of target genes (32) (Introduction, section
3.1). Amongst these target genes are E(spl)/Hes genes. Hes-1 is a bHLH protein that
functions primarily as a transcriptional repressor of the transcription factor Mash-1,
and is involved in many cell-fate decisions. Therefore, Notch signalling results in
Hes-1 up-regulation.
Another gene, Deltex, is also involved in regulating Notch signalling, through a
Su(H)/CBF-l-independent way (79, 203). Deltex encodes a protein that physically
interacts with the Notch ankyrin repeats in the intracellular portion (203, 204).
Matsuno et al (204) found that the functional phenotypes observed in Drosophila by
over-expression of Deltex were similar to those induced by over-expression of an
activated Notch receptor, and these phenotypes were modulated in identical fashion
by changing the Notch activity in the genetic background. They proposed that Deltex
was acting as a positive regulator of the Notch pathway.
Additionally Deftos et al (85) have proposed that Deltex is a target of Notch
signalling in T cell development. They found that over expression of NotchIC in a
double positive thymoma cell line, led to an up regulation of Deltex.
An increase in Hes-1 is associated with Notch signalling (32, 214), therefore, an up-
regulation of the gene in CD4+ T cells during the course of tolerance or priming
would suggest that Notch signalling in these cells has taken place. Figure 9 shows
that there were no changes in expression of Hes-1 in CD4+ T cells from the LT-
control or LT-primed groups of mice compared to untreated CD4+ T cells, implying
that the Hes-1-dependent Notch signalling may not be important in this type of
immune response.
Similarly, an increase in Deltex is associated with Notch signalling (85) therefore, I
was also interested in investigating if levels of expression of Deltex were affected in
CD4+ T cells after priming or tolerising mice with HDM pi 10-130.
In Figure 9 data is presented that shows Deltex was up regulated in the control group
of mice that received LT alone at day 4 after peptide treatment by about 2.5-fold with
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respect to the calibrator, but it was not significantly greater than the value of the LT
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Figure 9. The effect of priming mice to HDM pi 10-130 in gene expression
of mediators of the Notch signalling pathway. Splenic CD4+ T cells were
isolated by negative selection from mice that had been immunised intranasally
with 0.03pg of E.coli LT alone, or in the presence of lOOpg of pi 10-130 for
2, 4 or 7 days. The RNA was extracted and reversed transcribed for cDNA
synthesis. The samples were tested for gene expression {Hes-l and Deltex) by
real-time PCR analysis. Each gene was run with a positive control, which was
the untreated CD4+ T cell population (N) to which all the samples are relative,
and with a negative control (no cDNA) to ensure there was no genomic DNA
contamination. Furthermore, an internal control, 18srRNA, was included per
sample as a monitor of the PCR reaction and of the amount of cDNA used. A
2.5-fold increase above the positive control is regarded as significant (in
orange).
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Identical gene expression studies were carried out in mice that had been tolerised
with HDM pi 10-130 (Figure 10).
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Figure 10. The effect of tolerising mice to HDM pi 10-130 in gene expression of Notch
receptors and ligands. C57BL/6 mice were immunised intranasally on three consecutive
days with 25 pi of saline, or in the presence of lOOpg of pi 10-130. Splenic CD4+ T cells
were isolated by negative selection at days 2, 4 and 7 after the last treatment. The RNA
was extracted and reversed transcribed for cDNA synthesis. The samples were tested for
gene expression (Notch-J and Notch-2, Jagged-1 and Jagged-2, Delta-1) by real-time PCR
analysis. Each gene was run with a positive control, which was the untreated CD4+ T cell
population (N) to which all the samples are relative, and with a negative control (no
cDNA) to ensure there was no genomic DNA contamination. Furthermore, an internal
control, 18srRNA, was included per sample as a monitor of the PCR reaction and of the
amount of cDNA used. A 2.5-fold increase above the positive control is regarded as
significant (in orange).
Figure 10 shows that the Notch receptors, Notch-1 and-2 were not modulated during
the induction of peptide tolerance, however, the Notch ligand Jagged-1 was up-
regulated by more than 2.5-fold compared to the untreated CD4+ T cells and also
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level correlates with the peak of CD4+ T cell activation in response to pi 10-130
vitro, at day 4 after the last peptide treatment (Figure 5). This rise in Jagged-1
possibly corresponds to the time when the CD4+ T cells are differentiating into
regulatory T cells before becoming unresponsive to peptide stimulation vitro by
day 7 (Figure 5). Additionally there is a trend towards an up-regulation of Delta-1 in
CD4+ T cells at day 4 following intranasal peptide treatment.
Analysis of expression ofHes-1 and Deltex (Figure 11) reveal that only Deltex is up-
regulated by more than 2.5 fold at day 2 following the last peptide treatment in
comparison to untreated CD4+ T cells. However, the rise is not significant in
comparison to day 2 CD4+ T cells from mice that received saline alone, and


































Figure 11. The effect of tolerising mice to HDM pi 10-130 in gene
expression of mediators of the Notch signalling pathway. C57BL/6
mice were immunised intranasally on three consecutive days with 25 pi
of saline, or in the presence of lOOpg of pi 10-130. Splenic CD4+ T cells
were isolated by negative selection at days 2, 4 and 7 after the last
treatment. The RNA was extracted and reversed transcribed for cDNA
synthesis. The samples were tested for gene expression (Hes-1 and
Deltex) by real-time PCR analysis. Each gene was run with a positive
control, which was the untreated CD4+ T cell population (N) to which all
the samples are relative, and with a negative control (no cDNA) to
ensure there was no genomic DNA contamination. Furthermore, an
internal control, 18srRNA, was included per sample as a monitor of the
PCR reaction and of the amount of cDNA used. A 2.5-fold increase
above the positive control is regarded as significant (in orange).
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Thus, by examining Notch signalling in CD4+ T cells isolated from mice either
tolerised or primed to HDM pi 10-130 via the intranasal route, the following
observations can be made:
• The Notch receptors, -1 and -2 are not modulated during the induction of priming
(Figure 8) or tolerance (Figure 10).
• The Notch ligands, Jagged-1 and -2, and Delta-1 are not modulated under
conditions that induce priming (Figure 8).
• Jagged-1 and to a lesser extent Delta-1 appear to be up regulated in tolerance at
day 4 (Figure 10).
• Deltex is up regulated by LT alone (Figure 9) and by the presence of peptide in
saline (Figure 11) at days 4 and 2, respectively.
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SECTION 2
Phenotypic Characterisation of CD4+ T Cells during
Priming or Tolerance Induction
2.1. Background
Increasing evidence suggests that a population of T cells called regulatory T cells (Tr
cells), may act to down-regulate other T cell responses, including those that are
directed against self, and help maintain peripheral tolerance and immune
homeostasis.
Sakaguchi et al (20) defined Tr cells as a minor subset of CD4+ T cells (10%)
expressing the IL-2 receptor a-chain (CD25) that are present in the spleen, lymph
nodes and peripheral blood of normal adult mice. CD4+CD25+ T cells are capable of
preventing certain autoimmune diseases (20, 21), remain unresponsive to TCR
stimulation and can inhibit the response of CD4+CD25~ T cell in co-culture
experiments in vitro.
Other Tr cells have also been defined on the basis of different cell surface markers,
such as CD38. Splenic CD4+CD38+ T cells do not secrete any cytokines upon
antigen-specific stimulation compared to the CD4+CD38" subset, and can induce a
Thl healing response in mice infected with Leishmania major (29). Another marker
that has been used to identify Tr cells is CD45RB. CD4+CD45RBlow cells are capable
of inhibiting CD4+CD45RBhlgh cells from inducing colitis in SCID mice (25).
Interestingly, these cells have also been further sub-divided into CD25+ and CD25"
populations (26), consistent with Sakaguchi's original observation (20), and have
been found to suppress CD4+CD25~CD45RBlow T cells in vitro, and to inhibit
CD45RBh'8h-mediated colitis in SCID mice (27).
One question that remains unresolved is what is the mode of action of Tr cells.
CTLA-4 is important in down regulating CD4+ T cell activation (215, 216) and has
been studied as a potential candidate that may be involved in the signalling pathway
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that leads to immune suppression by Tr cells. Read et al (27) showed that anti-
CTLA-4 monoclonal antibody inhibited the CD4+CD45RBlow T cells from
suppressing colitis in SCID mice, suggesting that the CD25+ cells were dependent on
CTLA-4. More recently, Nakamura et al (217) showed that CD4+CD25+ T cells
express cell-surface bound TGF-(3 and this may regulate the cell-cell contact-
mediated suppression of proliferation of the CD4+CD25~ T cells.
The Tr cells so far described have the potential to suppress autoreactive T cells that
can lead to autoimmune disorders. However, the host also needs to suppress or
prevent the induction of unwanted immune responses to non-pathogenic airborne or
dietary antigens, and this phenomenon is known as mucosal tolerance.
Experimentally, this can be induced by intranasal administration of the house dust
mite allergen, Der p 1, peptide 110-131 (section 1, Figure 5). This form of tolerance
induces a population of long-lived CD4+ Tr cells that are able to transfer tolerance to
recipient mice.
Therefore, the aim of this study was to gain further insight into the phenotype of
CD4+ T cells after induction of intranasal peptide tolerance or priming compared to
untreated CD4+ T cells. In an attempt to define the characteristics of the Tr cells that
are generated during intranasal peptide tolerance but not during intranasal priming,
the cells from all the groups were stained with antibodies to markers that define Tr
cells (CD25, CD38 and CD45RB) or Tr cell function (CTLA-4), and analysed by
flow cytometry.
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2.2. Charaterisation of untreated CD4+ T cells
2.2.1. Characterisation ofCD4+CD25+ and CD4+CD25 T cells
The initial part of this study consisted in characterising phenotypically CD4+ T cells
from untreated mice, so they could serve as a baseline against which all other CD4+
T cells from treated mice would be compared to. Since it has been previously
described that CD4+CD25+ T cells are a constitutive regulatory T cell population (20,
22), splenocytes from untreated mice were stained with CD4-CyChrome and CD25-
FITC to gate on CD25+ and CD25" populations. A third PE-labelled marker,
characteristic of Tr cells was used to determine the percentage of cells positive for
each of the PE-labelled markers tested, and the values used as the baseline which to
compare the samples from the peptide-treated groups. The cells were also stained
with CD4-CyC, and the appropriate isotype controls for CD25-FITC and each of the
PE-labelled markers tested (Figure 12). Table 1 and Figure 13 show the percentage
information from a typical experiment. It is important to mention at this point that for
all the flow data shown, the quadrant labels on the dot plots for each of the markers
examined were set according to the corresponding isotype controls, however, for
convenience the isotypes are not shown again in the thesis.
Splenocytes CD4+ T cells r!gG2a HsIgG iHsIgG
Figure 12. Phenotypic characterisation of untreated CD4+ T cells: a look at the isotype
controls. The spleens from C57BL/6 female mice were removed, and the spleen cells prepared
for flow cytometry by antibody staining using the markers of interest and the corresponding
isotype controls. For the isotype controls splenocytes were triple stained with Cy-Chrome-
CD4, rat FITC-IgM (rlgM, the isotype for CD25) and rat PE-IgG2a (rigG2a, the isotype for
CD38 and CD45RB) or hamster PE-IgG (FlsIgG, the isotype for CD69 and CTLA-4). For
intracellular staining, the cells were surface stained first (with Cy-Chrome CD4 and FITC-
rlgM), then fixed and permeabilised with the antibody of interest (iHsIgG for the isotype). For
data analysis, a lymphocyte gate (Rl) was drawn in the splenocyte population, and the CD4+ T
cells (R2) were gated on Rl. To determine the percentage of positive cells for each marker of
interest the cells were gated on Rl and R2, and quadrant labels set according to the isotype
controls.
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CD38+ CD45RBlow CD69+ CTLA-4+ iCTLA-4+
CD4CD25+ 75.5 66.3 34.5 6.3 30.1
CD25+CD38+ CD25+CD45RBlow CD25+CD69+ CD25+CTLA-4+ CD25+iCTLA-4+
CD4+ 4.8 4.2 2.3 0.1 1.3





























CD38+ CD45RBlow CD69+ CTLA-4+ iCTLA-4+
CD4CD25 34.9 44.8 11.9 1.2 2.3
CD25CD38+ CD25"CD45RBlow CD25CD69+ CD25CTLA-4+ CD25iCTLA-4+
CD4+ 32.9 39.4 10.2 0.7 1.8
Figure 13. Phenotypic characterisation of untreated CD4+ T cells. The spleen of an untreated
C57BL/6 female mouse was removed, and the cells prepared for antibody staining. They were
tripled stained with Cy-Chrome-CD4, FITC-CD25 and PE-CD38, CD45RB, CD69 or CTLA-4.
For intracellular staining of CTLA-4 (iCTLA-4) or the corresponding isotype control, cells were
surface stained, fixed and permeabilised. Each staining was done with the appropriate isotype
control (see Figure 12). A lymphocyte gate (Rl) was set within the splenocyte population and the
CD4+ T cells were gated (R2) on the Rl gate. The CD4+CD25+ (R4) and CD4+CD25" (R3) T cells
(gated on Rl and R2) were examined for expression of CD38, CD45RB, CD69 or CTLA-4. The
tables shows the percentage of CD4+CD25+/" T cells (in R3 or R4) positive for each of the markers
tested, or the percentage of CD4+ T cells (in Rl and R2) positive for each of the markers in the
CD25+/" populations. The quadrant labels for CD38, CD69 and CTLA-4 correspond to their
respective isotype controls. The quadrant label for CD45RB corresponds to an arbitrary
CD45RBh,gh and low population. The data is representative of three independent experiments.
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Cell-surface CD4+CD25+ (%) CD4+CD25+ (%) CD4+CD25 (%)
marker (expected) (observed) (observed)
CD25+ 10(1) 7
CD38+ 60 (2) 75.5 34.9
CD45RBlow/int Majority (2) 66.3 44.8
sCTLA-4+ Yes (3) 6.3 1.2
iCTLA-4+ 47.4 (4) 30.1 2.3
CD69+ 25(1) 34.5 11.9
Table 1. Expression levels of T cell markers on CD4+ T cells from untreated
mice. Expression is shown as a percentage of CD4+CD25+ and CD4+CD25~ T
cells positive for all the antibodies tested (based on Figure 13). The first column
shows the values published by other groups.





The data presented in Figure 13 and Table 1 show that about 7% of splenic CD4+ T
cells from untreated mice are CD25+. Compared to the CD25" population more of
them are CD45RBlow/int (66.3% versus 44.8%), and CD38+ (75.5% versus 34.9%).
Additionally a higher number of cells are CD69+ (34.5% versus 11.9%) which has
been described as an early activation marker. I consistently found CD4+ T cells to be
CD69 positive, irrespective of the immunological status of the mice, and this may
reflect on the health status of the animals kept in our Animal House facilities.
Furthermore, surface CTLA-4 was also expressed at a higher level on the CD25+ T
cells compared to the CD25" (6.3% versus 1.2%), and when the cells were
permeabilised to detect intracellular CTLA-4 the percentage was further increased
(30.1% versus 2.3%). Typically expression of CTLA-4 is measured intracellularly as
this molecule has been primarily localised in intracellular vesicles and may cycle
between intracellular stores and the cell surface (218).
Therefore, the data presented in Table 1 show that the splenic CD4+CD25+ T cells
analysed express a range of cell surface markers that are consistent with those
reported by other groups.
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2.2.2. Expression ofNotch signalling genes in CD4+CD25+/~ T cells
The finding that Jagged-1 was up-regulated in a murine model of intranasal peptide
tolerance (section 1, Figure 10), a treatment that generates Tr cells, prompted to
investigate if the constitutive CD4+CD25+ Tr cells also displayed increased levels of
Jagged-1 or other Notch ligand genes. For this, CD4+ T cells were isolated from the
spleens of untreated C57BL/6 mice by positive selection using MACS, and the cells
prepared for FACS sorting by double staining with CD4-PE and CD25-FITC (Figure
14). Having sorted the CD4+ T cells into CD25+ and CD25", the total RNA was
extracted and the samples were prepared for real-time PCR analysis (Figure 15).












Figure 14. FACS sorting of CD4+CD25+/" T cells. CD4+ T cells were
isolated by positive selection using MACS from the spleens of untreated
C57BL/6 mice. The cells were double stained with PE-CD4 and FITC-
CD25 for FACS sorting. The CD25+/~ subsets were processed for total
RNA extraction. The value corresponds to the % of CD25+ cells in the




































Figure 15. Differential regulation of genes of the Notch pathway in murine
CD4+ T cell subsets. CD4+ T cells were purified from the spleens of untreated
C57BL/6 mice. The cells were double stained with PE-CD4 and FITC-CD25 for
FACS sorting. The CD25+/~ subsets were processed for total RNA extraction and
reverse transcribed for cDNA synthesis. The samples were tested for gene
expression (Notch-1 and 2, Jagged-1 and 2, Delta-1, Deltex and Hes-1) by real-time
PCR. For each gene there was a positive control, which was the untreated (N)
population to which all the samples are relative, and a negative control (no cDNA)
to ensure there was no genomic DNA contamination. Furthermore an internal
control, 18srRNA, was included per sample as a monitor of the PCR reaction and of
the amount of cDNA used. A 2.5-fold increase above the positive control is
regarded as significant.
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The data in Figure 15 show that for the CD4+CD25+ subset either the genes were
expressed at lower levels (Notch-1, Notch-2, Jagged-1, Jagged-2 and Deltex) or at
the same levels (Delta-1 and Hes-1) as the CD25" cells. This could be explained by
the fact that the regulatory CD4+CD25+ T cells need TCR triggering to exert their
suppressive function (22, 26). Therefore, if the CD4+CD25+ T cells were activated
may be they would up-regulate expression of these genes as was seen for Jagged-1 in
CD4+ T cells during tolerance induction (section 1, Figure 10). Interestingly the only
other study to date where they have analysed by real-time PCR changes in the
expression of components of the Notch pathway in CD25+A T cells, (187) showed
that unstimulated CD25+ and CD25" T cells displayed very subtle differences in the
expression of Delta-1, Notch-4 or Hes-1 genes. However, when the cells were
stimulated with anti-CD3/anti-CD28 antibodies, transcripts for Notch-4, Delta-1 and
Hes-1 increased considerably in the CD25+ compared to the CD25"CD4+ T cells.
They also found that transcripts for Notch-1, Jagged-1 and Jagged-2 were similar
amongst the CD25+A of unstimulated and stimulated cells. Therefore, this study
demonstrates the need to activate the CD25+ T cells to appreciate significant changes
in components of the Notch pathway.
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2.3. Charaterisation of CD4+ T cells from mice tolerised or
primed by intranasal peptide administration
In the experiments that follow, I addressed the question of whether the regulatory
CD4+ T cells induced in the model of intranasal peptide tolerance expand their
CD25+ T cell population as well as increasing markers of Tr cells (CD38, CD45RB,
CTLA-4), compared to primed or untreated mice. For this the following groups of
mice were set up. One group received LT alone intranasally (Figure 16), and another
group was primed with LT in the presence of pi 10-130 to induce a T helper response
(Figure 17). A third group received saline alone (Figure 18) and another group was
given pi 10-130 in saline to induce tolerance, and generate Tr cells (Figure 19).
All the experimental groups were compared to the untreated CD4+ T cells described
in Figure 13.
Isolated splenocytes were stained with CD4-CyC and CD25-FITC to gate on CD25+/"
cells. Thus, if the regulatory CD4+ T cells generated during intranasal peptide
tolerance were CD25+, I would be able to detect an increase in numbers by flow
cytometry compared to the primed and control groups (Table 2). Additionally, the
cells were stained with other markers, which have been described for Tr populations,
like CD38 and CD45RB (25, 27, 29), or with CTLA-4 which is important in Tr
function (27, 28). Gating on the CD4+CD25+/" would allow detecting changes in the
other Tr markers, and help explain if they belong to the same regulatory T cell or
may represent distinct subsets of regulatory T cells. The flow data is represented as
dot plots. It should be stressed that each sample was accompanied by its
corresponding isotype control. Figure 12 shows a representative example of the
isotypes used in this study. The quadrant labels in the dot plots of the flow data,
therefore, were set according to the corresponding isotypes. However, for
convenience the isotypes controls for each of the samples in all the experimental
groups are not shown in the rest of the thesis.
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CD4+ CD25+CD38+ CD25+CD45Bkw CD25+CD69+ CD25+CTLA-4+ CD25+i-CTLA-4+
day 2 8.7 8.2 4.6 0.6 0.4
day 4 7.8 7.4 4.9 0.2 0.2
day 7 10.7 NA 6.10 0 0
CD4+ CD25CD38+ CD25'CD45Blow CD25CD69+ CD25CTLA-4+ CD25 i-CTLA-4+
day 2 45.9 47.7 13.7 0.2 1.1
day 4 72.5 54.5 13.5 0.4 0.6
day 7 48.2 NA 15.6 0 0
Figure 16. Phenotypic characterisation of CD4 T cells from control mice treated intranasally with a
mucosal adjuvant derived from E.coli heat-labile enterotoxin (LT). Mice were administered 0.03pg of
LT intranasally once, and the spleens were removed 2, 4 or 7 days after treatment. Each group contained
two mice and the spleens were pooled and the cells prepared for antibody staining. They were tripled
stained with CyChrome-CD4, FITC-CD25 and PE-CD38, CD45RB, CD69 or CTLA-4. For intracellular
staining of CTLA-4 (iCTLA-4) or the corresponding isotype control, cells were surface stained, fixed and
permeabilised. The CD4+CD25+/" T cells (gated on R1 and R2, see Figure 13 for details) were examined for
expression of CD38, CD45RB, CD69 or CTLA-4. The quadrant labels were set up according to the
corresponding isotype controls, except for CD45RB where an arbitrary gate was set up to divide the RBhlgh
and low populations. The table shows the percentage of CD4+ T cells positive for each of the markers
depicted within the CD25+/~ populations. If the isotype controls gave non-specific binding of a value greater
than 1 this was subtracted from its corresponding marker. NA=not available.
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CD4+ CD25+CD38+ CD25+CD45Bkw CD25+CD69+ CD25+CTLA-4+ CD25+i-CTLA-4+
day 2 8.7 8.1 4.6 0.3 0.2
day 4 8.5 7.4 3.6 0.1 0
day 7 11.2 NA 5.6 0.4 0
CD4+ CD25CD38+ CD25CD45Bkw CD25CD69+ CD25CTLA-4+ CD25 i-CTLA-4+
day 2 45.4 50.6 15.8 0.4 0
day 4 47.2 53.9 13.7 0.3 0.2
day 7 84.6 NA 15.3 1 0
Figure 17. Phenotypic characterisation of CD4+ T cells from experimental mice primed
intranasally with HDM peptide 110-130 in the presence of E.coli LT. Mice were immunised once
intranasally with 0.03pg of LT and 100pg of pi 10-130, and the spleens were removed 2, 4 or 7 days
after treatment. Each group contained two mice and the spleens were pooled and the cells prepared for
antibody staining. They were tripled stained with Cy-Chrome-CD4, FITC-CD25 and PE-CD38,
CD45RB, CD69 or CTLA-4. For intracellular staining of CTLA-4 (iCTLA-4) or the corresponding
isotype control, cells were surface stained, fixed and permeabilised. The CD4+CD25+ ~ T cells (gated on
R1 and R2, see Figure 13 for details) were examined for expression of CD38, CD45RB, CD69 or
CTLA-4. The quadrant labels were set up according to the corresponding isotype controls, except for
CD45RB where an arbitrary gate was set up to divide the RBhlgh and low populations. The table shows
the percentage of CD4+ T cells positive for each of the markers depicted within the CD25+ and CD25"
populations. If the isotype controls gave non-specific binding of a value greater than 1 this was
subtracted from its corresponding marker. NA=not available.
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Untreated Day 2 Day 4 Day 7
7% LT 10.8 10.3 10.5
LT + pll0-130 10.2 9.9 10.3
PBS 8.4 8 10.2
PBS + pll0-130 9.7 8.6 9
Table 2. Percentage of CD4+CD25+ T cells. The values were taken from
untreated mice, or mice that had been intranasally primed (LT plus pi 10-130)
or tolerised (PBS plus pi 10-130), or had received LT alone or PBS alone.
Splenocytes from each group were stained with CD4-Cyc and CD25-FITC. To
determine the percentage values gates were drawn (R1 and R2 to gate on the
CD4+ T cells and R3 and R4 to gate on the CD25+/" populations) as
represented in Figure 13.
Table 3: CD4+CD25+ T cells
CD4+ CD25+CD38+ CD25+CD45RBl<m CD25+CD69+ CD25*CTLA-4+ CD25+iCTLA-4+
Untreated 4.8 4.2 2.3 0.1 1.3
day 2 - LT 8.7 8.2 4.6 0.6 0.4
day 4 - LT 7.8 7.4 4.9 0.2 0.2
day 7 - LT 10.7 NA 6.10 0 0
day 2 - LT + pep 8.7 8.1 4.6 0.3 0.2
day 4 - LT + pep 8.5 7.4 3.6 0.1 0
day 7 - LT + pep 11.2 NA 5.6 0.4 0
Table 4. CD4+CD25 T cells
CD4+ CD25CD38* CD25 CD45RB|0W CD25CD69* CD25CTLA-4* CD25iCTLA-4+
Untreated 32.9 39.4 10.2 0.7 1.8
day 2 - LT 45.9 47.7 13.7 0.2 1.1
day 4 - LT 72.5 54.5 13.5 0.4 0.6
day 7 - LT 48.2 NA 15.6 0 0
day 2 - LT + pep 45.4 50.6 15.8 0.4 0
day 4 - LT + pep 47.2 53.9 13.7 0.3 0.2
day 7 - LT + pep 84.6 NA 15.3 1 0
Table 3 and 4. Summary of the percentage of CD4+CD25+/" T cells positive for CD38,
CD45RBlow, CD69 and CTLA-4 (surface or intracellular) in untreated, LT and LT+peptide-
treated mice (taken from Figures 13,16 and 17).
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A point to mention is that by looking at the dot plots some seem to have less events
than others for a given marker, but the percentage of positive cells is higher. This
reflects on the number of events that were picked up by the flow cytometer, as
sometimes not enough cells were available to collect 10,000 events in the CD4+ gate.
Table 2 shows that the percentage of CD25+ T cells increased from 7% in untreated
mice to about 10% in both the LT and LT/peptide groups by day 2, through to day 7.
Additionally the percentage of CD25+CD38+, CD45RBlow/int and CD69+
approximately doubled in both experimental groups compared to untreated mice over
the 7 day period (Table 3), and this corresponded to the increase in CD25+ numbers
observed. There were no detectable changes in CTLA-4 expression (surface or
intracellular) between the groups, other than intracellular CTLA-4 being higher in
the untreated group. A comparison of the LT plus peptide group and LT group
revealed that there are no major differences in the percentage of CD4+ T cells that
were CD25+CD38+, CD45RBlow/int, CD69+ and CTLA-4+ (surface and intracellular)
over the time course followed. These findings suggest that the increase in numbers of
the CD25+ population and the equivalent rise in the other surface markers may be
due to the activating effect of the mucosal adjuvant and not the peptide, as CD38,
CD45RBk'w and CD69 are also markers of T cell activation. LT when used as an
adjuvant may be activating CD4+ T cells in a non-specific manner, as Figure 4
(section 1) shows that cells from mice receiving LT alone did not respond to pi 10-
130 in vitro.
The numbers of cells that were CD25" and expressed CD38+, CD45RBlow/inl CD69+
also increased (Table 4). However, similar to the CD25+ findings this increase was
no different in the LT and LT plus peptide groups. Therefore, these findings
reinforce the capacity of LT on its own to activate CD4+ T cells. The only striking
difference came from the CD25~CD38+ numbers in the control group which
increased from 45.9% at day 2 after LT administration, to 72.5% at day 4, and
dropped to 48.2% by day 7. In contrast, the LT plus peptide treated group showed an
increase in the CD4+CD25"CD38+ population at day 7 instead (84.6% versus 45.4%
at day 2 and 47.2% at day 4). This may represent a difference in the kinetics of
expression of CD38 as a result of LT being or not in the presence of peptide.
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CD4+ CD25+CD38+ CD25+CD45Bkm CD25+CD69+ CD25+CTLA-4+ CD25i-CTLA-4+
day 2 6.1 7.7 3.9 0.4 0.2
day 4 5.9 6.7 3.6 0.5 0.5
day 7 8.1 6.9 NA 0.2 0.6
CD4+ CD25CD38+ CD25CD45B1™ CD25CD69+ CD25CTLA-4+ CD25 i-CTLA-4+
day 2 43.7 45.3 11.9 0.3 0.2
day 4 39.3 40.2 8.5 0.2 0.1
day 7 41.8 49.2 NA 0.3 0.3
Figure 18. Phenotypic characterisation of CD4+ T cells from control mice treated intranasally
with saline (PBS) alone. Mice were administered 25pi of saline intranasally on three consecutive
days, and the spleens were removed 2, 4 or 7 days after treatment. Each group contained two mice
and the spleens were pooled and the cells prepared for antibody staining. They were tripled stained
with CyChrome-CD4, FITC-CD25 and PE-CD38, CD45RB, CD69 or CTLA-4. For intracellular
staining of CTLA-4 (iCTLA-4) or the corresponding isotype control, cells were surface stained first
with the other antibodies, fixed and permeabilised. The CD4+CD25+/" T cells (gated on R1 and R2,
see Figure 13 for details) were examined for expression of CD38, CD45RB, CD69 or CTLA-4. The
quadrant labels were set up according to the corresponding isotype controls, except for CD45RB
where an arbitrary gate was set up to divide the RBhlgh and low populations. The table shows the
percentage of CD4+ T cells positive for each of the markers depicted within the CD25+ and CD25"
populations. If the isotype controls gave non-specific binding of a value greater than 1 this was
subtracted from its corresponding marker. NA=not available.
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CD4+ CD25+CD38+ CD25+CD45Bkm CD25+CD69+ CD25+CTLA-4+ CD25+i-CTLA-4+
day 2 8.4 8.4 6.2 1.1 0.9
day 4 7.1 8 3.8 0.2 0.5
day 7 7 6.2 4.3 0.3 0.6
CD4+ CD25CD38+ CD25CD45B,ow CD25CD69+ CD25CTLA-4+ CD25 i-CTLA-4+
day 2 41.7 43.2 27.7 2.4 0.7
day 4 39.8 41.4 10.1 0.1 0.3
day 7 32.8 41.8 10.4 0.2 0.7
Figure 19. Phenotypic characterisation of CD4+ T cells from experimental mice treated
intranasally with pll0-130 in saline. Mice were administered lOOpg of pi 10-130 in saline
intranasally on three consecutive days, and the spleens were removed 2, 4 or 7 days after the last
treatment. Each group contained two mice and the spleens were pooled and the cells prepared for
antibody staining. They were tripled stained with CyChrome-CD4, FITC-CD25 and PE-CD38,
CD45RB, CD69 or CTLA-4. For intracellular staining of CTLA-4 (iCTLA-4) or the corresponding
isotype control, cells were surface stained first with the other antibodies, fixed and permeabilised. The
CD4+CD25+/" T cells (gated on R1 and R2, see Figure 13 for details) were examined for expression of
CD38, CD45RB, CD69 or CTLA-4. The quadrant labels were set up according to the corresponding
isotype controls, except for CD45RB where an arbitrary gate was set up to divide the RBh,gh and low
populations. The table shows the percentage of CD4+ T cells positive for each of the markers depicted
within the CD25+ and CD25" populations. If the isotype controls gave non-specific binding of a value
greater than 1 this was subtracted from its corresponding marker.
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Table 5. CD4+CD25+ T cells
CD4+ CD25+CD38+ CD25tCD45RIilow CD25+CD69+ CD25+CTLA-4* CD25+iCTLA-4+
Untreated 4.8 4.2 2.3 0.1 1.3
day 2 - PBS 6.1 7.7 3.9 0.4 0.2
day 4 - PBS 5.9 6.7 3.6 0.5 0.5
day 7 - PBS 8.1 6.9 NA 0.2 0.6
day 2 - PBS+pep 8.4 8.4 6.2 1.1 0.9
day 4 - PBS+pep 7.1 8 3.8 0.2 0.5
day 7 - PBS+pep 7 6.2 4.3 0.3 0.6
Table 6. CD4+CD25 T cells
CD4+ CD25CD38+ CD25 CD45RB|0W CD25CD69* CD2SCTLA-4* CD25iCTLA-4+
Untreated 32.9 39.4 10.2 0.7 1.8
day 2 - PBS 43.7 45.3 11.9 0.3 0.2
day 4 - PBS 39.3 40.2 8.5 0.2 0.1
day 7 - PBS 41.8 49.2 NA 0.3 0.3
day 2 - PBS+pep 41.7 43.2 27.7 2.4 0.7
day 4 - PBS+pep 39.8 41.4 10.1 0.1 0.3
day 7 - PBS+pep 32.8 41.8 10.4 0.2 0.7
Table 5 and 6. Summary of the percentage of CD4+CD25+/' T cells positive for CD38,
CD45RBlow, CD69 and CTLA-4 (surface or intracellular) in untreated, PBS and PBS+
peptide-treated mice (taken from Figures 13,18 and 19).
The data in Table 2 also show that the CD25+ numbers in the tolerised and control
groups increased modestly by equivalent numbers (about 9%) over the three time
points followed, compared to the numbers in the untreated mice (7%). This rise also
corresponded to a small increase in CD38+, CD45RBlow and CD69+ numbers within
the CD25+ population of both experimental groups (Table 5). Thus saline alone
seems to have an effect on the expansion of the CD25+ population. The peptide-
treated group showed almost a two-fold increase in CD25+CD69+ cells and more
than a two-fold increase in CD25+CTLA-4+ cells (surface and intracellular) at day 2
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after the last peptide treatment compared to the control group (Table 5). However,
this may not be of biological relevance as the numbers drop to normal by day 4.
Giving mice saline alone or with pi 10-130 intranasally also increased the numbers of
CD25"CD38+, CD45RBlow and CD69+ cells compared to untreated mice, although
not to the extent that LT did (Table 6). The numbers of CD25"CD69+ and CTLA-4+
more than doubled in the peptide-treated group compared to the saline group at day 2
but dropped to levels of the untreated mice by day 4, which corresponds to the
finding in the CD25+ population.
In summary, priming mice with peptide and a mucosal adujvant (E. coli LT) led to an
increase in CD4+CD25+ T cell numbers by day 2 after intranasal treatment through to
day 7, which seemed to be associated with the presence of LT rather than peptide.
This rise was also accompanied by an increase in CD25+CD38+, CD45RBlow and
CD69+ by day 2, which may reflect on the capacity of LT to activate these cells.
Therefore, the antigen-driven response of CD4+ T cells to pi 10-130 in vitro at day 7
(section 1, Figure 4), did not correlate to any distinct phenotypic changes, as far as
the markers that were chosen in this study are concerned.
Giving mice saline or peptide in saline to induce tolerance, also led to a modest
increase in CD4+CD25+ numbers, which were seen in both experimental groups,
therefore, the rise was again not specific to the presence of peptide. Within the
CD25+ and CD25" populations, the peptide-treated group showed an increase in the
percentage of CD69+ (about two-fold) and CTLA-4+ cells (more than two-fold) at
day 2 only compared to the saline group.
In general, the increase in markers detected for both the primed and tolerised groups
of mice correspond more to an activated phenotype of the CD4+ T cells rather than to




Notch signalling is a highly conserved developmental pathway, which has been
described in many cell fate decisions. It is involved in the differentiation of cell
lineages during thymocyte development (73, 74, 75), and work in the group has
demonstrated that it may also play a part in the differentiation of regulatory CD4+ T
cells during the induction of peripheral tolerance (99). Therefore, the question I
wished to address was if Notch signalling was involved in CD4+ T cell
differentiation during ongoing peripheral immune responses. To study this I relied on
a model of CD4+ T cell recognition of the house dust mite peptide 110-131. If the
peptide is administered intranasally in saline it generates a population of Tr cells,
which are unresponsive to re-stimulation in vitro with the whole protein or peptide
derivatives (11, 12, 13) and can transfer tolerance to recipients. However, if the
peptide is given intraperitoneally with CFA, it leads to a Th-l-like response and
productive immunity. Initially this model was used to induce Tr cells or Th cells, and
study expression of genes associated with the Notch pathway. Additionally, in an
attempt to characterise the CD4+ T cells from the two experimental groups the cells
were analysed for expression of CD25, CD38, CD45RB and CTLA-4, all of which
are markers that describe Tr cells (25, 26, 27, 28, 29).
Furthermore, the requirement for antigen presentation in the induction of helper or
regulatory CD4+ T cells, prompted an investigation of the gene expression of Notch
receptors and ligands in APC populations from tolerised or primed mice. Therefore,
splenic B cells and enriched DCs were positively selected from both experimental
groups and analysed.
However, this approach is limited in that different routes of antigen administration
are used and arguably, by giving peptide either intranasally or intraperitonally this
may affect the kinetics of antigen uptake, delivery to the spleen and activation of the
resident CD4+ T cells differently.
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As well it raises the question of where the APCs come from. Splenic APCs may have
a very different pattern of expression of Notch signalling genes to those that have
migrated from the draining lymph nodes, where they will have encountered antigen.
Additionally, the APC populations in the spleen of tolerant or primed mice may
differ functionally. The former will have encountered antigen in the cervical lymph
nodes, possibly in an environment which already favours tolerance by default (from a
continuous exposure to inhaled antigens), and the latter encounters antigen in the
mesenteric lymph nodes and spleen in the presence of complete Freund's adjuvant.
Therefore, the concern raised by the route of antigen administration and the added
complexity of studying gene expression in APC populations prompted to change the
experimental design and procedures.
First I decided to concentrate only on CD4+ T cells, and therefore I did not analyse
gene expression of APC populations in the experiments reported in this thesis.
Second, the experiments were repeated keeping the route of antigen administration
for both tolerance and priming the same, namely the nasal route. Priming mice
intranasally with antigen has been achieved with mucosal adjuvants, one of which is
E.coli heat labile toxin (LT). LT when used at a high concentration has powerful
immunogenic effects and on its own can induce antibody secretion and modulate
cytokine profiles. It can also induce a selective increase in the cell surface expression
of B7.1, but not B7.2, MHC class II or CD40 on mouse bone marrow-derived DCs
(206), and it can activate B cells (219). These are reasons that add to the complexity
of studying expression of Notch signalling genes in APC populations.
Therefore, it was important to determine the optimal concentration of LT, which on
its own would not be immunogenic, but in combination with peptide would act as an
adjuvant. When used alone at 5pg, it could prime mice to environmental house dust
mite present in the Animal House facilities where the mice were kept. Splenocytes
responded in vitro to HDM pi 10-130 in a dose-dependent manner at day 7 after LT
administration (section 1, Figure 1). Therefore, lower doses of LT were given to
mice and it was found that as low as 0.3pg of LT could still prime mice to
environmental HDM (Figure 2). From these experiments it was found that LT given
intranasally at 0.03pg did not prime mice to HDM, but in combination with pi 10-
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130 retained its adjuvant effect (Figures 2 and 3). Therefore, the mice were primed
with 0.03|ig of LT and 100(ig of peptide once, and the spleens removed at days 2, 4
and 7 after treatment. CD4+ T cell responses to pi 10-130 in vitro were measured at
each time point and the data revealed that the antigen-driven response took place at
day 7 (Figure 4).
The tolerance protocol was based on the work of Hoyne et al (11, 12 13). Mice were
given 100p,g of pi 10-130 in saline on three consecutive days and the spleens were
removed at days 2, 4 and 7 after the last peptide treatment. The CD4+ T cells from
this mice were initially activated in response to pi 10-130 in vitro by day 2 and
displayed maximal proliferative responses to the peptide at day 4, before becoming
unresponsive at day 7 (Figure 5).
The priming and tolerance protocols clearly differ in the dose and frequency of
antigen administration, which it could still be argued, may have differential effects
on the expression of Notch signalling genes. However in experiments that are not
shown in this thesis if I kept the antigen dose and frequency of administration the
same as for the priming experiments (lOOpg of pi 10-130), this did not induce
tolerance. The CD4+ T cells proliferated to a similar extent at days 2, 4 or 7 after the
intranasal treatment when re-stimulated in vitro with pi 10-130. Similarly, if I gave a
higher concentration of peptide (300pg) once, to keep the frequency of antigen
administration constant, the CD4+ T cells re-stimulated in vitro to pi 10-130 did not
respond as well to the peptide as they had when lOOpg were given on 3 consecutive
days. Therefore, for these reasons the dose and frequency of antigen administration
differ in both experimental protocols, and this is why the two groups are not
compared to each other, but to an untreated group of mice.
The CD4+ T cells were isolated by negative selection (Figure 7) to avoid the risk that
a positive selection method may introduce in activating signalling pathways that
interfere with expression of components of the Notch pathway.
Analysis of gene expression by real-time PCR revealed that CD4+ T cells from mice
primed with LT and peptide (Figure 8), showed no significant differences in levels of
expression of the Notch receptors (Notch-1, and -2) or ligands (Jagged-1, -2 and
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Delta-1), compared to CD4+ T cells from mice receiving LT alone or from untreated
mice. Additionally the expression of the signalling molecules, Hes-1 and Deltex
(Figure 9), which are both up regulated as a result of Notch signalling (32, 85, 214),
did not vary much amongst the different groups. Only Deltex was up regulated by
about 2.5-fold in the CD4+ T cells of the LT-treated mice at day 4 compared to
untreated CD4+ T cells. However, this was not significant compared to the
LT/peptide-treated group at day 4.
A note of caution should be introduced. Arguably, the LT on its own may be
affecting the expression of Notch signalling genes in CD4+ T cells to such an extent
that even in the presence of antigen, and after the cells have been activated by day 7,
the effects are not appreciated. And it could be for this reason that the pattern of
expression for all the different genes is not modulated to a great extent for any of the
time points examined, between the LT and LT plus peptide groups of mice.
The CD4+ T cells from mice that were tolerised did not show significant modulation
of the Notch receptors Notch-1 and -2 compared to mice that received saline alone
(Figure 10). However, interestingly Jagged-1 was significantly up regulated by more
than 2.5-fold at day 4 after the last peptide treatment, with respect to untreated or
saline-treated mice. As well, Delta-1 was up regulated at this time point, although
not to the same extent. Interestingly, day 4 is the time point at which the cells
maximally proliferate in response to peptide in vitro before becoming regulatory and
unresponsive by day 7. The observation that this feature is not seen at day 7 after
peptide priming, would suggest it is not simply a result of CD4+ T cell activation.
Therefore, it could be a feature unique to the differentiation of Tr cells in this model
of peptide tolerance.
Having said that some points need to be addressed. The finding that Jagged-1 was up
regulated is not indicative of Notch signalling. Other signalling pathways that are
activated at the time of Tr cell differentiation may be affecting the expression of
Jagged-1. Indeed the finding that Hes-1 and Deltex (Figure 11), which would have
been up regulated following Notch activity, did not display significant differences in
their patterns of expression compared to the saline-treated groups, supports this
observation.
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Sakaguchi et al (20) defined a susbset of CD4+ T cells that expressed the IL-2
receptor a-chain, CD25, which constituted 10% of the total splenic CD4+ T cell
population, and that could prevent organ-induced autoimmunity in mice. I was
interested in investigating the pattern of expression of Notch signalling genes in this
population, as any similarities to the CD4+ T cells previously described in the model
of intranasal peptide tolerance would indicate that may be these Tr cells are also
CD25+. Therefore, the CD4+ T cells were sorted into CD25+ and CD25" and basal
levels of gene expression were analysed by real-time PCR. The data revealed that
CD4+CD25+ T cells did not up-regulate any of the Notch receptors (Notch-1, and -2)
or ligands studied (Jagged-1, -2 and Delta-1) with respect to unsorted CD4+ T cells
or CD25" T cells. As well, expression of Hes-1 and Deltex was not modulated
(Figure 15). Therefore, this would indicate that Notch activity is not important in the
CD25+ T cells. However, it should be mentioned that the cells in this study had not
been activated, and it has been reported that CD25+ T cells require TCR triggering to
exert their suppressive function (22, 26). Therefore, 1 would need to re-address this
question by activating the CD25+ and CD25" subsets and analyse expression of
Notch signalling genes. Interestingly, the only other study to date which has looked
at CD4+CD25+ and CD25" populations in the context of Notch signalling, reported
that unstimulated CD25+ and CD25" cells did not differ greatly in the expression of
Notch-4, Delta-1 and Hes-1 (187). However, when the cells were activated with anti-
CD3/anti-CD28 antibodies they greatly up regulated these three genes in the CD25+
compared to the CD25" population.
I was also interested in studying the CD25+ population after peptide priming or
tolerance. I would hope that if the Tr cells generated in peptide tolerance were
CD25+ they would expand, whereas numbers would remain the same in the primed
group. Additionally I wanted to study the expression of other markers that have
described Tr cell populations, [CD38 (29), CD45RB (25, 26)] or Tr function [CTLA-
4 (27, 28)]. An increase in the number of cells expressing these markers within the
tolerised but not the primed group would be indicative of Tr cells. If they were also
confined to the CD25+ population this would also suggest that they belong to the
same Tr lineage.
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At first I characterised CD25+ T cells from untreated mice which would serve as the
control group to which all other experimental groups would be compared. They
constituted about 7% of the whole CD4+ T cell population (Table 2) and more of
them were CD38+, CD45RBlow and CTLA-4+ compared to their CD25" counterparts
(Figure 13). These findings are consistent with the work of other groups (22, 28).
When the mice were given LT and LT plus peptide the numbers of CD25+ T cells
increased to about 10% from day 2 through to day 7 (Table 2). This suggests that the
expansion of the CD25+ T cells is more the effect of the LT rather than the peptide,
and may be due to the activating properties of LT on T cells, as CD25 is up-regulated
on activated CD4+ T cells. Indeed Nashar et al (219) found that mice injected
intraperitoneally with 30pg of LT in CFA caused an increase in the numbers of
CD4+CD25+ T cells in the mesenteric lymph nodes compared to mice that received
the same dose of a mutated form of LT.
The increase in CD25+ T cells also correlated with an increase within this population
of CD38+, CD45RBlow and CD69+ T cells, in the LT and LT/peptide-treated mice
(Figures 16 and 17). As these markers are also specific to CD4+ T cell activation, it
appears as if the increase in expression of all the surface markers examined are a
result of the activating properties of LT on CD4+ T cells. This observation raises a
point of concern for investigating expression of Notch signalling genes. Therefore,
the finding that no modulation in the expression of these genes was observed for the
LT and LT/peptide groups (Figures 8 and 9) could be attributable to the effects of the
LT, as has been previously discussed.
When mice were treated with saline or saline plus peptide, there was also an increase
from day 2 through to day 7 of CD4+CD25+ numbers (Table 2), which also
correlated with a rise in CD25+CD38+, CD45RBlow and CD69+ cells. This suggests
that this general increase was also a result of injecting saline into the mice. The only
main difference observed between the saline and the saline/peptide-treated groups
was that CD25+CD69+ and CD25+CTLA-4+ numbers about doubled in the peptide-
treated group compared to the control group (Figures 18 and 19). However, this was
not peptide-specific as the numbers dropped to levels in the control group at day 4,
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when there was maximal proliferation of the CD4+ T cells in response to the peptide
in vitro (Figure 5).
Clearly, it has proven difficult to characterise the Tr cells generated in the model of
intranasal peptide tolerance used in this study. However, there was a significant up-
regulation of Jagged-1 message in the CD4+ T cells of these mice prior to the cells
becoming unresponsive to the peptide in vitro, and this could be a feature unique to
the differentiation of Tr cells.
In the discussion to the experiments conducted prior to the review of this thesis I
discussed how new experiments would help determine if the CD4+CD25+ T cells are
responsible for inducing tolerance in the model of intranasal peptide tolerance used
throughout this work. This is what I wrote:
"An experiment I can conduct to expand our knowledge on the regulatory T cell
population is to isolate lymphoid CD4+CD25+ and CD4 CD25" T cells from mice
immunised intranasally with the house dust mite peptide. As a control group I can
use the same CD4+ subsets from unimmunised mice. I could culture them on their
own, or at varying ratios with unsorted CD4+ T cells from unimmunised mice, and
stimulate them with the house dust mite peptide, an irrelevant antigen such as OVA
to test for antigen-specificity, a self-peptide such as MBP to test for self-reactivity,
and via the TCR using anti-CD3/anti-CD28 antibodies. These experiments would tell
us if the CD25+ and CD25" T cells from the unimmunised mice behave the same or
differently to those derived from the peptide-treated mice. This would provide us
with clues relating to the regulatory properties of the CD25+ versus CD25" subsets,
and answer if the Tr cells are generated upon specific antigenic challenge or they
derive from the constitutive population found in the spleen, and which can regulate
potentially autoreactive T cells."
Interestingly, these experiments have since been conducted in the ovalbumin (OVA)
TCR transgenic mice, clone DO11.10, where all or the majority of the CD4+ T cells
are specific for the OVA peptide 323-339 (220). The OVA-specific CD4+ T cells can
be identified by use of the clonotypic antibody KJ 1-26. The use of a transgenic
mouse model has obvious advantages over using a polyclonal TCR mouse model, as
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in the former all, or the majority, of the CD4+ T cells are specific for one peptide and
the antigen-reactive cells can be identified by the KJ 1-26 antibody. This facilitates
the characterisation of the antigen-specific cells and makes gene expression studies a
lot more accurate as most of the CD4+ T cells are antigen-specific, therefore the
signals detected by real-time PCR after antigenic challenge would derive from the
majority of CD4+ T cells.
In this OVA TCR transgenic study, Zhang et al (220) investigated if oral
administration of OVA at a dose that would induce tolerance, resulted in the
activation of the CD4+CD25+ T cells in vivo. They found a significant increase in the
percentage of KJ l-26+CD25+CD4+ T cells in inguinal, mesenteric lymph nodes and
spleen from OVA-fed mice compared to unfed or BSA-fed mice. Furthermore the
CD25+CD4+ T cells were better at suppressing the proliferation of the CD25* T cells
from fed or unfed mice in vitro in response to OVA, than the CD25+CD4+ T cells
from unfed mice. The CD25+ T cells from fed mice secreted more TGF-(3 in response
to anti-CD3 stimulation in vitro, compared to those of unfed mice. They also found
an up-regulation of CTLA-4 in the CD25+ from fed mice compared to unfed mice,
but inhibiting CTLA-4 signalling in vitro or TGF-(3 signalling, only partially
abrogated the suppressive activity of CD25+ T cells from fed mice, suggesting other
factors also come into play.
In addition, in the same discussion I also mentioned adoptive transfer studies to gain
further insight into the immune regulatory properties of the CD25+ population. This
is what I wrote:
"In vivo I could adoptively transfer the CD4+CD25+ or CD4+CD25~ from peptide-
treated mice into recipient mice, and immunise them with an immunogenic dose of
Der p 1 protein. In vitro stimulation of the recipient CD4+ T cells with house dust
peptide or protein, or an irrelevant antigen, would reveal information regarding the
immune-regulatory properties of the CD25+ population compared to the CD25"
subset."
Zhang et al also addressed this issue in their OVA TCR transgenic model. They
found that in co-culture experiments the CD25+ T cells from OVA-fed mice were
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better at inhibiting the antigen-specific responses of CD25" T cells, compared to
CD25+ T cells from unfed mice. However, when CD25+ T cells from unfed and fed
mice were transferred intravenously to BALB/c mice they both suppressed delayed
type hypersensitivity responses to immunisation with OVA to a similar extent.
In another recent study, Thorstenson and Khoruts (221) also conducted adoptive
transfer experiments to investigate the role of CD4+CD25+ T cells in the induction of
peripheral tolerance to antigen administered intravenously or orally. They transferred
CD4+ T cells from DOl 1.10 mice on a
RAG-2"7" background into BALB/c mice. The RAG-2 /_ mice lack T cells and B cells,
and the DOl 1.10 RAG-2; mice contain less than 1% of CD4+CD25+ T cells as
opposed to DOl 1.10 BALB/c, which contain about 5% CD4+CD25+ T cells. This
difference results from the contribution of the endogenous TCR-a chain during TCR
rearrangement in CD4+ T cell development. Therefore, the use of these mice ensures
that the differentiation of the CD4+CD25+ T cells is exclusive to peripheral antigen
exposure. Typically, intravenous administration of antigen results in an antigen-
specific expansion of the CD4+ T cells followed by clonal deletion and functional
inactivation of the remaining antigen-specific CD4+ T cells. Thorstenson et al found
that low-dose intravenous injection of OVA peptide led to an increase in KJ 1-
26+CD25+CD4+ T cells between days 3 and 8 after injection compared to mice
primed with peptide and LPS. As well they found that antigen administration had an
inverse correlation to the percentage of KJ l-26+CD25+ T cells. Thus low-dose
antigen resulted in a higher percentage of KJ l-26+CD25+ T cells than high-dose
antigen, and these cells went through less cycles of cell division than the high-dose
antigen exposed cells. This observation was interesting as dividing cells are
associated with IL-2 production, and the KJ l-26+CD25+ T cells were found not to
produce IL-2 in vivo. They also found that low-dose intravenous and oral
administration of antigen both had similar effects on the cycling of KJ 1-
26+CD25+CD4+ T cells.
Finally they demonstrated that CD25+ T cells generated following peripheral
tolerance induction by low dose intravenous antigen exposure, or CD25+ T cells from
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transgenic DO11.10 mice could inhibit the IL-2 secretion of DO11.10 responder cells
to specific OVA peptide, to a similar extent.
Therefore, it appears that to re-address the question of CD4+CD25+ Tr cell
involvement during intranasal peptide tolerance, the DO11.10 TCR transgenic mouse
system can be effectively relied upon. Preliminary experiments would be needed to
determine the right concentration and frequency of OVA peptide administration to
induce tolerance. After optimising the protocol the antigen-specific cells from these
mice would be phenotyped as described previously, and the CD4+ T cells would be
analysed for expression of components of the Notch signalling pathway.
To test if the Tr cells generated in the DO11.10 mice are CD25+ T cells these cells
could be re-stimulated with OVA peptide in vitro, and compared to the proliferative
responses of CD25+ T cells from mice that received saline, or to their CD25"
counterparts. Co-culture of the CD25+ with the CD25 population from the peptide-
treated and saline-treated mice would also address the issue of their immune
suppressive capacity in response to antigen recognition.
CD25+ cells could also be depleted from peptide or saline-treated DO 11.10 CD4+ T
cells, transferred into BALB/c and mice then primed with OVA peptide. If the
CD25+ T cells were required for inducing and transferring tolerance, mice receiving
CD25+-depleted CD4+ T cells would respond to the peptide in vitro upon re-
stimulation of the antigen-specific CD4+ T cells.
If the antigen-specific cells during tolerance induction were CD25+ DOl 1.10
RAG-2"7" mice could be used to test if the generation of CD25+ T cells is specific to a
tolerogenic exposure of antigen or results from the expansion of the constitutive
CD4+CD25+ T cells. Adoptive transfer experiments could also be carried out to
ensure that only the antigen-specific CD4+ T cells are taken into account. CD4+ T
cells from DOl 1.10 RAG-2"7" mice can be adoptively transferred into BALB/c mice
and these mice tolerised by intranasal administration of antigen. If the CD4+CD25+ T
cells are the Tr cells in this system, their expansion in the different lymphoid
compartments can be followed over time, to study if the initial expansion of the cells
correlates with the site of antigen administration. Other experiments similar to the
ones conducted by Zhang et al and Thorstenson et al could also be conducted.
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This study has demonstrated that using a polyclonal TCR murine model of
recognition of the house dust mite CD4+ T cell epitope, peptide 110-130 has proven
difficult in an attempt to characterise the CD4+ T cells that are generated under
conditions that induce tolerance or priming. Still, expression of components of the
Notch pathway revealed that Jagged-1 was up regulated in CD4+ T cells after day 4
of peptide tolerance as opposed to peptide priming. The observation that it did not
seem to correlate merely with activation of the CD4+ T cells suggests that this
finding may be unique to the differentiation of Tr cells in this model of intranasal
peptide tolerance. Therefore, repeating these experiments in a transgenic mouse
model such as the DO 11.10 TCR transgenic system would give clearer answers to
the characterisation of CD4+ T cells generated after intranasal peptide administration.
Additionally, it would provide with more valuable and significant information
regarding the expression of components of the Notch signalling pathway.
144
CHAPTER V
Role of TGF-(3, Activin A and BMP-4 in CD4+ T Cell
Responses and Effects on Notch Signalling Genes
1. Background
The involvement of Notch signalling during development in cell fate decisions is
well documented (31, 32, 33, 34). We have also demonstrated (99) that Notch
signalling may play a role during peripheral immune responses in the differentiation
pathway that generates CD4+ Tr cells from naive cells after antigenic encounter.
However, the potential role of Notch signalling in CD4+ T cell differentiation during
antigen-specific responses is a novel area of study. Rather, the contribution of
inhibitory cytokines such as TGF-P in the generation of Tr cells in vivo, has been
investigated more thoroughly (63, 64, 222, 223).
Data from Chapter III (Figures 2, 3 and 5) demonstrate that genes associated with the
Notch and TGF-P signalling pathways are differentially expressed in peripheral
lymphoid organs and cells. Furthermore, the Notch ligands, the downstream
signalling gene, Hes-1, and the TGF-(3-like molecule, Activin A, were up-regulated as
early as 24 hours after in vitro activation of CD4+ T cells (Figure 6).
Due to its immune-regulatory capacity I went on to investigate the effect of TGF-P
and the TGF-P superfamily members, activin A and BMP-4, on CD4+ T cell
activation. Apart from belonging to the TGF-P superfamily, evidence has implicated
them all in similar biological processes, such as erythropoiesis and fracture repair
(Chapter I, Table III). Furthermore, activin A uses the same downstream effector
molecules as TGF-P, and has been found to affect proliferation of several cell types.
Therefore, the prediction is that functionally the different TGF-p-like molecules,
such as activin A and BMP-4, may display similar immune-regulatory properties to
those attributed to TGF-p in vitro (224, 225, 226).
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As well, I wished to investigate interactions between the TGF-(3 and the Notch
pathway. In development, activin A/BMP-4 and Notch/Notch ligands are highly
conserved and both can act to inhibit neurogenesis in favour of alternate fates.
Additionally, both have been implicated in similar biological processes such as
haematopoiesis, cancer, apoptosis and cell growth (Chapter I, Table III).
My hypothesis proposes that signals derived from Notch and TGF-(3 superfamily
genes may contribute to the outcome of CD4+ T cell function in vivo and in vitro.
Therefore, the question I wished to address was twofold. First, how do activin A and
BMP-4 affect CD4+ T cell responses in vitro. Second, if any effect on CD4+ T cell
responses mediated by these molecules may correlate with changes in expression of
genes associated with the Notch pathway. To carry out this work I used an antigen-
specific CD4+ human T cell clone (section 2.1), and murine splenic CD4+ T cells
activated with anti-CD3 and anti-CD28 antibodies (section 2.2).
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2. Results
2.1. Effect ofTGF-P-like Molecules on a Human CD4+ T cell clone
2.1.1. Effect ofTGF-p-like Molecules on HA1.7 T Cell Proliferation
The HA1.7 is a human CD4+ T cell clone reactive with the influenza haemagglutinin
(HA) peptide (HA306-318) and restricted by HLA-DRB1*0101. Murine
recombinant TGF-(3, activin A and BMP-4 were used to study the effects of these










Figure 1. TGF-P and activin A inhibit HA1.7 T cell proliferation. 2x10 HA1.7 T cells/well were
cultured in the presence of 10% IL-2, (lymphocult, blue bars), or 2.5x104 irradiated human peripheral
blood mononuclear cell (PBMCs) and 1 pg/ml of HA peptide (purple bars), or in 1 pig/ml of peptide
alone (yellow bars). Human recombinant TGF-P (A), activin A (B) or BMP-4 (C) were added at
varying concentrations. Cells were cultured for 3 days, and the plates were pulsed with 2.5pCi of 3[H]-
TdR for 18 hours before harvesting. The cells were cultured in triplicates in round-bottomed 96-well
plates.
- = not significant, a = p<0.001, b = p<0.01, c = p<0.05 for each bar versus the media alone bar of the
same colour.
Figure 1 reveals that BMP-4 had no effect on HA1.7 T cell proliferation regardless of
the concentration used, and the method of T cell activation. On the contrary, TGF-P
and activin A strongly inhibited proliferation ofHA1.7 in a dose-dependent manner.
This effect was achieved when the cells were stimulated with IL-2 alone
(lymphocult) or with the peptide, in the presence or absence ofAPCs.
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The ability of TGF-(3 to inhibit human T cell responses is well documented (224,
225, 226), and therefore my findings (Figure 1) are consistent with the published
literature. Interestingly, activin A had the same effect. This molecule has been shown
to modulate the proliferation of a number of cell types. For example, it has been
found to inhibit proliferation of mid-gestation human foetal adrenal cells in vitro in a
dose-dependent manner, and the effect is additive when TGF-(3 is also added (227).
Similarly, it inhibits proliferation of the BALB/c fibroblast cell line, 3T3 (136) and
the rat intestinal epithelial cell line, IEC-6 (228) in a concentration-dependent
manner. Other groups have also reported activin A and TGF-(3 to have similar
inhibitory effects in different cell types. They can both inhibit proliferation of rat
hepatocytes (134), murine primordial germ cells (229) and porcine thyrocyte cell
growth (230). Interestingly, in the latter study the authors investigated the effects of
TGF-(3, activin A and BMP-7. Like Figure 1 reveals, they found that the growth
inhibitory effect of activin A was not as pronounced as that of TGF-(3, and BMP-7
did not significantly inhibit cell growth.
Furthermore, activin A has been found to inhibit rat testicular CD4+ and CD8+ T cell
proliferation (165) and proliferation of rat T cells isolated from peripheral blood
(231).
2.1.2, Effect ofTGF-p-like Molecules on HA1.7 T Cell Cytokine Production
Having determined the effects of TGF-(3-like molecules on T cell proliferation, I
analysed if they had differential effects on cytokine production. The supernatants
from cultures of HA1.7 T cells incubated with APCs and HA peptide, in the presence
of increasing doses of TGF-|3, activin A or BMP-4 were tested for cytokine secretion
of IL-4, IL-5, IL-10 and IFN-y (Figure 2). Figure 2 shows that addition of BMP-4
had little effect on cytokine production. On the contrary, activin A and TGF-(3
inhibited Th2 cytokine secretion (IL-4, IL-5 and IL-10) in a dose-dependent manner.
In contrast, the levels of ILN-y secretion (Thl cytokine) remained constant regardless
of the protein concentration added.
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not be done. Although this limits the interpretation of these results, a trend towards
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Figure 2. TGF-P and activin A inhibit HA1.7 T cell cytokine secretion. 2x10
HA 1.7 T cells/well were cultured in the presence of 2.5xl05 irradiated PBMCs,
HA peptide and human recombinant activin A (blue bars, at 1, 10, lOOng/ml),
BMP-4 (purple bars, at 1, 10 lOOng/ml) or TGF-beta (yellow bars, at 0.1, 1,
lOng/ml) in round-bottomed 96-well plates. The supernatants were collected after
2 days. The ELISA plates were coated with IL-4, IL-5, IL-10 or IFN-y at 2pg/ml
and the supernatants added. Recombinant human IL-4 and IL-5 at 4ng/ml, IL-10
at 2ng/ml and IFN-y at 66ng/ml were used as the standards by double dilutions.
The biotinylated detection antibody was used at lpg/ml.
Therefore, it appears from these data that TGF-(3 and activin A may be capable of
down regulating Th2-type cytokines, but have only a minimal effect on Thl cytokine
production. In agreement with this observation is the work of Fargeas et al (232) who
showed that human T cells purified from peripheral blood and stimulated in vitro
with anti-CD3 antibody and TGF-(3, suppressed the production of IL-4 whereas IFN-
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showed that human T cells purified from peripheral blood and stimulated in vitro
with anti-CD3 antibody and TGF-(3, suppressed the production of IL-4 whereas IFN-
Y secretion was unaffected. Furthermore, recent work by different groups has
reported the same finding in the mouse. Ludviksson et al (233) showed that addition
of TGF-(3 during primary or secondary antigen-driven responses in vitro,
significantly decreased Thl (IFN-y) and Th2 (IL-4) cytokine production, although
the effect was more profound on the Th2 cytokines. Similarly, Heath et al (234)
showed that antigen-specific primary responses in the presence of TGF-(3 also led to
a marked decrease in IL-4, IL-5 and IL-10 production.
Little is known about the effects of activin A on cytokine production by CD4+ T
cells, and the only studies that have been carried have been using monocytes and
macrophages. Ohguchi et al (168) found that activin A could inhibit IL-1 production
by different human monocytic cell lines, whereas others (169) showed that activin A
caused release of TNF-a and IL-1 (3 in rat bone marrow-derived macrophages.
Further still, activin A has been found to suppress IL-6-mediated biological activities
(235). Therefore, most of the work that has been carried out using activin A has been
in connection with pro-inflammatory cytokines. In this study I report for the first
time how activin A may have the potential to inhibit Th2 cytokine production by a
human CD4+ T cell clone, although its significance in vivo is still unknown.
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2.1.3. Effect ofCombining TGF-|3-like Molecules on HA1.7 T Cell Proliferation
The observation that activin A and TGF-|3 had an inihibitory effect on the
proliferation ofHA 1.7 T cells prompted me to investigate whether these two proteins
in combination might have a synergistic effect on T cell growth. Therefore, I
stimulated cells with IL-2 (or lymphocult) in the presence of a sub-optimal dose of
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Figure 3. TGF-|3 and activin A act in synergy to inhibit HA1.7 T cell
proliferation.
A. 2xl04 HA 1.7 T cells/well were cultured in the presence of 10% lymphocult and
increasing concentrations of human recombinant TGF-|3 (A, blue bars) plus
lOng/ml of activin A (purple bars) or lOng/ml of BMP-4 (yellow bars). The cultures
were set up in triplicates in round-bottomed 96-well plates.
B. Alternatively, HA 1.7 T cells were cultured under the same conditions in the
presence of increasing concentrations of activin A (B, blue bars) plus 1ng/ml of
TGF-(3 (purple bars) or lOng/ml ofBMP-4 (yellow bars).
The plates were left in the incubator for 3 days, pulsed with 2.5 pCi of 3[H]-TdR
and harvested after 18 hours.
- = not significant, a = p<0.001, b = p<0.01, c = p<0.05 for each bar versus the
media alone bar of the same colour.
Figure 3B reveals that addition of lng/ml of TGF-|3 to increasing amounts of activin
A has a synergistic dose-dependent effect. The same outcome is observed when
lOng/ml of activin A are added to increasing concentrations of TGF-p (Figure 3A),
but the effect is not as pronounced, suggesting TGF-(3 is a more potent inhibitor of T
cell proliferation. This result suggests that activin A and TGF-(3 are having the same
effect but are not competing for the same receptors.
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When BMP-4 was added at lOng/ml to increasing concentrations of activin A or
TGF-(3, it promoted more HA1.7 T cell proliferation than cells grown in its absence.
However, the stimulatory capacity of BMP-4 did not override the inhibitory signals
of TGF-(3 and activin A which were still capable of suppressing proliferation of
HA 1.7 T cells in a dose-dependent manner.
The finding that activin A and TGF-(3 have similar inhibitory effects on HA1.7 T
cells, and in combination their effects are additive, whereas BMP-4 alone has no
effect on T cell proliferation, could be explained in terms of the receptors they bind
to and the signalling pathways they activate.
The members of the TGF-(3 superfamily bind type I and type II serine/threonine
kinase receptors (Chapter I, section 6.1). Initially, the ligand (TGF-P, activin A or
BMP-4) binds its type II receptor and this results in recruitment of the type I
receptor. The type II receptor then phosphorylates the type I, and this stimulates
intracellular interactions with distinct signal transducers called Smads. Smad 1, 5 and
8 are involved in BMP signalling and Smad 2 and 3 are mediators of TGF-(3 and
activin signalling. The fact that activin A and TGF-(3 bind to different receptors but
share a common signalling pathway could explain why they both have similar
inhibitory effects on T cell proliferation, and why when added in combination have
an additive effect. In contrast, the observation that BMP-4 had no effect on T cell
growth could be explained by the fact that this molecule signals through a different
pathway to TGF-J3 and activin A.
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2.1.4. The Effect ofTGF-|3-like Molecules is Direct on HA1.7 T cells
Having demonstrated that TGF-P and activin A can inhibit the proliferation and Th2-
type cytokine production ofHA1.7 T cells, I wanted to study whether this effect was
mediated by signals derived from the APCs, or by direct interaction on the HA1.7 T
cells. This question was addressed in two ways. First, the APCs were incubated for
three hours with TGF-|3, activin A or BMP-4. After the incubation period they were
washed and added to cultures containing HA1.7 T cells and HA peptide (Figure 4).
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Figure 4. Pre-treatment of APCs with activin A, BMP-
4 or TGF-p does not affect HA1.7 T cell proliferation.
PBMCs were pre-treated with lOOng/ml of activin A,
lOOng/ml of BMP-4 or lng/ml of TGF-P for 3 hours on
ice. They were washed with PBS, irradiated and added to a
round-bottomed 96-well plate at 2.5x105/ well, in the
presence of2xl04 HA1.7 T cells, and lpg/ml of peptide.
As a positive control HA1.7 T cells were cultured without
the proteins, in the presence of 1 pg/ml of peptide (pep bar)
and 2.5x105 irradiated PBMCs (APC+pep bar). The plates
were left for 3 days, and pulsed with 2.5pCi of J[H]-TdR
18 hours before harvesting.
Figure 4 reveals that pre-treating the APCs with any of the recombinant proteins did
not affect the proliferation of the HA1.7 T cells, suggesting that these cytokines are
not inducing changes in the APCs which could affect T cell growth.
The second experiment was set up to assess if the TGF-(3-like molecules were acting
directly on the T cells. This involved activating the HA1.7 T cells with plate-bound
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anti-CD3 and soluble anti-CD28 antibodies, in the absence of signals delivered by
APCs (Figure 5).
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Figure 5. Activin A and TGF-P inhibit growth of anti-
CD3 antibody-activated HA1. 7 T cells. 2xl04 HA1.7 T
cells/well were incubated in a flat-bottomed 96 well plate
that had been pre-coated with 5pg/ml of anti-CD3
antibody. The cells were cultured with 5pg/ml of anti-
CD28 antibody and increasing concentrations of activin A
(1, 10, 100 ng/ml), BMP-4 (1, 10, lOOng/ml) or TGF-P
(0.1, 1, 1Ong/ml). The plates were left for 3 days, and
pulsed with 2.5pCi of 3[H]-TdR 18 hours before
harvesting.
a = p<0.001, b = p<0.01 for each bar versus the media
alone bar in each treatment group.
Figure 5 reveals that activin A and TGF-P can markedly inhibit HA1.7 T cell
proliferation in the absence ofAPC and peptide, indicating that these molecules must
mediate their effects directly on the T cell, via recruitment of their type I and II
receptors. BMP-4 has the opposite effect, rather, it increases HA1.7 T cell
proliferation even at the lowest concentration.
In summary, the data revealed that activin A like TGF-|3, inhibited HA1.7 T cell
responses to specific antigen and to stimulation via antibody-mediated TCR
triggering. Furthermore, this was associated with a decrease primarily in Th2-type
cytokine production. If activin A and TGF-P were combined, their suppressive effect
was additive. BMP-4 on the contrary, had no effect on HA1.7 T cell proliferation
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when it was added on its own to antigen-stimulated cultures, and similarly it did not
modify cytokine production. However, when it was added in combination with
activin A or TGF-(3 to antigen-stimulated cells or on its own to anti-CD3-activated
cells, it stimulated HA1.7 T cell growth above controls. The most likely explanation
for the results observed is that all the molecules tested bind to different type I and
type II receptors. However, only TGF-(3 and activin A signal through the same
pathway and, therefore, have the same effect on T cell growth.
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2.2. Effect of TGF-(3-like Molecules on Murine CD4+ T cells
2.2.1. Effect of TGF-P-like Molecules on Murine CD4+ T Cell Proliferation
To determine if TGF-(3-like molecules had the same effect on murine CD4+ T cell
proliferation as they had on the human HA1.7 CD4+ T cell line, the cells were
isolated by MACS from the spleens of 6-8 week old wild type (wt) BALB/c or
C57BL/6 mice, and the purity checked by flow cytometry. Freshly isolated CD4+ T
cells were stimulated with increasing concentrations of plate-bound anti-CD3
antibody and 5(ig/ml of soluble anti-CD28 antibody (Figure 6), and increasing
concentrations of the recombinant proteins, to determine the optimum conditions of
the assay. Consistent with the HA 1.7 results (Figure 5), activin A and TGF-(3 could
inhibit proliferation of BALB/c and C57BL/6 CD4+ T cells. For BALB/c CD4+ T
cells, if the concentration of anti-CD3 antibody exceeded 1 jig/ml, the inhibitory
effects of activin A or TGF-(3 were masked. At lp,g/ml of anti-CD3 antibody, the
effect of TGF-(3 was dose-dependent, whereas activin A was only effective at
lOOng/ml, suggesting that TGF-(3 is a more potent inhibitory cytokine like in the
HA1.7 T cell clone. Interestingly, anti-CD3 antibody used at 5 or 10|ig/ml reversed
the inhibitory effects of TGF-(3, and instead the cells proliferated above controls.
BMP-4 on the contrary, did not inhibit proliferation regardless of the concentration
used.
For C57BL/6-derived CD4+ T cells, the concentration of anti-CD3 antibody did not
affect the inhibitory capacity of TGF-(3 and activin A, although at lpg/ml both
suppressed CD4+ T cell proliferation in a dose-dependent manner. BMP-4 also had
an inhibitory effect. The data reveal that the inhibitory capacity of TGF-(3 and activin
A are as effective on human as on murine CD4+ T cells and, furthermore, this is not
mouse-strain related. However, in this study the BALB/c assays gave more
consistent results than the C57BL/6 assays, therefore the work described here was
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Figure 6. Activin A and TGF-P inhibit growth of anti-CD3/anti-CD28
antibody-activated murine CD4+ T cells. CD4+ T cells were isolated by
magnetic beads from the spleens of wt BALB/c or C57BL/6 mice. 2.5x105
cells/well were added to flat-bottomed 96 well-plates that had been pre-coated
with varying concentrations of anti-CD3 antibody (1, 5, lOpg/ml). At each anti-
CD3 antibody concentration, anti-CD28 antibody was added at 5pg/ml along with
1, 10 and 1OOng/ml of activin A or BMP-4, or 0.1, 1 and 1Ong/ml of TGF-p. The
cells were cultured for 3 days, and pulsed for 18 hours with 2.5pCi of 3[H]-TdR
before harvesting.
- = not significant, a = p<0.001, b = <0.01, c = p<0.05 of a specific bar versus the
media alone bar in its treatment group. Significant values are only plotted for
responses that were inhibited.
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2.2.2. Effect of TGF-P-like Molecules on BALB/c CD4+ T Cell Viability
The optimum conditions for the BALB/c CD4+ T cell proliferation assay were set up
at 1 pg/ml of anti-CD3 antibody and 5pg/ml of anti-CD28 antibody for stimulating
the cells, and lOOng/ml of activin A, lng/ml of TGF-|3 and lOOng/ml of BMP-4 to
determine their effects on T cell growth. It was important to determine if the
suppressive effects of activin A and TGF-(3 were a consequence of apoptosis,
therefore, the cultures were set up as described above. In addition, cells were also
grown in the presence of dexamethasone as a positive control, as this reagent induces
apoptosis in lymphocytes. Three days later the percentage of total live cells was
assessed by FACS analysis with Annexin V and PI staining (Figure 7).
Annexin V binds to the membrane phospholipid phosphatidylserine (PS), which is
translocated from the inner to the outer leaflet of the plasma membrane during the
early stages of apoptosis. PI is permeable to the membrane of dead or damaged cells
and, therefore, distinguishes viable from nonviable cells. Cells that stain positive for
Annexin V and negative for PI are in the early stages of apoptosis. Cells that stain
positive for both Annexin V and PI are either in the later stages of apoptosis, are
undergoing necrosis, or are already dead. Cells that are negative for both Annexin V
and PI staining are viable.
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UL 5.58 3.59 3.02 2.92 4.62 1.16
UR 77.63 70.34 71.43 73.19 66.67 93.36
LL 14.92 15.14 16.77 14.53 21.85 2.20
LR 1.87 10.93 8.79 9.37 6.87 3.28
Figure 7. TGF-(3 molecules do not induce apoptosis in murine CD4+ T cells. 10 /ml CD4+ T
cells were cultured in media alone (A), or activated with 1 ug/m 1 of anti-CD3 and 5 pg/m 1 of anti-
CD28 antibodies (B) in the presence of lOOng/ml activin A (C), lOOng/ml BMP-4 (D), lng/ml
TGF-(3 (E) or 10"4M dexamethasone (F). After 3 days in culture the cells were washed and double-
stained with FITC-Annexin V and PI to assess for cell viability. The quadrant labels were set
according to where gated live cells or dead cells alone appeared in the dot plots (not shown). The
dot plots represent the total, ungated CD4+ T cell population.
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In Figure 7, the UR quadrant staining positive for Annexin V and PI are late stage
apoptotic cells, or necrotic cells. Cells in the LR quadrant are early apoptotic cells,
staining positive for Annexin V but not for PI. Activated cells (dot plots B to E) have
a higher percentage of early apoptotic cells than unstimulated cells (dot plot A), and
this may represent the effects of activation-induced cell death. Cells in the LL
quadrant represent the viable cells. Figure 7 and 8 show that the addition of activin
A, BMP-4 or TGF-P to CD4+ T cells is not affecting their viability over a three-day
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Figure 8. TGF-p and TGF-P-like molecules do not induce apoptosis
in murine CD4+ T cells. A. 2.5x105 CD4+ T cells/well were activated
with lpg/ml of anti-CD3 and 5pg/ml of anti-CD28 antibodies (aCD3)
plus lOOng/ml of Activin A (ActA) lOOng/ml of BMP-4 (BMP-4) or
lng/ml TGF-P (TGF-b). The cells were cultured for 3 days, and pulsed
for 18 hours with 2.5pCi of 3[H]-TdR before harvesting. B. 106/ml CD4+
T cells were stimulated as described for A including 10"4M
dexamethasone (DEX). The percentage of total live cells in each
treatment was assessed by Annexin V and PI staining after 3 days in
culture, and represents the mean from three different experiments,
a = p<0.001, b = p<0.01 for each bar versus the aCD3 bar.
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2.2.3. Effect of TGF-|3-like Molecules on BALB/c CD4+ T Cell Cytokine Production
To determine if TGF-|3 and activin A had the same effect on CD4+ T cell cytokine
production as on the HA1.7 T cell line (Figure 2), cells were cultured as described
earlier, and two days later the supernatants were collected to assess levels of IL-4,
IL-10 and IFN-y secretion. Unlike the data from the HA1.7 CD4+ T cells (Figure 2),
TGF-p or the TGF-P-like molecules had negligible effects on CD4+ Thl or Th2-type
cytokine production (Figure 9).
IL-4 IFN-y IL-10
media aCD3 ActA BMP-4 TGF-b media aCD3 ActA BMP-4 TGF-b media aCD3 ActA BMP-4 TGF-b
Treatment
Figure 9. TGF-P and TGF-p-like molecules do not affect cytokine production of anti-
CD3/anti-CD28 antibody-activated BALB/c CD4+ T cells. 2.5x10s BALB/c CD4+ T cells/well
were cultured in media only (media bar), or with lpg/ml of anti-CD3 and 5pg/ml of anti-CD28
antibodies (aCD3 bar) plus lOOng/ml of activin A (ActA bar), lOOng/ml BMP-4 (BMP-4 bar) or
lng/ml of TGF-P (TGF-b bar). The supernatants were collected after 2 days. The ELISA plates
were coated with IL-4, IL-10 or IFN-y at lpg/ml and the supernatants added. Recombinant mouse
IL-4 at 20ng/ml, IL-10 at 30ng/ml and IFN-y at 40ng/ml were used as the standards by double
dilutions. The biotinylated detection antibody was used at 1 pg/ml.
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2.2.4. TGF-p and activin A Induce CD4+ T Cell Unresponsiveness
Previous reports have demonstrated that IL-10 and TGF-(3 can induce long-lasting
unresponsiveness in CD4+ T cells. The first study on IL-10 was carried out by Groux
et al(213) and they found that human CD4+ T cells activated by anti-CD3 antibody
in the presence of IL-10 for 10 days, remained unresponsive to re-stimulation with
anti-CD3 antibody and IL-2, or anti-CD3 and anti-CD28 antibodies. Similarly,
Ludviksson et al(233) showed that OVA-TCR CD4+ T cells stimulated with APC
and OVA peptide in the presence ofTGF-|3, remained unresponsive to subsequent re-
stimulation with anti-CD3 and anti-CD28 antibodies, or exogenous IL-2. These
observations prompted to investigate if activin A and TGF-(3 were also able to induce







Figure 10. Activin A and TGF-P induce unresponsiveness in anti-
CD3 antibody-activated BALB/c CD4+ T cells. 106 CD4+ T
cells/well were incubated in 24-well plates in media containing
0.5pg/ml of plate-bound anti-CD3 antibody only (aCD3), plus
lOOng/ml activin A (aCD3+ActA), lOOng/ml BMP-4 (aCD3+BMP-4)
or lng/ml TGF-P (aCD3+TGF-b). On day 4, 105 cells/well were
transferred to flat-bottomed 96-well plates and the cells were re-
stimulated with media only (blue bars), or 0.5pg/ml of plate-bound
anti-CD3 antibody (purple bars) and lOpg/ml of soluble anti-CD28
antibody (yellow bars). Cells were left in culture for 4 days before
measuring 3[H]-TdR incorporation.
- = not significant, a = p<0.001 for each bar versus the media alone bar
in each treatment group.
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Figure 10 shows that CD4+ T cells treated with activin A and TGF-(3 failed to
proliferate in response to re-stimulation with anti-CD3 antibody. In the presence of
anti-CD3 and anti-CD28 antibodies the inhibition was partly reversed in activin-A
treated cells and to a lesser extent in TGF-(3-treated cells, although the cells did not
proliferate as vigorously as activated cells grown in media only or in the presence of
BMP-4. Therefore, TGF-(3 and activin A can induce unresponsiveness in CD4+ T
cells to further stimulation via the TCR, in a similar manner as previously reported
by Groux et al (213).
2.2.5. Phenotypic Analysis of CD4+ T Cells After Treatment with TGF-(3-like Molecules
CD4+CD25+, CD4+CD45RBlow cells and CD4+CD38+ T cells have all been described
as Tr cells (20, 22, 25, 29). From the findings that activin A and TGF-(3 induce CD4+
T cell unresponsiveness, I was prompted to investigate if this effect was the result of
TGF-(3 signalling directing cells into a Tr pathway. Therefore, I cultured CD4+ T
cells as previously described, and after 3 days the cells were stained for surface
expression of CD25, CD38 and CD45RB, and analysed by FACS (Figure 11).
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CD45RB+ 98.8 99.8 99.9 99.8 99.7
CD25+ 7.5 96.7 95.3 96.4 95.3
CD38+ 26.6 32.8 38.9 37 40.7
Figure 11. TGF-|3-like molecules do not modulate expression of Tr markers. 106/ml
BALB/c CD4+ T cells were cultured in media alone (A), or activated with lpg/ml anti-CD3 and
5pg/ml anti-CD28 antibodies (B) in the presence of lOOng/ml activin A (C), lOOng/ml of BMP-
4 (D) or lng/ml of TGF-f3 (E). After 3 days in culture the cells were washed and single stained
with PE-CD25, -CD38 and -CD45RB for FACS analysis (in red). Ml was set according to the
isotype control specific for each marker (shaded grey). The values represent the percentage of
live, positively staining cells in the CD4+ T cell population.
The high affinity IL-2 receptor (IL-2R) consists of 2 polypeptide chains, each
containing IL-2 binding sites. One is constitutively expressed, IL-2Rp chain and the
other is induced upon T cell activation, IL-2Ra chain or CD25 (236). The FACS data
(Figure 11) show that upon activation, CD4+ T cells up-regulate CD25 as would be
expected. However, treatment with any of the proteins does not modulate CD25
expression, suggesting that inhibition of CD4+ T cell proliferation is not the result of
down-regulated IL-2Rmaking cells less responsive to IL-2. Our results are similar to
what other groups have reported. Ahujas et al (226) found that pre-treating human T
cells with TGF-P prior to activation did not affect their IL-2Ra chain expression.
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However, they did observe that TGF-P could inhibit phosphorylation of the IL-2R(3
chain, and thus, of the IL-2 signalling pathway. In a more recent report Sudarshan et
al (237) found that TGF-P did not inhibit IL-2-induced phosphorylation of Jak-1 and
Stat-5 in activated human T cells, and they proposed that inhibition of IL-2-induced
activities by TGF-P may result from IL-2 signalling-independent events.
Activation of CD4+ T cells also led to a slight up-regulation of CD38 compared to
resting T cells, which is consistent with the role it is thought to play in lymphocyte
activation (238). Adding TGF-P, activin A or BMP-4 slightly up-regulated
expression of this marker but to the same extent in all three treatments, and no
changes were observed in the expression of CD45RB. Therefore, activating CD4+ T
cells in vitro and adding activin A or TGF-P led to a state of T cell unresponsiveness,
which was not affecting expression of Tr cell surface markers, only to the extent that
may be expected following CD4+ T cell activation.
2.2.6. Effect of TGF-(3 and TGF-P-like Molecules on Notch Signalling Genes
I have focused my interest on the role that highly conserved molecules, such as
Notch and its ligands may be playing in specifying Tr cells during the establishment
of peripheral tolerance. In addition, it is well-known that TGF-P is required for Tr
cell function (65), and the data provided in this study show that TGF-P and the TGF-
P-like molecule, activin A, can induce CD4+ T cell unresponsiveness. Therefore, I
wanted to investigate if the Notch signalling genes were differentially regulated by
treatment of CD4+ T cells in vitro with TGF-P and the TGF-p-like molecules, activin
A and BMP-4. For this, CD4+ T cells were cultured in the presence of either
molecule and after 3 days in culture, the cells were washed and prepared for
extraction of total RNA and real-time PCR analysis (Figure 12).
The cells in Figure 12 were stimulated with 0.5 pg of anti-CD3 only like in Figure
10, as at this concentration the cells still retained their proliferative capacity if re-
stimulated with anti-CD3, but remained unresponsive if they had been pre-treated
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Figure 12. Differential regulation of Notch and its related genes in anti-CD3 antibody-
activated BALB/c CD4+ T cells. 2x106 BALB/c CD4+ T cells/well were cultured in media only
(naive bar), or with 0.5pg/ml of anti-CD3 (aCD3 bar) plus lOOng/ml of activin A (ActA bar),
lOOng/ml BMP-4 (BMP-4 bar) or lng/ml of TGF-p (TGFb bar). Three days later the cells were
processed for total RNA extraction and reverse transcribed for cDNA synthesis. The samples were
tested for gene expression {Notch-1 and 2, Jagged-1 and 2, Delta-1, Hes-1 and Deltex) by real-time
PCR. For each gene, the samples were run with a positive control, which was the untreated (naive)
population to which all the values are relative, and with a negative control (no cDNA) to ensure
there was no genomic DNA contamination. Furthermore an internal control, 18srRNA, was included
per sample as a monitor of the PCR reaction and of the amount of cDNA used. A 2.5-fold increase
above the positive control is regarded as significant (in orange).
The real-time PCR data show that the Notch receptors, Notch-1 and -2 were not
modulated significantly with any of the treatments. Activating the cells with anti-
CD3 led to a marked drop in the expression of Deltex, which was unaffected by
addition of TGF-|3, activin A or BMP-4. Interestingly, only in the presence of TGF-(3
there was a significant up-regulation of Delta-1, Jagged-1 (about seven-fold), and
Hes-1 (2.5-fold) relative to untreated or anti-CD3-activated cells by 72 hours. In
contrast, activating the cells with anti-CD3 led to an up regulation of Jagged-2 (3.5-
fold), which was not modulated by BMP-4, but was down regulated in the presence
of activin A and TGF-|3.
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Therefore, although activin A and TGF-(3 were both capable of inducing CD4+ T cell
unresponsiveness and both signal through the same intracellular mediators, they
displayed differential regulation of Notch ligand (Jagged-1 and Delta-1) and Hes-1
expression. BMP-4, which did not affect CD4+ T proliferation, did not modulate the
expression of the genes studied to any significant extent compared to untreated cells,
or anti-CD3 activated cells.
The data presented in Figure 12 can be compared to the data from CD4+ T cells
stimulated with lpg of anti-CD3 and 5|ig of anti-CD28 (Chapter III, Figure 6).
It is apparent that the Notch receptors are not greatly modulated by activating the
CD4+ T cells via the TCR alone (anti-CD3), or in the presence of co-stimulation
(anti-CD28). Delta-1 is significantly up regulated with anti-CD3 and anti-CD28
antibodies by 24 hours (about 50-fold) and transcripts are still high after 48 hours of
activation (about 10-fold). Although treatment with anti-CD3 did not seem to affect
Delta-1 expression after 72 hours, this could reflect differences in kinetics.
Levels of Jagged-1 in the anti-CD3 and anti-CD28-activated CD4+ T cells drop to
about 5-fold with respect to untreated cells by 48 hours, suggesting that by 72 hours
levels may be closer to those in Figure 12. Similarly, Jagged-2 also shows similar
kinetics of expression in anti-CD3 and anti-CD3/anti-CD28 activated CD4+ T cells.
As far as the intracellular mediators are concerned, Deltex is down-modulated
irrespective of the mode of activation, and Hes-1 in anti-CD3/anti-CD28-activated
CD4+ T cells is down-modulated to levels in untreated cells after 48 hours, identical
to 72 hours of activation in anti-CD3 alone. Therefore, from these observations it
emerges that different modes and length of activation may tightly regulate the
kinetics and levels of expression of Notch signalling genes.
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3. Discussion
In this study I have compared the effects of the TGF-(3-like molecules, activin A and
BMP-4, on CD4+ T cell responses in vitro, with respect to TGF-|3, which is a well
known inhibitory cytokine of T cells (224, 225, 226). The RT-PCR and real-time
data from Chapter III had revealed that BMP-4 was not expressed in lymphoid
tissues or lymphocyte populations of untreated mice. However, Activin A and TGF-
(3, were both highly expressed. The availability of activin A and BMP-4 allowed us
to study their effects on a human T cell clone, and on murine splenic CD4+ T cells in
vitro, as this had not been investigated before.
Interestingly, activin A and TGF-(3 inhibited human and murine T cells activated via
the TCR, and their effects were additive when they were added in combination.
These data agrees with other reports on the inhibitory actions of activin A and TGF-|3
(134, 229, 230). BMP-4, on the contrary, did not affect T cell proliferation. These
results suggest that TGF-(3/activin A and BMP-4 mediate their effects differently.
Indeed, activin A and TGF-(3 signal through different intracellular mediators
compared to BMP-4. The latter binds to type I and II receptors that activate
intracellular Smads 1, 5 and 8, whereas activin A and TGF-|3 activate Smads 2 and 3.
Furthermore, the CD4+ T cells that had been activated in the presence of activin A or
TGF-|3 remained unresponsive to further re-stimulation with anti-CD3 and this was
only partly reversed by anti-CD3/anti-CD28 antibodies. However, there was no
difference in the expression of various cell surface markers (CD25, CD38, CD45RB)
when the cells were cultured in the presence of activin A or TGF-|3. Therefore, the
inhibitory effects exerted by TGF-(3 and activin A did not lead to modulation of cell
surface markers that are normally expressed by Tr cells. Nevertheless, it would be
interesting to characterise this population further. Other necessary experiments
involve re-stimulating the cells with IL-2 or mitogens (con A and PMA/ionomycin),
to study if the cells regain their proliferative capacity.
Our belief that the TGF-|3 and Notch signalling pathways may co-operate in the
induction of Tr cells, prompted to investigate the effect of activin A, BMP-4 or TGF-
(3-treated CD4+ T cells in the expression of Notch signalling genes. BMP-4 did not
modulate expression of any of the genes studied compared to untreated cells or anti-
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CD3 activated CD4+ T cells. Surprisingly, activin A and TGF-(3 did not affect gene
expression in the same way. TGF-(3 induced a significant up-regulation of the Notch
ligands, Jagged-J and Delta-1, and the transcription factor Hes-1, which was not
found in the activin A-treated cells. Interestingly, however, both activin A and TGF-
(3 down-regulated the expression of Jagged-2 induced upon anti-CD3 activation.
Therefore, the similar inhibitory effects observed in vitro did not always correlate to
gene expression profiles of the Notch signalling genes tested, suggesting these
molecules might signal through the same intracellular mediators, but activate
different target genes.
Although it is not known how TGF-(3 may modulate expression of these genes, this
the first time an association is made between both signalling pathways, and this




1. The role of the Notch pathway in the adult immune system
The mucosal immune system can discriminate between pathogenic microorganisms
and innocuous matter, such as dietary antigens, inhaled particles or commensal
microorganisms (1, 2, 3) by promoting specific immunological unresponsiveness.
This form of tolerance is referred to as mucosal tolerance and some mechanisms that
have been associated with it include clonal deletion, anergy or regulatory T cells (Tr
cells). Breakdown of tolerance and the recognition of pathogenic substances leads to
the differentiation of CD4+ T helper cells, which induce productive immunity.
These opposing outcomes of the immune response are controlled by many factors,
which include the nature of the antigen (pathogenic or harmless), its route of entry,
the microenvironment at the site of antigen presentation (including cytokines, APCs,
and co-stimulatory molecules), as well as signals derived from the innate immune
system. In addition, I propose that the tightly regulated genetic pathway, the Notch
signalling pathway may also contribute to whether the immune system responds to
antigen or becomes unresponsive. This statement is supported by our observations
that DCs which over-express the Notch ligand, Jagged-1, are capable of inducing a
population of Tr cells which can transfer tolerance (99).
Over the last 5 years intense research has focused on elucidating the role of Notch
signalling during thymocyte development. Interestingly, the Notch receptors and
ligands are expressed in thymocyte subsets, as well as in thymic stroma (73, 180),
and numerous reports have reported on the contribution of Notch signalling in T cell
differentiation and lineage commitment (74, 75, 81, 83).
The involvement of Notch signalling in cell fate decisions during development raises
the question of whether or not the pathway may also be involved in decision making
processes in the adult, such as its participation in determining the outcome of
peripheral immune responses.
In the work presented in this thesis I have investigated if components of the Notch
signalling pathway are differentially regulated during CD4+ T cell responses in vitro
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and in vivo, and if this may be associated to the functional differentiation of helper or
regulatory CD4+ T cells.
The experiments conducted in this thesis have demonstrated that
1. Components of the Notch pathway are differentially expressed in adult lymphoid
tissues (spleen and lymph nodes) and cells (splenic CD4+ T cells, CD8+ T cells, B
cells and enriched DCs).
2. Activating CD4+ T cells and B cells in vitro with anti-CD3/anti-CD28 antibodies
and LPS, respectively, up-regulate significantly expression of Jagged-2 and
Delta-1.
3. Activating CD4+ T cells in vivo by intranasal administration of HDM peptide
under conditions that induce T helper cells does not modulate expression of
components of the Notch pathway. However, under conditions that induce
regulatory T cells there is a significant up-regulation of Jagged-1.
4. It is difficult to rely on a polyclonal CD4+ TCR murine model for recognition of
a HDM peptide to define the cell surface phenotype of CD4+ T cells under
conditions that induce productive immunity or tolerance via the respiratory
mucosa.
I. Components of the Notch pathway are differentially expressed in adult
lymphoid tissues (spleen and lymph nodes) and cells (splenic CD4+ T cells,
CD8+ T cells, B cells and enriched DCs).
Initially expression of genes of the Notch pathway was measured by RT-PCR, as
there are only very limited availability of antibody reagents. I noted that the Notch
receptors, Notch-1, -2 and -4, and the Notch ligands, Jagged-1, -2 and Delta-1, were
differentially expressed in all the different lymphoid tissues (spleen, thymus and
LNs) and cells (lymphocytes and DCs) studied (Chapter III, Figures 2, 3 and 5).
Activation of the pathway is associated with an up-regulation of two signalling
components, which operate independently of each other. One is the transcriptional
repressor, Hes-1 (32), and the other is Deltex (85), a protein which interacts with the
intracellular domain of the Notch receptor, and positively regulates Notch activity
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(204). I observed that Hes-1 is expressed in the different tissues and cell populations
of the immune system, suggesting that the pathway may contribute to the control of
peripheral immunity. Deltex was not analysed in this study.
2. Activating CD4+ T cells and B cells in vitro with anti-CD3/anti-CD28
antibodies and LPS, respectively, up-regulate significantly expression of
Jagged-2 and Delta-1.
In order to obtain a more quantitative measure of gene expression I opted to use real¬
time PCR (Section 3.5). Regulation of Notch signalling genes during the activation
of B cells and CD4+ T cells in vitro was determined. B cells were activated with
LPS, and CD4+ T cells by ligation of the TCR using anti-CD3 and anti-CD28
antibodies. The data (Chapter III, Figures 6 and 7) showed that only Notch-1 was
significantly up regulated in B cells (more than 15-fold) throughout the 72 hour
period of activation. However, Jagged-2 and Delta-1 were significantly up regulated
in both populations after 24 hours of activation. An interesting finding was that Hes-
1 was only increased in CD4+ T cells but not B cells, and Deltex in B cells but not
CD4+ T cells. This could result from the intracellular signalling events specific to B
cells or CD4+ T cells after LPS or antibody-mediated activation, respectively.
The marked up-regulation of some of these genes after 24 hours (50-fold for Delta-1
and 20-fold for Jagged-1 in CD4+ T cells) suggests that these genes may have earlier
kinetics which show a more gradual induction, but their expression was only
measured in this study after 24 hours.
Based on these observations I suggest that activation of lymphocytes affects a
common downstream signalling pathway that results in transcriptional activation of
the Notch ligand genes, Jagged-2 and Delta-1. Indeed one possible candidate is NF-
kB, which is activated in B cells after mitogenic stimulation (196) and in T cells after
anti CD3/anti-CD28 activation (197, 198). Evidence for this has been provided by
the studies of Bash et al (191) who used the CCR43 cell line, which conditionally
expresses the NF-kB subunit, c-Rel, under the control of a tetracycline-regulated
transactivator. c-Rel expression in these cells led to induction of Jagged-1
transcripts. Similarly, they used PMA plus ionomycin to activate endogenous NF-kB
factors in human Jurkat T cells. They found that under these conditions, there was a
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4-fold increase in Jagged-1 mRNA levels compared to unstimulated cells. In
addition, a more recent study (239) has demonstrated that B cells from Notch-1
deficient mice had a reduced capacity to proliferate in response to LPS, supporting
an interaction between NF-kB and Notch signalling.
The biological significance of the cross talk between the NF-kB and Notch signalling
pathways remain to be fully elucidated. There are several conflicting reports about
possible interactions between Notch and NF-kB. One group demonstrated an ability
of Notch-1 to mimic IkB and to sequester NF-kB dimers, thus preventing NF-kB-
dependent activation of transcription (199). More recently (240) this inhibitory
interaction has been shown to require a domain of Notch-1 in the intracellular portion
that interacts directly with the p50 subunit of NF-kB, preventing it from binding to
its DNA binding site and initiating transcription of specific genes. In contrast, a
different group reported that constitutive Notch-1 mediated stimulation of the p52
promoter (200), and Bellavia et al (98) reported that Notch-3 induced
phosphorylation and degradation of IkB, which in turn resulted in nuclear
translocation of NF-kB dimers and activation of transcription. A more recent study
has demostrated that Notch-1 deficient hematopoeitic progenitor cells have reduced
NF-kB activity (239).
Despite the discrepancies, the published observations have demonstrated a physical
interaction between Notch and NF-kB components, and this may be important in the
regulation of cellular differentiation, activation, proliferation and survival.
3. Activating CD4+ T cells in vivo by intranasal administration of HDM peptide
under conditions that induce T helper cells does not modulate expression of
components of the Notch pathway. However, under conditions that induce
regulatory T cells there is a significant up-regulation of Jagged-1.
I also investigated the regulation of components of the Notch pathway in CD4+ T
cells during in vivo immune responses. I used a murine model of responsiveness to
the HDM peptide 110-130 in which productive immunity or tolerance can be
generated through the induction of CD4+ T helper cells and regulatory CD4+ T cells,
respectively. With this model I was able to investigate if the functional outcome of
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CD4+ T cells after antigen encounter was associated with a differential regulation of
Notch signalling genes.
In the initial experiments, the mice were primed and tolerised by different routes of
antigen administration, which restricts the interpretation of the gene analysis studies.
Therefore, the experiments were extended using the intranasal route for antigen
delivery. To induce tolerance the mice were given lOOptg of pi 10-130 on three
consecutive days, following the protocol established by Hoyne et al (11).
The protocol for intranasal priming relied on the use of the mucosal adjuvant E.coli
heat labile enterotoxin (LT). The concentration of LT required modifications to what
other studies had reported. Initially I used LT at a concentration of 5|ig, which is
within the range of what other groups have used as a mucosal adjuvant (208, 209,
210). However, I found that this concentration on its own was sufficient to prime
mice to the HDM, which is presumably present in the Animal House (Chapter IV,
Figure 1). In control experiments, I established the concentration of LT required to
prime mice in the presence of pi 10-130 but not on its own (Chapter IV, Figures 2
and 3) namely priming with 100p,g of pi 10-130 in the presence of 0.03pg of LT.
Thus, mice were primed or tolerised to pi 10-130 and the CD4+ T cells were isolated
at 2, 4 or 7 days after the last peptide treatment to study expression of Notch
signalling genes.
The kinetics of the response in priming and tolerance induction differed. In the
presence of LT, the CD4+ T cells responded to peptide re-stimulation in vitro at day
7 after peptide treatment (Chapter IV, Figure 4). On the contrary, CD4+ T cells from
tolerised mice responded to peptide re-stimulation by day 2, which peaked at day 4,
before becoming unresponsive on day 7 (Chapter IV, Figure 5). This difference may
question the interpretation of the real-time data if it is argued that the difference in
kinetics of CD4+ T cell activation may also reflect differences in gene expression.
However, given that the experiments were adequately controlled and that the route of
antigen administration was kept constant, the CD4+ T cells from both experimental
groups were not compared to each other in terms of kinetics. Rather, they were
compared to CD4+ T cells from untreated mice. Therefore, the gene expression of
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untreated CD4+ T cells was taken as the baseline, to which the expression of genes in
the other samples was related.
The real-time PCR data revealed that the Notch receptors (Notch-1 and -2) and
ligands (Jagged-1 and-2, and Delta-1) were not modulated over the time points
investigated in CD4+ T cells under conditions that primed the mice (Chapter IV,
Figure 7). In contrast, tolerising mice to the peptide resulted in a significant increase
in Jagged-1 at day 4 after the last peptide treatment, and to a lesser extent, in Delta-1
(Chapter IV, Figure 9). The observation that up-regulation of Jagged-1 was not
observed in priming suggests that it is not a consequence of CD4+ T cell activation
after antigen presentation, but rather it may be a feature unique to the induction of
peptide tolerance. Furthermore, an interesting observation was that the up regulation
of Jagged-1 occurred at a time prior to the cells becoming unresponsive, when the
decision is made to become Tr cells.
The increase in ligand expression was not accompanied by an increase in Hes-1 or
Deltex up regulation in the peptide treated group compared to the saline alone group
(Chapter IV, Figure 10). These two signalling mediators have been associated with
Notch activity, and therefore, the finding that they were not significantly modulated
under conditions that induce tolerance would suggest that Notch signalling has not
occurred. Therefore, it may be more plausible to speculate that the up regulation of
Jagged-1 in CD4+ T cells during tolerance induction may result from signals derived
from the APCs and the site of antigen presentation under conditions that favour
tolerance induction.
4. It is difficult to rely on a polyclonal CD4+ TCR murine model for recognition
of a HDM peptide to define the cell surface phenotype of CD4+ T cells under
conditions that induce productive immunity or tolerance via the respiratory
mucosa.
The relevance of Tr cells in controlling immune responses both to self and non¬
pathogenic foreign antigens highlights their importance as a potential candidate for
immunotherapy, in individuals where tolerance breakdown leads to disease
progression. The attention focused in this thesis in the generation of Tr cells, led to
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an attempt to characterise the Tr cells generated in the model of intranasal peptide
tolerance discussed previously.
Peripheral lymphoid compartments contain a population of CD4+CD25+ T cells that
are unresponsive to numerous stimuli in vitro (22), and can suppress the autoreactive
potential of CD4+CD25" T cells in vitro and in vivo (19, 20, 21, 22). In addition
CD25+ T cells have been found to be predominantly CD45RBlow (26, 27), and to
express constitutive CTLA-4 at higher levels than their CD25" counterparts (28),
similar to the data I have presented. Recent studies have also attributed a role to the
CD25+ population in the induction of oral tolerance in OVA TCR transgenic mice
(220, 221).
Therefore, I investigated if CD4+ T cells in mice that were primed or tolerised
intranasally to HDM pi 10-130 expressed the same surface phenotype reported for Tr
cells. Splenocytes were isolated from mice that had been primed or tolerised at days
2, 4 or 7 after the last peptide treatment, and stained with antibodies to CD4 and
CD25, to gate on CD4+CD25+/~ populations, and with a third marker, being CD38,
CD45RB, CTLA-4 or CD69. CD38 has also been associated with Tr cells (29) and
CD69 is an early activation marker.
Characterisation of these cells was hampered by the low frequency of antigen-
reactive cells (about 1 inlO5) and therefore, it is very difficult to detect changes in the
phenotype of these cells. The flow cytometry data revealed that intranasal
administration of the mucosal adjuvant LT on its own led to an increase in the
numbers of CD4+CD25+ T cells (10%) compared to untreated CD4+ T cells (7%)
(Chapter IV, Table 2). This increase also corresponded to a rise in the numbers of
CD25+CD38+, CD69+ and CD45RBlow cells (Chapter IV, Table 3). However, there
were no differences between the control group and the primed group that received
LT and peptide, which suggests that the increase was a feature of the activating
properties of the adjuvant on the CD4+ T cells, rather than of the antigen-driven
response. Indeed Nashar et al (219) found that mice injected intraperitoneally with
30pg of LT in CFA caused an increase in the numbers of CD4+CD25+ T cells in the
mesenteric lymph nodes compared to mice that received the same dose of a mutated
form of LT.
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CD4+ T cells from mice that received saline alone also had an increased number of
CD25+ T cells (9%) compared to CD25+ T cells from untreated mice (7%), which
corresponded to an increase in the numbers of CD25+CD38+, CD45RBl0W, CD69+
cells (Chapter IV, Tables 2 and 5). Similar increases were also observed in CD4+ T
cells from mice that were tolerised with pi 10-130 in saline. Only CD69 and CTLA-4
were increased by two-fold or more, respectively, at day 2 after the last peptide
treatment, but it is difficult to ascertain the biological relevance of this finding.
Therefore, these results demonstrate the limitation in using a polyclonal TCR murine
model to characterise Tr cells that are generating during the induction of peptide
tolerance. It also demonstrates that these markers are characteristic of activated cells
and treatments that would not normally be considered as modulators of CD4+ T cell
phenotype, were capable of inducing changes in the expression of cell surface
markers that were not driven by antigen.
To gain further insight into the characterisation of CD4+ T cells and the involvement
of Notch signalling during peripheral immune responses, I will address this question
in the OVA transgenic TCR system, clone DO11.10. The majority of CD4+ T cells
from these mice express TCRs specific for the OVA peptide 323-329, which can be
recognised by the clonotypic antibody KJ 1-26. This facilitates the characterisation
of the antigen-specific cells and allows gene expression to be linked to antigen driven
events.
2. The role of TGF-(3 signalling in the adult immune system
TGF-(3 is a well known immune-regulatory cytokine and numerous studies have
reported that its secretion by regulatory T cells has important implications in the
control of autoimmune disorders. Hence, Powrie et al (65) showed that TGF-(3 was
prerequisite for the function of the regulatory CD4+CD45RBlow T cells in inhibiting
colitis. As well, TGF-(3 production is associated with the protective effects seen in
animal models of mucosal tolerance of both collagen-induced arthritis (CIA) and
experimental allergic encephalomyelitis (EAE) (16, 223). Additionally, TGF-P can
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inhibit CD4+ T cell-mediated immune responses, both in vitro (224, 225, 226) and in
vivo (63, 64, 222).
Other members of the TGF-beta superfamily include activin A and BMP-4.
Specifically, I have analysed their effects on CD4+ T cell function because, like
members of the Notch signalling pathway, they are highly conserved and also
regulate developmental processes (45, 46, 54, 55). Additionally, they also participate
in numerous biological processes in adult life (127, 153). From an immunological
point of view they were interesting because of their potential to function like TGF-(3.
Activin A uses the same intracellular mediators (Smads 2 and 3) as TGF-(3 for signal
propagation (105), which suggests that functionally both may function in a similar
manner. Indeed, studies on targeted disruption of Smad 3 (109) have shown that T
cells display an activated phenotype and are not inhibited by TGF-(3l in vitro, and
therefore, activin A which signals through Smad 3, may have similar effects. As far
as BMP-4 is concerned, it mediates signalling via different Smads to activin A and
TGF-(3. Activation of the pathway recruits Smads 1, 5 and 8, and therefore it is
possible that signalling through BMP-4 might have different effects on the outcome
of immune responses compared to activin A or TGF-(3.
In the work presented in this thesis I have investigated if members of the TGF-(3
superfamily, like components of the Notch pathway, are differentially regulated
during CD4+ T cell responses in vitro and in vivo, and if this may contribute to the
functional differentiation of CD4+ T cells.
In addition in an attempt to establish a link between the Notch and TGF-(3 signalling
pathways during CD4+ T cell responses in vitro, I have investigated how TGF-(3
superfamily members may be regulating expression of genes of the Notch pathway.
The experiments conducted in this thesis have demonstrated that
1. TGF-/3 and activin A are highly expressed in splenic CD4+ T cells, CD8+ T
cells, B cells and enriched DCs. However, BMP-4 is weakly expressed in
these cells.
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2. Activin A is significantly up-regulated by 24 hours in CD4+ T cells (50-fold)
and B cells (4.5-fold) following anti-CD3/anti-CD28 and LPS activation,
respectively. TGF-(3 is only gradually up regulated in B cells.
3. Activin A and TGF-p can inhibit proliferation of a human CD4+ T cell clone
and of primary splenic CD4+ T cells. BMP-4 has no effect.
Analysis of their effects in T cell responses in vitro revealed that activin A and TGF-
(3 could inhibit proliferation of the human CD4+ T cell clone, HA 1.7, in response to
specific antigen, and of murine CD4+ T cells in response to antibody-mediated
activation (Chapter V, Figures 1 and 8). Furthermore, both proteins could induce a
state of CD4+ T cell unresponsiveness, which could not be reversed by anti-CD3 re-
stimulation, and only partially by both anti-CD3 and anti-CD28 re-stimulation
(Chapter V, Figure 10). BMP-4, in contrast, had no effect on CD4+ T cell
proliferation. Thus the differential effects of activin A and TGF-(3 versus BMP-4
may be attributed to signalling via different intracellular mediators. Activin A and
TGF-P signal via Smad 2 and 3, whereas BMP-4 signals through Smad 1, 5 and 8.
In an attempt to describe the cell surface phenotype of the CD4+ T cells treated with
the different TGF(3 superfamily members, the cells were surface stained with
antibodies characteristic of Tr cells. The data (Chapter V, Figure 11) demonstrated
that these treatments did not affect the increase in expression of CD25, CD38 or
CD45RB triggered by antibody-mediated CD4+ T cell activation. This could indicate
that the unresponsiveness induced by the activin-A or TGF-(3-treated cells might not
be attributable to changes in the expression of the markers examined.
4. TGF-(3, but not activin A or BMP-4, can up-regulate expression of Jagged-1,
Delta-1 and Hes-1 in CD4+ T cells.
Activin A and TGF-(3 had differential effects on the expression of Notch signalling
genes, which may suggest that these molecules might signal through the same
intracellular mediators, but activate different target genes (Chapter V, Figure 12).
The experiments demonstrated that TGF-(3 was a more potent inhibitor of CD4+ T
cell activation, as lng/ml was sufficient to suppress activation, whereas lOOng/ml
were required for activin A. This concentration dependent difference may interfere
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with the type of intracellular mediators activated, or the effect to which they affect
transcription of target genes.
Both molecules down regulated the induction of Jagged-2 mediated by TCR
triggering in CD4+ T cells. However, only TGF-(3 significantly up regulated Jagged-
1 and Deta-1, and this was also accompanied by a rise in Hes-1. Hes-1 is known to
act as a transcriptional repressor and has been studied for its ability to block neuronal
differentiation in the brain and retina (202). An interesting parallel can be drawn to
the rise in Hes-1 observed by TGF-(3 treatment, as inducing CD4+ T cell
unresponsiveness inhibits the cells from their capacity to differentiate into effector
cells.
In trying to unify the results presented in this thesis one consistent finding is that the
expression of the Notch receptors in CD4+ T cells (Notch-1 and -2) was not
modulated by any form of activation in vivo or in vitro.
In contrast, Notch ligand expression was differentially modulated in response to
different CD4+ T cell treatments. An interesting observation is that peptide-induced
tolerance in vivo and TGF-(3 treatment of CD4+ T cells in vitro, both lead to an up-
regulation of the Notch ligands Jagged-1 and Delta-1, although the latter was only
significant in the in vitro treatment.
The common feature in these two very different experiments is that they both lead to
CD4+ T cell unresponsiveness and both are involved in the generation of Tr cells. It
is difficult to make a direct comparison between these two experimental protocols.
Although there were some functional similarities, the cells induced in vivo and in
vitro may differ in their phenotype and this may explain why there is a differential
regulation of Hes-1. Furthermore, in the model of peptide tolerance used in this study
Hoyne et al reported that TGF-(3 was not involved in Tr cell induction (12), which
indicates that the CD4+ T cells from the in vivo and in vitro studies are different, and
therefore the genes they express may differ too.
Nevertheless, despite the differences, an interesting finding is that Jagged-1, and to a
lesser extent Delta-1, were up regulated during conditions in vivo and in vitro that
favour Tr cell differentiation or CD4+ T cell unresponsiveness.
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However, there are additional discrepancies between the data sets. In vitro activation
of CD4+ T cells with anti-CD3 and anti-CD28 antibodies led to a significant up
regulation of Delta-1 and Jagged-1, and of the transcriptional repressor, Hes-1, by 24
hours of activation. This would argue against these genes being up regulated under
conditions that favour generation of Tr cells.
However, I should stress the importance of kinetics in the expression of these genes.
The CD4+ T cells proliferate in respond to TCR-mediated activation after about 3
days in culture, and the effect in gene expression seen for TGF-(3 occurs at a time
when CD4+ T cell proliferation is inhibited. Therefore, the pattern of gene regulation
noted for CD4+ T cell activation after 24 hours may not directly relate to the
functional state of the cells, but rather to the early effects that activation of
intracellular pathways have, on the transcription of Notch ligand genes and Hes-1.
These pathways may involve NF-kB as it has been previously discussed.
Additionally, the threshold of CD4+ T cell activation in an antibody-mediated
response is possibly much lower than that driven by antigen, and this may also affect
the type and levels of genes transcribed.
In summary, the work in this thesis has provided evidence to demonstrate that
components of the Notch signalling pathway and members of the TGF-(3 superfamily
are expressed in different lymphocyte and APC populations and in peripheral
lymphoid organs. Whereas the Notch receptors are highly expressed in cells and
organs of the immune system, they are not differentially modulated in CD4+ T cells
during the course of different treatments in vivo and in vitro. In contrast, activation of
lymphoytes (CD4+ T cells with anti-CD3/anti CD28 antibodies and B cells with
LPS) via pathways that activate NF-kB, lead to the up regulation of the Notch
ligands Jagged-2 and Delta-1, as well as of activin A. The intracellular mediator Hes-
1 is only up regulated in CD4+ T cells, and Deltex in B cells.
I have also established an experimental protocol of intranasal priming to the HDM
pi 10-130 using E.coli heat labile enterotoxin as a mucosal adjuvant and have primed
or tolerised mice to pi 10-130 to induce CD4+ T helper or Tr cells, respectively. This
allowed me to study how Notch signalling genes may be modulated.
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This work was extended to include an in vitro model of CD4+ T cell
unresponsiveness by treating cells with TGF-(3. In an attempt to define the immune
regulatory properties of other TGF-(3-like molecules, I have made the novel
observation that activin A, like TGF-(3, can inhibit splenic CD4+ T cell proliferation
and induce CD4+ T cell unresponsiveness, whereas BMP-4 had no effect.
The induction of peptide tolerance in vivo or the induction of CD4+ T cell
unresponsiveness in vitro by TGF-(3, led to the up regulation of the Notch ligands
Jagged-1 and Delta-1, as was observed by CD3/CD28 mediated activation. The up
regulation of the Notch ligands upon antibody-mediated activation may reflect early
effects in CD4+ T cell activation.
A final personal note to add is that overall the work reported in this thesis has
attempted to gain further insight into the regulation of Notch signalling genes during
the outcome of different CD4+ T cell responses. I have shown that lymphocyte
activation differentially regulates components of the Notch signalling pathway.
However, this may have been a direct consequence of gene transcription following
activation, and the early kinetics of gene expression may not reflect protein
expression and function.
Additionally I have also shown that the Notch ligands are up regulated during
antigen-driven responses that induce tolerance in vivo, or after treatment of CD4+ T
cell with TGF-(3 in vitro. However, it is difficult to ascertain the biological relevance
of these demonstrations as they only represent gene analysis studies, and a link
between the in vivo and in vitro data is highly speculative. I believe future
experiments using a TCR transgenic murine model will provide a clearer
understanding of the questions I have tried to address.
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